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Abstract 
Vitamin A, or retinol, is a fat-soluble vitamin, essential for many important 
processes including proliferation, reproduction, vision and 
immunocompetence. Retinol binding protein (RBP) is the principal carrier 
of retinol in the blood from its storage site, the liver, to retinol dependant 
tissues. The long sought RBP receptor was recently identified as stimulated 
by retinoic acid gene 6 (STRA6), a 74 kDa multitransmembrane protein 
with no similarity to any other protein receptor.  At present, receptor 
function, architecture and structure-function relationships remain relatively 
unexplored. Identification of any protein(s) that interact with STRA6 is 
imperative in identifying any other role STRA6 may play in the body.  
The membrane yeast two hybrid (MYTH) represents a powerful tool to 
facilitate the characterisation of membrane protein interactions and was 
utilized to detect proteins that interact with full-length STRA6. A human 
kidney and a human brain library were screened. The human kidney screen 
was repeated in the presence of RBP-ROH to identify any protein 
interactions dependent on the presence of holo-RBP. The MYTH screens 
resulted in 11 unique protein interactions for STRA6. These interactions 
could not be verified using pull-down experiments despite numerous 
attempts. 
In the hope of gaining insights into STRA6’s architecture and function, the 
predicted large third intracellular loop (ICL3) of STRA6 was extracted from 
the full length protein, introduced into a carrier protein, Im7, and 
characterised. STRA6-ICL3 was found to form a tetramer. The native Im7 is 
monomeric; therefore, the domain conferred tetrameric behaviour. These 
data suggest that native STRA6 is likely to occur as a tetramer and that at 
least some of the oligomerization sites are located on this large intracellular 
loop. By determining the circular dichroism spectra for STRA6-ICL3, 
iii 
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the first structural data for STRA6 was collected. These data revealed that 
STRA6-ICL3 was mostly composed of β-sheet and random coil. 
Crystallization trials were also attempted and a crystal is eagerly awaited. 
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1.1 Retinol  
Vitamin A, or retinol, is a fat-soluble vitamin, essential for many important 
processes including proliferation, differentiation, reproduction, vision and 
immunocompetence (Blomhoff and Blomhoff, 2006). Retinol is obtained from the 
diet and is stored as retinyl esters in hepatic stellate cells, white adipose tissue and 
the lung (Lobo et al., 2013). Once retinol reaches the target tissues, it is usually 
converted into retinoic acid (RA) (Desvergne, 2007). RA regulates the expression of 
hundreds of genes, encoding a wide range of proteins including transcription factors, 
enzymes, structural proteins, cell-surface receptors and growth factors (Albalat, 
2009) by directly activating its nuclear hormone receptors, retinoic acid receptors 
(RARs), γ, α, and β2. RARs associate with a partner, retinoid X receptors (RXR), γ, 
α2, and β (McKenna, 2012). RARs bind the abundant form of RA, all-trans RA and 
9-cis-RA, as illustrated in Figure 1.1, whereas RXRs bind 9-cis-RA only. RAR/RXR 
heterodimers and RAR homodimers bind RA-responsive elements (RARE) in the 
regulatory regions of direct target genes (Duester, 2008). These cognate binding sites 
correspond to a 5 bp-spaced direct repeat of polymorphic arrangements of the 
canonical motif 5'-PuG(G/T)TCA (Gudas and Wagner, 2011).   
RARs and RXRs are members of the nuclear receptor (NR) superfamily. NRs are 
modular proteins, with evolutionarily conserved DNA binding domains (DBD) and 
ligand binding domains (LBD). The DBD confers sequence specific DNA 
recognition. The LBD is a highly structured domain comprising a ligand dependent 
activation function, as well as being required for nuclear localization and homo- 
and/or heterodimerization. In the absence of a ligand (e.g. all-trans RA), RAR–RXR 
heterodimers (apo-heterodimers) are believed to be bound to RAREs of target genes 
together with transcriptional co-repressors, nuclear receptor corepressor (N-CoR) or 
silencing mediator for retinoid and thyroid hormone receptors (SMRT), which then 
recruit histone deacetylases (HDACs). This results in local chromatin condensation 
and gene silencing. Binding of the ligand leads to co-repressor dissociation and 
results in the recruitment of histone acetyltransferase (HAT) co-activators, such 
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as CREB-binding protein (CREBBP) and p160, relieving the chromatin mediated 
silencing induced by HDACs. Recruitment of ATP-dependent chromatin 
remodelling machineries, such as SWItch/Sucrose NonFermentable (SWI–SNF), 
prepares the template for the action of the basal transcriptional machinery, consisting 
of the RNA polymerase II holoenzyme, together with the TATA-binding protein 
(TBP) and TBP-associated factors (TAFs), and mediator complexes (MEDs) (Wurtz 
et al., 1996). After ligand addition, many genes that do not possess RAREs are 
transcriptionally regulated indirectly. This indirect regulation occurs because the 
direct target genes of RA include many different transcription factor genes, these 
transcription factors then transcriptionally activate their target genes to 
generate secondary responses (Gudas and Wagner, 2011). 
RXRs also form heterodimers with several metabolic regulators, including 
peroxisome proliferator-activated receptors (PPARs) (Desvergne, 2007), thyroid 
hormone receptors (TRs) and vitamin D receptor (VDR) (Bugge et al., 1992). In 
vision, the RA precursor, 11-cis-retinal acts as the chromophore for the visual 
pigment rhodopsin (Zhong et al., 2012). Photon absorption isomerizes the 
chromophore to all-trans, leading to the generation of an active intermediate, 
metarhodopsin II, that initiates a cascade of reactions resulting in a change in 
membrane potential and hence the conversion of light to an electrical signal 
(Blakeley et al., 2011).   
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Figure 1.1:  Intracellular Retinoid Signalling Pathway. Taken from (Marceau et al., 
2006) 
Retinol is converted into retinal and retinoic acids, before either it acts 
through nuclear retinoid receptors or is inactivated by hydroxylation 
(Marceau et al., 2006).  
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1.1.1 Retinol Metabolism 
Retinoids describes the family of molecules comprising both natural and synthetic 
analogues of retinol and includes retinol, retinal and retinoic acid (Sporn and 
Roberts, 1983). Retinoid is obtained from the diet as preformed retinol (primarily as 
retinol and retinyl ester) from the likes of red meat  (Frey and Vogel, 2011) or as 
proretinol carotenoid (usually as α-carotene, β-carotene or β-cryptoxanthin) from 
plant sources e.g. carrots and red peppers (Desvergne, 2007). Dietary retinol is taken 
up directly from the intestinal lumen into the enterocyte. Dietary retinyl esters must 
first undergo enzymatic hydrolysis within the intestinal lumen, by pancreatic 
triglyceride lipase (PTL) or pancreatic lipase related protein 2 (PLRP2) or at 
the enterocyte brush border, to allow for uptake of the hydrolysis product retinol.  
Dietary proretinoid cartenoids are taken up intact in the enterocyte, scavenger 
receptor class B, type I (SR-B1) has been identified as a key mediator for uptake of 
β-carotene from the intestinal lumen into the enterocyte. Once inside the enterocyte, 
they can undergo conversion to retinoid or are packaged unmodified into 
chylomicrons. Two structurally related proteins, β-carotene-15,15′-monooxygenase 
(BCMO1), encoded by Bcmo1, and β-carotene-9′,10′-monooxygenase (BCMO2), 
encoded by Bcmo2, are the sole mammalian enzymes known to cleave carotenoids  
(D'Ambrosio et al., 2011).  
Inside the enterocyte, retinol is bound to cellular retinol binding protein II (CRBPII). 
In the adult, CRBPII is reported to be expressed solely in the intestinal mucosa and 
is proposed to facilitate optimal retinol absorption from the diet.  Re-esterication of 
newly absorbed dietary retinol to retinyl esters is performed by lecithin:retinol 
acyltransferase (LRAT) and acyl-CoA:retinol acyltransferase (DGAT1), as 
illustrated in Figure 1.2. LRAT catalyses the transesterification of retinol and 
DGAT1 catalyses the fatty acyl-CoA-dependent esterification of retinol. Together 
with phospholipids, cholesterol and triglycerides, the retinyl esters are packed into 
chylomicrons and released into the lymph (Ong, 1994). Dietary carotenoid that has 
not undergone conversion to retinoid is also incorporated into the nascent 
chylomicrons. After entering the general circulation, the nascent chylomicrons 
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undergo a process of remodelling that involves primarily the hydrolysis of 
triglyceride by lipoprotein lipase (LpL) and the acquisition of apolipoprotein E 
(apoE) from the circulation, resulting in the formation of chylomicron remnants. The 
majority of dietary retinoid (chylomicron and chylomicron remnant retinoid) is taken 
up by the liver where it is stored in hepatic stellate cells (HSCs), with the remainder 
being cleared by peripheral tissues (D'Ambrosio et al., 2011). 
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Figure 1.2:  Uptake and Metabolism of Dietary Retinoids and Proretinoid 
Carotenoids within the Intestine. Taken from (D'Ambrosio et al., 2011). 
Dietary proretinoid carotenoids, like β-carotene, are taken up into the 
enterocyte through a process that involves SR-B1. Once inside the 
enterocyte, β-carotene can be converted to retinal or can be incorporated 
intact and unmodified along with dietary fat and cholesterol into nascent 
chylomicrons. Dietary retinyl ester is either hydrolysed in the lumen of the 
intestine or undergoes hydrolysis at the intestinal brush border catalysed by 
a brush border retinyl ester hydrolase (REH). Retinol taken into the 
enterocyte binds to CRBPII and is esterified to retinyl ester. LRAT will 
catalyse approximately 90% of retinyl ester formation, while the intestinal 
DGAT1 catalyses the remainder of retinyl ester formation. The resulting 
retinyl ester is then packed along with dietary fat and cholesterol into 
nascent chylomicrons, which are secreted into the lymphatic system 
(D'Ambrosio et al., 2011).  
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1.1.2 Retinol in Health and Disease 
Retinol has numerous important functions and in humans; when retinol intake is not 
sufficient to meet the body’s needs, retinol deficiency occurs. Such deficiency is 
strongly associated with suppressed immune function and higher morbidity and 
mortality (Azaïs-Braesco and Pascal, 2000). Retinol deficiency is one of the most 
prevalent deficiencies of public health importance in developing countries (Radhika 
et al., 2002), the most common clinical symptom of which is night blindness 
(Christian et al., 1998). The prevalence of night blindness, in some developing 
countries,  has been found to be as high as 12 % (Radhika et al., 2002). 
Xerophthalmia designates the group of ocular signs and symptoms related to this 
deficiency. As already mentioned, 11-cis-retinal acts as a chromophore for the visual 
pigment rhodopsin. Night blindness is the first symptom of xerophthalmia as 
rhodopsin requires high concentrations of 11-cis-retinal to create a highly sensitive 
visual film (Diniz and Santos, 2000). Retinol can potentially induce and modulate 
epithelial growth and differentiation. Its deficiency causes epithelial alterations such 
as loss of mucous secreting cells and squamous metaplasia, thereby causing corneal 
epithelial keratinization and desquamation of surface epithelium (Hayashi et al., 
1989). In addition, retinol deficiency causes the disorganization of rod photoreceptor 
outer segments, degeneration of cone photoreceptor cells, and the loss of LRAT 
expression in the retinol pigment epithelial (Zhong et al., 2012). 
Retinol supplements have been shown to reduce mortality by up to 80 % in South 
Africa, in patients suffering from acute complicated measles by reducing 
complications such as diarrhoea (Klein and Hussey, 1990). The underlying basis for 
the use of retinol supplementation to reduce infectious disease morbidity and 
mortality is its role in enhancing immunity. Retinoids influence many aspects of 
immunity, including mucin and keratin expression, haematopoiesis, apoptosis, the 
growth, differentiation and function of neutrophils, natural killer cells, 
monocytes/macrophages, Langerhans cells, T and B lymphocytes. Retinoids also 
influences balance between T helper  type 1-like and T helper type 2-like immune 
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responses, immunoglobulin production and expression of cytokines, such as tumor 
necrosis factor alpha (TNF-α) and adhesion molecules (Semba, 1998).   
Interestingly, the suppression of immunity seen in retinol deficiency may be 
connected to the vitamin D bioactive metabolite, 1α25-dihydroxyvitamin D3 
(1α,25(OH)2VD3). 1α,25(OH)2VD3 complexes with the nuclear vitamin D receptor 
(VDR). VDR heterodimerizes with RXR receptors and binds to VD3 response 
elements (VDREs) in the promoters of VD3-responsive genes to exert an inhibitory 
effect on adaptive immune cells. RA enhances cytotoxicity and T-cell proliferation 
in the adaptive immune system. By heterodimerizing with RXR receptors, 
1α,25(OH)2VD3 competes for the same nuclear partner as RA. In retinol deficient 
mice, RA does not compete with 1α,25(OH)2VD3 for their common nuclear binding 
partners and, therefore, the inhibitory effects of 1α,25(OH)2VD3 on adaptive 
immune cells are not offset by RA (Mora et al., 2008). 
Retinol deficiency also causes an increase in the incidence of respiratory tract 
disease, in accordance with its role in immunity as well as its role in the lung, to 
ensure the regulation of the cellular differentiation of the respiratory epithelium and 
lung epithelium (Biesalski, 2003). Furthermore, retinol deficiency compromises 
mucosal immunity by altering the integrity of mucosal epithelia, including those of 
the respiratory tract. Retinol deficiency in rats and hamsters leads to loss of ciliated 
epithelial cells and mucus in the tracheobronchial tree and replacement by stratified, 
keratinized epithelium. These pathologic alterations of the respiratory epithelium 
cause an increased risk of developing respiratory disease (Semba, 1998). Retinol 
supplements have been shown to decrease repeated infections (Biesalski, 2003). 
Retinol is essential in pregnancy for the developing embryo and deficiency results in 
severe abnormalities (Zile, 2001). Retinol deficiency can lead to resorption of the 
foetus (Sivaprasadarao and Findlay, 1988b). It is believed that improving retinol 
levels of all deficient individuals could save over a million lives annually (Sommer, 
1996). 
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Conversely, retinol intake at marginally above the recommended dietary intake is 
connected too with risk and is associated with embryonic malformations in 
pregnancy (Rothman et al., 1995), reduced bone mineral density and increased risk 
for hip fracture (Melhus et al., 1998). An excess of retinol suppresses osteoblast 
activity and promotes osteoclast formation thereby stimulating bone resorption and 
inhibiting bone formation. Excess retinol also dampens the effects of vitamin D, 
which plays a critical role in bone metabolism by competing for the same nuclear 
receptors, RXRs (Mata-Granados et al., 2013). Excessive intake, during pregnancy, 
can cause teratogenic changes, especially during the critical periods of organ and 
limb development (Sivaprasadarao and Findlay, 1988b). Retinol excess is associated 
with malformations of the nervous system, ocular malformations, malformations of 
the ear, craniofacial malformations, cleft palate, defects of the circulatory system, 
defects of the respiratory systems, defects of the digestive tract, urogenital defects, 
skeletal malformations, and abnormal postnatal development (Geelen, 1979). Due to 
the importance of retinol, at the correct concentration, a tightly regulated mechanism 
for the delivery of retinol to target cells has evolved.  
 
1.2 Retinol Binding Protein 
Retinoids are very insoluble in water and consequently within the aqueous 
environment of the body are usually found bound to specific retinoid-binding 
proteins (D'Ambrosio et al., 2011). Plasma retinol binding protein (RBP; also known 
as RBP4) is the principal carrier of retinol in the blood from its storage site, the liver, 
to retinol dependant tissues (Kanai et al., 1968). RBP circulates in the plasma 
associated with a second protein, the homotetramer transthyretin (TTR, 54 kDa) 
which is believed to stabilise the protein and  prevent the glomerular filtration and 
excretion of the relatively small (21 kDa) RBP molecule through renal filtration (van 
Bennekum AM et al., 2001).  Transthyretin has been recognized as one of the most 
interesting proteins identified to date, because of its multifunctionality. Besides 
distributing thyroid hormones (THs) in the blood, it indirectly transports retinol 
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bound to RBP. The first transthyretin to have its 3D structure revealed was from 
human plasma. Approximately 60 of 127 amino acid residues in the transthyretin 
monomer are arranged into eight β-strands (named A through H) that are connected 
by loops to form a sandwich of two β-sheets. Only 5 % of the residues in the 
monomer, which corresponds to nine amino acid residues, are in a short α-helix. 
Dimers of transthyretin are composed of a pair of twisted eight stranded β-sheets. 
The association of two dimers results in a tetrameric structure with two pairs of 
eight-stranded β-sheets, as illustrated in Figure 1.3. The dimer–dimer contacts 
predominantly involve hydrophobic interactions of residues in two loops (i.e. A–B 
and G–H loops) at the edge of the sheets (Prapunpoj and Leelawatwattana, 2009).  
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Figure 1.3:  The 3D Structures of Human Transthyretin. Taken from (Prapunpoj 
and Leelawatwattana, 2009) 
Ribbon diagrams of transthyretin tetramer. The four identical monomers (A, 
B, C and D) form a tetramer (shown in colour ramping from blue to red) 
with a central channel (along the z axis) where two binding sites for THs 
exist (Prapunpoj and Leelawatwattana, 2009).  
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RBP belongs to the lipocalin family, a group of widely distributed, mostly 
extracellular proteins occurring in animals, plants and bacteria (Grzyb et al., 2006). 
The term ‘lipocalin’ is derived from the Latin ‘lipos’, meaning fats, and ‘calyx’, 
meaning drinking vessel, referring to the binding of lipophilic molecules inside a 
cup-shaped pocket (Pervaiz and Brew, 1987). RBP is the first member of the 
lipocalin superfamily for which the X-ray structure was determined (Newcomer et 
al., 1984). Lipocalins share a highly conserved 3 dimensional structure, an eight 
stranded β-barrel (Grzyb et al., 2006). The sequence conservation between different 
members of the lipocalin protein family is low, and alignment is only possible within 
particular region sequences, illustrated in Figure 1.4. Lipocalins are classified as 
kernel or outlier lipocalins. The ‘kernel’ lipocalins are characterized by three 
common conserved stretches of residues, while ‘outlier’ lipocalins match no more 
than two of these three diagnostic motifs (Dittrich et al., 2013). 
Lipocalins were first identified for their ability to transport small hydrophobic 
molecules and are now known to have an important role in the regulation of 
immunological and developmental processes as well as enzymatic activities, 
metabolic homeostasis and are involved in the reactions of organisms to various 
stress factors and in the pathways of signal transduction (Ramana and Gupta, 2009).  
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Figure 1.4:  Structure of the Lipocalin Fold. Taken from (Flower, 1996) 
The nine β-strands of the antiparallel β-sheet are shown as arrows and 
labelled A-I. The N-terminal 310-like helix and C-terminal α-helix (labelled 
A1) are also marked. The hydrogen-bonded connection of two strands is 
indicated by a pair of dotted lines between them. Connecting loops are 
shown as solid lines and labelled L1-L7. Those parts which form the three 
main structurally conserved regions (SCRs) of the fold, SCR1, SCR2 and 
SCR3, are marked as boxes. Three sequence motifs which correspond to 
these SCRs are shown (MOTIF 1, MOTIF 2 and MOTIF 3). The first three 
sequences are from kernel lipocalins and include RBP. The second three 
from outlier lipocalins (Flower, 1996).  
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1.2.1 RBP Regulation 
Although adequate amounts of retinol are essential to the well-being and survival of 
the individual, excess intake can be toxic, even to the extent of fatality (Duerbeck 
and Dowling, 2012).  Therefore, the availability and use of retinol has to be under 
tight control. One molecule of RBP is consumed for the delivery of one molecule of 
retinol – a remarkably expensive process which attests to the tight control applied to 
the utilisation of this vitamin.  Consistent with this, the turnover of RBP is very high 
(half-life is hours compared to 2 days for TTR) (Smith et al., 1973), (Ando and Jono, 
2008). RBP is synthesised mainly in the liver, with some from the kidney, testis, eye, 
brain and adipocytes (Redondo et al., 2008). RBP secretion is retinol-dependent 
(Shirakami et al., 2012). Binding of retinol to RBP is believed to initiate the 
translocation of holo-RBP (retinol bound) from the endoplasmic reticulum to the 
golgi complex followed by secretion of holo-RBP into plasma (Blomhoff and 
Blomhoff, 2006). Retinol deficiency inhibits RBP secretion, leading to protein 
accumulation in the endoplasmic reticulum of hepatic parenchymal cells (Bushue 
and Wan, 2010).  
It is now long established that retinol is absorbed in the small intestine, stored in the 
liver, and secreted into circulation bound to RBP (Kanai et al., 1968). However, how 
retinol enters the cell has been the topic of much debate. Due to the hydrophobic 
nature of retinol, cellular membranes do not constitute a barrier and retinol can 
spontaneously cross the membrane. It was shown that binding to RBP is not required 
for movement of retinol into or out of cells. It was thus proposed that cellular uptake 
of retinol from RBP in blood occurs spontaneously and simply follows the 
concentration gradients of free retinol (Noy, 2000). However, although free retinol 
can also diffuse through membranes, it seldom exists in its free form. Furthermore, 
direct binding of RBP to a plasma membrane receptor has been demonstrated in 
pigment epithelial cells (Heller, 1975) and human placental membrane vesicles. It 
was further shown that free, rather than TTR-associated, RBP bound to the receptor 
and subsequent receptor mediated retinol uptake occurred. On the release of retinol 
to the receptor, RBP assumes a low-affinity conformation for both the receptor and 
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TTR and now, being uncomplexed, is excreted via the kidney (Sivaprasadarao and 
Findlay, 1988a, Sivaprasadarao and Findlay, 1988b). 
It was not until recently that the long sought RBP receptor was finally identified as 
stimulated by retinoic acid gene 6 (STRA6), in bovine retinal pigment epithelial cells 
(Kawaguchi et al., 2007). Described as a 74 KDa multi-transmembrane domain 
protein, STRA6 was shown to satisfy all three criteria expected of the RBP receptor, 
that is; (i) conferring high affinity RBP binding to cells transfected with bovine 
STRA6 cDNA; (ii) mediating retinol uptake; and (iii) showing localisation 
consistent with its function as the RBP receptor (Kawaguchi et al., 2007). 
Particularly strong expression of STRA6 occurs in cells that compose human blood-
organ barriers e.g. the adult brain (Bouillet et al., 1997), the placenta and testis 
(Quadro et al., 2005, Sivaprasadarao and Findlay, 1988a), the spleen and thymus 
(Sommer, 1997) as well as in the retinal pigment epithelial (RPE) in the adult eye 
(Kawaguchi et al., 2007). 
 
1.2.2 Structure and Ligand Binding 
RBP binds specifically to TTR, as illustrated in Figure 1.5, and the RBP receptor, 
STRA6 (Sivaprasadarao et al., 1998). The protein is folded into an orthogonal β-
barrel. This barrel is made up of eight anti-parallel β-strands and is open at one end 
and closed at the other. The retinol binding site is located at the interior of the barrel 
and is lined largely by hydrophobic amino acid side-chains. The open end of the 
barrel is lined by loops of structure which connect the β strands, A+B, C+D, and 
E+F, which form the entrance/exit site for retinol, and G-H. These are known as the 
AB loop, CD loop, EF loop and GH loop respectively. Structure-function studies, 
using mutants of RBP and the placental receptor, as well as X-ray diffraction, show 
that the AB, CD and EF loops bind with TTR; however the EF loop binds with the 
highest affinity (Sivaprasadarao and Findlay, 1994). Deletion of the EF loop results 
in much reduced affinity of RBP for TTR (Redondo et al., 2006). The CD and EF 
loop bind the receptor, the CD loop being the major site. Mutations in the CD loop 
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resulted in loss of the ability of RBP to bind STRA6. The movement of retinol in and 
out of the binding pocket is facilitated by the AB loop by switching between the 
closed and open conformation states. It is believed that binding of the EF loop and 
TTR stabilizes the closed conformation and that the binding of the CD loop to the 
receptor stabilizes the open conformation, through a conformational switch of the 
AB loop (Sivaprasadarao and Findlay, 1994). Another study explored if the binding 
properties of RBP can be transferred to epididymal retinoic acid binding protein 
(ERABP). These two proteins display only minor differences with respect to their 
ligand-binding specificities: whereas RBP binds all the three physiologically relevant 
retinoids, including retinol, retinaldehyde and retinoic acid, the specificity of 
ERABP is restricted to retinoic acid. The results demonstrated that substitution of the 
EF loop alone was sufficient to confer the TTR-binding properties on to ERABP and 
that RBP binds to the receptor via its loops at the entrance/exit site of the retinol-
binding pocket (Sundaram et al., 2002).  
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Figure 1.5:  Holo-RBP in Complex with TTR. Taken from (Naylor and Newcomer, 
1999).   
Three-dimensional structure of holo-RBP and TTR complex; TTR (shown 
in green) can bind two molecules of RBP (shown in purple) in vitro, as 
illustrated. Due to a limiting plasma concentration of RBP, however, a 1:1 
stoichiometry is observed in vivo.  (PDB entry 1qab) (Naylor and 
Newcomer, 1999).    
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1.2.3 RBP in Health and Disease 
To date, only two human RBP mutations have been identified (Quadro et al., 2002). 
RBP deficient patients display only a mild clinical phenotype that includes night 
blindness and modest retinal dystrophy (Biesalski et al., 1999). RBP knock-out mice, 
totally lacking RBP, have reduced levels of plasma retinol, abnormal vision at birth, 
which could be corrected with a retinol adequate diet by 5 months of age, and an 
inability to mobilize retinol from hepatic stores. This suggests that RBP is only 
essential in times of insufficient retinol intake and for normal vision in young 
animals (Quadro et al., 1999).  
It has been suggested that RBP, from adipose tissue, may have a role in insulin 
resistance, obesity and ultimately type-II diabetes (T2D). RBP levels are elevated in 
these states and its normalisation enhances insulin sensitivity (Graham et al., 2006). 
This will be covered in more detail hereafter, given its pertinence to this thesis. 
 
 1.3 Insulin & Diabetes 
Insulin (Latin insula, meaning “island”) is a hormone produced in β-cells in islets of 
Langerhans in the pancreas. Insulin regulates energy metabolism by initiating several 
signalling cascades that control cell growth and survival, as well as protein, glycogen 
and lipid uptake, synthesis and hydrolysis. Where low insulin levels arise glycogen 
is converted to glucose. After a meal, increased nutrients in the blood cause the 
secretion of insulin. Insulin prevents gluconeogenesis in the liver and promotes 
glucose uptake into muscle and adipose tissue through regulated trafficking of 
glucose transporter type 4 (GLUT4) from intracellular stores to the plasma 
membrane. GLUT4 is predominantly expressed in muscle cells and adipocytes and 
mediates insulin-stimulated glucose transport in fat and muscle (Leto and Saltiel, 
2012).  
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Type 1 diabetes is an autoimmune disease whereby T-cell mediated attack of β-cells 
occur, resulting typically in a dramatic loss of β-cells before type 1 diabetes is 
diagnosed. In Type-II diabetes, insulin-sensitive tissue loses response to insulin, 
resulting from an inhibition of insulin signalling. Insulin resistance leads to 
hyperinsulinemia as β-cells try to control blood glucose levels. Eventually pancreatic 
β-cells can no longer compensate for insulin resistance causing high blood and urine 
glucose levels due to impaired cellular uptake (Alberti and Zimmet, 1998). GLUT4 
expression is reduced in insulin-resistant states, causing a reduction in insulin-
stimulated glucose transport. Glucose intolerance then occurs (Graham et al., 2006). 
The World Health Organization has estimated that the number of adults with 
diabetes will more than double from an estimated 143 million in 1997 to 300 million 
by 2025 (Kumanyika et al., 2002).  
 
1.3.1 Insulin Signalling 
Binding of insulin to its receptor, the insulin receptor (IR), triggers the 
phosphorylation and activation of the IR tyrosine kinase, as illustrated in Figure 1.6. 
Recruitment and tyrosine phosphorylation of the insulin receptor substrates (IRSs), a 
family of adapter proteins, including IRS-1, IRS-2, IRS-3, IRS-4, Gab1, and Shc 
ensues followed by subsequent activation of the phosphoinositide 3-kinase  (PI3K) 
pathway (Leto and Saltiel, 2012, Yadav et al., 2012). Tyrosine phosphorylated IRS 
proteins serve as docking sites for the SH2 domain of the p85 regulatory subunit of 
class I PI3K, and the interaction of IRS proteins and PI3K results in PI3K activation 
and the subsequent synthesis of phosphatidylinositol-3,4,5-trisphosphate 
[PtdIns(3,4,5)P3] from PtdIns(4,5)P2 at the plasma membrane. PtdIns(3,4,5)P3 in 
turn serves as a docking site for several PH domain-containing Ser/Thr kinases that 
are implicated in glucose uptake, including phosphoinositide-dependent kinase 1 
(PDK1) and AKT. PDK1 and mTORC2 activate AKT through dual Ser/Thr 
phosphorylation. AKT then phosphorylates numerous substrates, resulting in 
GLUT4 translocation to the membrane (Leto and Saltiel, 2012, Saltiel and Kahn, 
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2001).   Insulin produces most of its metabolic actions through the PI3K pathway. 
Another pathway proceeds through growth factor receptor-bound protein 2 (Grb2)/ 
Son of Sevenless (Sos) and ras, leading to activation of the mitogen-activated protein 
kinase 1 (MAP kinase) isoforms ERK1 and ERK2 (Cusi et al., 2000).   
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Figure 1.6:  Insulin Signalling Pathway. Taken from (Turner, 2013) 
Phosphorylation of the IR recruits IRS proteins to the membrane. IRS-1 is 
phosphorylated resulting in binding to the p85 regulatory subunit of PI3K. 
PI3K then catalyses the production of PIP3 at the plasma membrane. PIP3 
recruits PDK1 which causes AKT activation. Activated AKT then 
phosphorylates various substrates  (Turner, 2013). 
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1.3.2 Insulin Resistance and Obesity 
An obese adult is classified as having a Body Mass Index equal or greater than 30 
(Alberti and Zimmet, 1998). Obesity is believed to be caused by an imbalance 
between energy ingested in food and the energy expended (Bray, 2004). This excess 
energy is then stored in adipocytes, which over time will increase in number and 
size. Adipocytes, in addition to having a role as lipid storage depots, are an active 
endocrine organ regulating fat mass and nutrient homeostasis (Yadav et al., 2012). 
Adipocytes are therefore critical for modulating fat mass but as a person gets heavier 
and the adipocytes enlarge, these control mechanisms become dysregulated, 
macrophages accumulate in the adipose tissue and inflammation ensues (Greenberg 
and Obin, 2006), resulting in macrophages constituting up to 40 % of adipose tissue. 
This chronic inflammation results in cytokine and adipokines, adipose tissue related 
cytokines, production resulting in a number of pathologies associated with obesity 
including T2D.  Up to 65% of cases of T2D can be attributed to obesity. 
Furthermore, two thirds of diabetic deaths may be caused by obesity (Bray, 2004).  
Adipokines include hormones such as leptin, resistin, adiponectin, and inflammatory 
cytokines such as TNF-α, monocytes chemoattractant protein-1 (MCP-1) and 
interleukin 6 (IL-6) (Wozniak et al., 2009). TNF-α expression in adipocytes of obese 
animals is markedly increased and there is a significant correlation between BMI and 
plasma TNF-α  concentrations  (Dandona et al., 2004). TNF-α causes an inhibition of 
the auto-phosphorylation of tyrosine residues of the IR and an induction of serine 
phosphorylation of IRS-1,  which in turn causes serine phosphorylation of the insulin 
receptor in adipocytes and inhibits tyrosine phosphorylation. This is suggested to 
occur through activation of c-Jun N-terminal protein kinase (JNK), as illustrated in 
Figure 1.7 (Hirosumi et al., 2002). IL-6 has been shown to inhibit insulin signal 
transduction in hepatocytes. This effect has been shown to be related to suppressor of 
cytokine signalling-3 (SOCS-3), a protein that associates with the IR, inhibits its 
autophosphorylation, the tyrosine phosphorylation of IRS-1, the association of p85 
subunit of PI3K to IRS-1 and the subsequent activation of AKT (Dandona et al., 
2004).    
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Figure 1.7:  Proposed Mechanism for Inflammation Induced Insulin Resistance in 
Muscle. Taken from (Toit and Donner, 2012) 
IL-6 activates the STAT3-SOCS3 pathways while TNF-α activates JNK to 
phosphorylate IRS-1. Serine phosphorylation of IRS-1 inhibits GLUT4 
translocation to the membrane and attenuates the insulin signalling pathway  
(Toit and Donner, 2012).  
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1.3.3 RBP and T2D 
The significance of the RBP system, especially in terms of human health, reached an 
enhanced level of interest with the claim that RBP is deeply implicated in the genesis 
of insulin resistance and T2D – specifically, that elevated levels of RBP attenuate 
intracellular responses to insulin by a mechanism independent of insulin levels or 
insulin-receptor interactions. The hypothesis holds that RBP causes a reduction in 
the expression and translocation of GLUT4 which results in the development or 
worsening of insulin resistance. Down regulation of GLUT4 in adipose tissue is seen 
in nearly all insulin-resistant pathologies and increasing GLUT4 in adipose tissue 
has been shown to protect the body against insulin resistance (Yang et al., 2005). It 
has been shown that GLUT4 levels in adipose tissue and RBP levels correlate 
inversely in T2D patients (Graham et al., 2006). RBP may affect GLUT4 expression 
by inducing the expression of phosphoenolpyruvate carboxykinase (PEPCK), a 
regulatory enzyme of gluconeogenesis, which reduces insulin action and suppresses 
glucose production in hepatocytes (Yang et al., 2005). PEPCK catalyses the first step 
of gluconeogenesis and the increase in this enzyme alone is sufficient to induce the 
metabolic pathway and finally to cause insulin resistance (Valera et al., 1994).  
Serum TTR is also elevated in T2D. It is believed that increased amounts of the 
RBP: TTR complex may contribute to RBP elevation in T2D as TTR prevents the 
renal clearance of RBP (Klöting et al., 2007). Fenretinide (an anti-cancer synthetic 
retinoid), which accelerates RBP urinary excretion (and hence reduces serum levels), 
reduces insulin resistance and improves insulin sensitivity and glucose tolerance in 
obese mice (Yang et al., 2005). Furthermore, a study in approximately 6,500 aging 
adults showed that a gain-of-function single nucleotide polymorphism (SNP) in the 
RBP promoter is associated with a 2-fold-increased risk of T2D (van Hoek et al., 
2008).  The data provide some mechanistic insights into RBP mediated insulin 
resistance, but the underlying cellular mechanisms are not known. 
Emerging evidence suggests RBP may cause insulin resistance by development of 
the inflammatory state. RBP was shown to induce cytokine production in 
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macrophages. These cytokines include TNF-α, IL-6, MCP-1, IFN-γ, Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF), Interleukin-1 beta (IL-
1β), Interleukin-2 (IL-2), and Interleukin-12p70 (IL-12p70) (Norseen et al., 2012). 
As already mentioned, TNF-α is a JNK activator, which in turn phosphorylates IRS-
1 at Ser 307 (Hirosumi et al., 2002). A JNK specific inhibitor reversed the RBP 
dependent inhibition of insulin signalling. Toll-like receptor 4 (TLR4) has also been 
suggested to be involved in RBP mediated insulin resistance. In 
TLR4−/− macrophages, IL-6 and TNF-α secretion is attenuated by 60 to 80 %.  
TLR4 has previously been linked to insulin resistance (Shi et al., 2006). RBP 
attenuates insulin signalling independent of its binding to retinol. As STRA6 is not 
expressed in macrophages, this effect is also independent of STRA6. This is a novel 
alternative mechanism for RBP action and highlights differences in RBP signalling 
in adipocytes and macrophages. However, both direct and indirect effects of RBP on 
adipocyte insulin signalling may contribute to insulin resistance (Norseen et al., 
2012). 
A recent publication put forward evidence displaying how RBP, acting 
extracellularly but producing an intracellular effect, regulates energy homeostasis 
and insulin responses through a RBP-retinol/STRA6/JAK2/STAT5 signalling 
cascaded that induces the expression of STAT target genes including SOCS3, which, 
as already mentioned, inhibits insulin signalling (Berry et al., 2011, Berry and Noy, 
2012). This will be discussed in more detail in relevant chapters.  
 
1.4 STRA6 
STRA6 is a 74 kDa multitransmembrane protein, encoded by a gene originally 
identified as a retinoic acid-stimulated gene in cancer cell lines (Szeto et al., 2001). It 
is a new class of transmembrane protein, with no similarity to any other protein 
receptor (Kawaguchi et al., 2007). The predicted topology of STRA6 is illustrated in 
Figure 1.8. STRA6 is highly conserved among mammals and other vertebrates 
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(Bouillet et al., 1997). STRA6 specifically binds holo-RBP and is crucial in the 
delivery of retinol to the target tissues. The existence of a specific receptor for RBP 
was shown experimental in the 1970s using retinal pigment epithelium (Heller, 
1975). Its role in RBP binding and retinol uptake was characterised (Sivaprasadarao 
and Findlay, 1988a, Sivaprasadarao et al., 1994, Sivaprasadarao et al., 1998). The 
groups of Dollé and Chambon, identified STRA6 as the product of a retinoic acid 
inducible gene and suggested that it might have a transport – related function 
(Bouillet et al., 1997). Subsequently, the over expression of the gene was seen in 
human tumours (Szeto et al., 2001) with, interestingly, a potential connection to 
Wnt-1 signalling (Tice et al., 2002).  Using purified RBP derivatized with an 
ultraviolet crosslinking agent, Kawaguchi et al., were able to identify STRA6 as a 
protein present in membrane preparations from RPE cells that bound specifically to 
RBP (Kawaguchi et al., 2007). Although the existence of an RBP receptor 
previously was a contentious subject (Noy, 2000), it is now widely accepted that 
such a receptor exists and its role in retinol uptake (Sivaprasadarao and Findlay, 
1988b) has now been validated (Kawaguchi et al., 2007). The crystal structure of 
STRA6 has yet to be elucidated and any other functions STRA6 may have are yet to 
be clarified.  
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Figure 1.8:  Holo-RBP and the RBP Receptor STRA6. Taken from (Kawaguchi et 
al., 2008b). 
The high affinity cell surface receptor for RBP, STRA6, predicted topology. 
Crystal structure of holo-RBP is based on structure 1HBP in the Protein 
Data Bank (PDB). The predicted 9 transmembrane domains for STRA6 are 
indicated with roman numerals (Kawaguchi et al., 2008b). 
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1.4.1 STRA6 in Disease 
A number of natural STRA6 human mutations have been identified which give rise 
to devastating abnormalities, most of which are fatal (Pasutto et al., 2007, Golzio et 
al., 2007). These mutations cause a variety of serious malformations and 
dysfunctions most noticeably in the eye, diaphragm, lungs and heart, often 
accompanied by moderate to severe mental retardation.  Foetal or early death or 
termination of pregnancy is the usual outcome.  Some effects can clearly be related 
to disruption of the potential supply of retinol which remains bound to RBP and is 
not delivered in sufficient quantity to the developing tissues.  Whether there is also a 
separate or associated signalling function which is affected remains to be discovered.  
Some of these mutations produce stop codons and absence of the protein altogether; 
others are predicted to occur in extramembranous regions such as the loops between 
transmembrane segments or the N- and C- terminal “tails” (Pasutto et al., 2007). It 
has been postulated that these alterations may affect the architecture and or 
trafficking of the protein, e.g. by extending the transmembrane helices (Golzio et al., 
2007). STRA6 has been shown to be potentially important in cancer biology, as 
STRA6 mRNA levels are highly elevated in mammory gland tumours and human 
colorectal tumours (Szeto et al., 2001).  
 
 
1.4.2 STRA6 Mediated Retinol Transport 
STRA6 binds holo-RBP, facilitates the dissociation of the protein-ligand complex, 
and transfers retinol directly from extracellular RBP to cellular retinol binding 
protein (CRBP; also known as CRBP-1). Apo-RBP, which has lower affinity for the 
receptor (Sundaram et al., 1998), then dissociates from STRA6 and is excreted in the 
kidney since its affinity for TTR is also markedly reduced. The next holo-RBP will 
bind STRA6 and hereby the process continues. STRA6 thus employs a transport 
mechanism that is distinct from that of other transporters of small lipids (Kawaguchi 
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et al., 2007). STRA6 mediated retinol uptake is tightly coupled to intracellular 
retinoid storage proteins, CRBP and LRAT  (Kawaguchi et al., 2011). CRBP is 
involved in the intracellular trafficking of retinol (Franzoni et al., 2010) and delivers 
retinol to LRAT (Ong, 1994), an enzyme that catalyses retinyl ester synthesis (Jin et 
al., 2007). The coupling of STRA6 and LRAT enhances retinol uptake by converting 
it to its ester form (Amengual et al., 2012). LRAT and CRBP, therefore, provide 
high specificity in cellular uptake of retinol and prevent the excessive accumulation 
of free retinol (Kawaguchi et al., 2011). 
CRBP is widely distributed, found in almost all organs, particularly abundant in 
certain cells known to process considerable amounts of retinol, such as the pigment 
epithelial cells of the eye (Ghyselinck et al., 1999) as well as HSCs (Blomhoff and 
Blomhoff, 2006). CRBP is indispensable for efficient RE synthesis and storage, this 
is particularly evident under conditions of dietary retinol deprivation (Ghyselinck et 
al., 1999). Mutant mice, with the CRBP gene knocked out, are healthy and fertile 
when fed a retinol enriched diet. However, when reared on a retinol deficient diet, 
mice fully exhaust their RE stores within 5 months, and develop abnormalities 
characteristic of post-natal retinol deficiency (Ghyselinck et al., 1999). LRAT was 
the first protein shown to enhance STRA6’s vitamin A uptake activity (Kawaguchi et 
al., 2007) and is essential for retinol esterification: knockout mice have  reduced 
retinyl esters, shown to be reduced in the liver by more than 10,000-fold, and 
dramatically attenuated visual functions due to the lack of retinyl esters in the eye 
(Batten et al., 2004).  
STRA6 has been shown to function as a bidirectional transporter to mediate release 
of retinol under certain conditions (Sivaprasadarao and Findlay, 1988b). STRA6 
catalyses both retinol release from holo-RBP and loading of free retinol into apo-
RBP. This exchange occurs between intracellular holo-CRBP and extracellular holo-
RBP, both of which bind to STRA6 (Kawaguchi et al., 2012, Sundaram et al., 1998). 
LRAT expression is required to drive STRA6 mediated retinol transport 
directionally toward uptake rather than efflux (Amengual et al., 2012). It is unclear 
to what extent this efflux happens and in what context. STRA6’s retinol exchange 
30 
 
C h a p t e r  1 | I n t r o d u c t i o n  |  
 
  
may serve to refresh the intracellular retinoid pool to guard against depletion due to 
gradual oxidation occurring during long-term storage (Kawaguchi et al., 2012) or for 
times of retinol deficiency so retinol can be used for critically dependent tissues 
(Sivaprasadarao and Findlay, 1988b). 
 
1.4.3 Other Functions of STRA6 
A recent publication has proposed that STRA6 is not only a retinol transporter but 
also a cell-surface signalling receptor activated by the RBP–retinol complex, as 
illustrated in Figure 1.9. The belief is that association of holo-RBP with STRA6 
triggers tyrosine phosphorylation of STRA6, resulting in recruitment and activation 
of JAK2 and the transcription factor STAT5. Activation of STAT5 results in the 
expression STAT target genes, including SOCS3, which inhibits insulin signalling, 
and PPARγ, which enhances lipid accumulation (Berry et al., 2011). The group went 
on to suggest that STRA6-mediated uptake of retinol and transduction of a 
phosphorylation cascade are interdependent (Berry et al., 2012b).  
The authors believe that this signalling cascade is inhibited by TTR, as it blocks the 
ability of holo-RBP to associate with STRA6 (Berry et al., 2012a). The ability of 
TTR to block holo-RBP association with STRA6 has previously been discovered 
(Sivaprasadarao and Findlay, 1988b). The authors suggests that STRA6 functions 
only under circumstances where the plasma RBP level exceeds that of TTR and that, 
in addition to preventing the loss of RBP, TTR plays a central role in regulating 
holo-RBP/STRA6 signalling (Berry et al., 2012a). 
These findings remain controversial and have been contradicted by other groups. 
Chen et al. and Farjo et al. found that the signalling cascade occurred independent of 
retinol. Kawaguchi et al., heavily criticised the STRA6 antibody used by Berry et al., 
and their technique of producing holo-RBP (Kawaguchi et al., 2012).   
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Figure 1.9:  Model of the RBP-ROH/STRA6/JAK/STAT Pathway. Taken from 
(Berry et al., 2011). 
Binding of holo-RBP to STRA6 triggers tyrosine phosphorylation within an 
SH2 domain-binding motif in the receptor’s cytosolic domain. 
Phosphorylated STRA6 recruits and activates JAK2, which in turn, 
phosphorylates STAT5. Activated STAT5 translocates to the nucleus to 
regulate the expression of target genes, including SOCS3, which inhibits 
insulin signalling and PPARỵ, which enhances lipid accumulation (Berry et 
al., 2011).  
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1.4.4 STRA6 Domains 
STRA6’s predicted topology suggests 19 distinct regions, including 5 extracellular 
loops, 9 transmembrane segments and 5 intracellular loops (Kawaguchi et al., 
2008a). STRA6 is known to bind RBP. A number of imitational experiments were 
performed in hopes of discovering the RBP binding domain of STRA6, resulting in 
the discovery of three key residues. Mutations in these three residues, on STRA6’s 
third extracellular loop (EC3), abolish RBP binding: Tyr 336, Gly, 340 and Gly 342 
(Kawaguchi et al., 2008a). STRA6 also associates with CRBP (Sundaram et al., 
1998, Redondo et al., 2008) and the binding domain (intracellular loop 3, residues 
235 to 295) has been identified (Berry et al., 2012b) located in which is the human 
polymorphism P293L, shown to elicit a broad spectrum of severe birth defects. 
Interestingly, the  unusually large C-terminus for this protein accounts for almost one 
third of the molecular weight of the full-length ~ 74 kDa receptor and within which 
the human polymorphisms T644M and R655C are located (Pasutto et al., 2007). 
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Aims and Objectives 
STRA6 has been identified as the specific membrane receptor for RBP, mediating 
cellular retinol uptake from holo-RBP (Kawaguchi et al., 2007). The existence of a 
receptor for RBP has been controversial (Noy, 2000) and STRA6’s function remains 
at present to be characterised (Blaner, 2007). The vital necessity of STRA6 has been 
underlined by the discovery of human mutants of STRA6 which cause massive, 
devastating and ultimately fatal tissue malformations (Pasutto et al., 2007, Golzio et 
al., 2007). Given that STRA6 is not homologous to any other protein in the human 
genome and has been implicated in disease the elucidation of its actual purpose in 
the body is imperative.  
The objective of the work undertaken in this thesis is toward a greater understanding 
of STRA6, with specific interest in function, directed at the identification of novel 
protein interactions.  To this end, the MYTH was utilized to detect protein 
interactions and detected interactions were subsequently to be validated 
independently of the yeast based assay, described in Chapters 3 and 4.   
STRA6’s predicted topology suggests the presence of a large third intracellular loop. 
The presence of such a domain lends itself to the possibility of intracellular protein: 
protein interactions. Studies aimed at understanding the role of this region in relation 
to STRA6’s function should prove instructive. Characterization of the third 
intracellular loop of STRA6 is described in Chapter 5.  Finally, a summarizing 
discussion aims to place the findings outlined within this thesis in the context of the 
literature reviewed above.  
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Chapter 2 
Materials and Methods 
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2.1 Chemicals and Reagents  
All chemicals, reagents, and proteins were obtained from Sigma unless otherwise 
stated.  Enzymes and buffers were purchased from New England Biolabs, Fermentas, 
Promega and Stratagene.  All oligonucleotides used were acquired from Sigma.  
Size markers for DNA and protein gels were supplied by Fermentas. Plasmid DNA 
isolation and purification kits were procured from Fermentas, Invitrogen and Qiagen.  
IPTG was purchased from Ambion. E. coli strains were bought from Invitrogen.  
FuGENE® 6 transfection reagents were attained from Roche.  Lipofectamine 2000 
was obtained from Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) was 
supplied by Fisher. T75 Tissue culture flasks were purchased from Sarstedt.  
Protein purification was performed using Glutathione Sepharose™ 4 Fast Flow 
purchased from GE Healthcare, Ni-NTA agarose or Strep-Tactin Superflow Plus, 
both of which were acquired from Qiagen.  In the detection of proteins, ECL 
Western blotting substrate was supplied by Roche, stripping buffer was procured 
from ThermoScientific. PVDF transfer membrane was bought from GE healthcare.  
Antibodies were purchased from Sigma (α-rabbit-HRP, α-His-HRP), Origene (α –
DDK), Cell Signalling (α-myc), Promega (α-mouse-HRP), Abnova (α-STRA6), 
Dako (α -RBP), Covance (α-HA) and Santa Cruz Biotechnology Inc. (α -CRBP). 
2.2 Vectors, Host Strains and Cell Lines  
The coding sequence for human STRA6 (UniProt entry Q9BX79) was obtained in 
the pPICZA vector (OriGene), incorporating a C-terminal GFP and 6xHis tag. This 
vector was used in attempts to express the full length receptor in Pichia pastoris.  
The coding sequence for human STRA6 (UniProt entry Q9BX79) was also obtained 
in the pcDNA3.1 vector (Invitrogen), incorporating a C-terminal 6xHis tag, in the 
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pcDNA4 vector (Invitrogen), incorporating a C-terminal Myc and 6xHis tag and in 
the pN-TGSH vector (Dualsystems Biotech AG) incorporating a HA and STREPII 
tag.  These vectors were used in attempts to express the full length receptor in 
Human Embryonic Kidney 293T (HEK293T) cells. All expression attempts are 
described further in Chapter 4.   
The STRA6-ICL3 construct (in pETd9) and Im7 construct (in pTrc99A) were a kind 
gift from Dr. Conor Breen & Dr. Werner Vos, NUI Maynooth. 
The RBP construct (in pPICZ-α A) and CRPB construct (in pGEX-4T-3) were a kind 
gift from Dr. José Angel Campos-Sandoval and Dr. Lyndsey Brown.  
HEK293T lysates overexpressing [C-C motif chemokine 2 (CCL2), CXCL14, 
interferon-induced transmembrane protein 1 (IFITM1), interferon-induced 
transmembrane protein 3 (IFITM3), macrophage migration inhibitory factor (MIF), 
Stress-associated Endoplasmic Reticulum (ER) protein 1 (SERP1) and proteolipid 
protein 2 (PLP2)] were all obtained from Origene. Ovarian Cancer Immuno Reactive 
Antigen Domain Containing Protein 2 (OCIAD2) and osteopontin constructs (in 
pCMV6-Entry) were supplied by Origene.  
The coding sequences for human CD63 (UniProt entry P08962) and PDZK1-
Interacting Protein 1 (PDZK1-IP1) (UniProt entry Q13113) were obtained in the 
pcDNA3.1 vector, incorporating a C-terminal HA tag. These vectors were used in 
attempts to express the full length proteins in HEK293T cells.   
For cloning and plasmid amplification, supercompetent E. coli strain TOP10 cells 
were used.  Expression of full length human STRA6 was carried out in the P. 
pastoris strain KM71H and mammalian HEK293T cells (Invitrogen).  STRA6-ICL3, 
Im7 and CRBP were expressed in the E. coli strain BL21(DES). Expression of 
human RBP was carried out in P. pastoris strain KM71H. Expression of CD63, 
PDZK1-IP1, OCIAD2 and osteopontin were carried out in mammalian HEK293T 
cells.  
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2.3 Subcloning 
Subcloning of the coding sequences of interest into appropriate vectors was by 
amplification from the host vector by polymerase chain reaction.  Both PCR product 
and destination vector were linearized by double restriction digestion, followed by 
ligation of the coding sequence into the destination vector.  Competent E. coli cells 
were transformed with plasmid DNA and spread onto LB agar plates containing 
appropriate antibiotics for growth and selection.   
Methods will be explained in more detail hereafter and in relevant chapters. 
 
2.3.1 The Polymerase Chain Reaction (PCR) 
DNA template (10 ng) was incubated with each of the primers (at a final 
concentration of 0.4 µM) and dNTPs (at a final concentration of 0.2 mM each), in 
the appropriate 1x reaction buffer [20 mM Tris-HCl (pH 8.8), 2 mM MgSO4, 10 mM 
KCl, 10 mM (NH4)2SO4, 0.1% Triton® X-100, 0.1 mg/ml nuclease-free bovine 
serum albumin (BSA)] to a final volume of 49 µL.  After thorough mixing, 1 µL (at 
a final concentration of 0.05 U) Pfu Turbo Hot Start DNA polymerase (Strategene) 
was added.   
Following polymerase activation at 95 °C for 5 minutes, PCR was performed for 
thirty cycles of denaturation at 95 °C for 30 seconds, annealing at the 5 °C below 
lowest primer Tm °C for 30 seconds and extension at 72 °C for 1 min/kb.  Total 
reaction mixture was analysed on a 0.8 % (w/v) agarose gel [50 ml 1x Tris 
base, acetic acid and ethylenediaminetetraacetic acid (EDTA) buffer (TAE), 0.4 g 
agarose] as described in 2.3.11.  
Where a single PCR product of expected size was observed, the band was excised 
under UV light and purified using the QIAquick gel extraction kit (Qiagen) 
according to the manufacturer’s instructions.   
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2.3.2 Restriction Digestion 
Purified PCR product was digested with the appropriate restriction enzymes. The 
PCR product was incubated with both enzymes (at a final concentration of 0.17 U) 
and BSA (at a final concentration of 100 ng/mL) in a 1x reaction buffer [MULTI-
CORE™ Buffer (Promega), 25mM Tris-acetate (pH 7.5 at 37 °C), 100 mM 
potassium acetate, 10 mM magnesium acetate, 1 mM dithiothreitol (DTT)] for at 
least four hours at 37 °C.  The destination vector was digested with the same 
restriction enzymes.    
The double digested vector and insert were analysed on a 0.8 % (w/v) agarose gel as 
described in 2.3.11. The bands were excised under UV light and purified using the 
QIAquick gel extraction kit (Qiagen) according to manufacturer’s instructions.  
 
2.3.3 Zero Blunt TOPO Cloning 
For a number of constructs, plasmids were initially ligated into pTOPO (Invitrogen) 
before ligation into the destination vector. Gel extracted PCR product concentrations 
were determined using a UV-Vis Spectrophotometer (NanoDrop™ 1000 
Spectrophotometer, Thermo Scientific)  and 10 ng-50 ng of PCR product added to 1 
µl pCR®-Blunt II-TOPO® vector (10 ng/μL plasmid DNA in 50 % glycerol, 50 mM 
Tris-HCl, pH 7.4, 1 mM EDTA, 2mM DTT, 0.1 % Triton X-100, 100 μg/mL BSA, 
30 μM bromophenol blue) in the presence of 1 µl salt solution (1.2 M NaCl, 0.06 M 
MgCl2) and made up to 5 µl with water. The reaction was gently mixed and 
incubated for 5 minutes at room temperature (20-22 °C). 2 l of the reaction mixture 
were added to TOP10 chemically competent E.coli cells and incubated on ice for 5 
minutes.  Cells were then heat-shocked at 42 °C for 30 seconds before being returned 
to ice for a further 2-3 minutes. 250 µL super optimal broth with catabolite 
repression (SOC) medium (20 g/L bacto tryptone, 5 g/L bacto yeast extract, 0.5 g/L 
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sodium chloride, 0.186 g/L potassium chloride, 0.932 g/L magnesium chloride, 1.2 
g/L MgSO4, 3.603 g/L glucose, pH 7) was added prior to incubation at 37 °C, with 
shaking (200-250 rpm) for one hour.   
Following this incubation period, approximately 200 µL of the transformation 
mixture were spread onto an Luria-Bertani (LB) agar plate (10 g/L tryptone, 5 g/L 
yeast extract, 10 g/L NaCl, pH 7.0, 10 g/L agar) containing 50 µg/mL kanamycin 
(for the selection of transformants), followed by incubation overnight at 37 °C. A 
number of resulting colonies were cultured and the plasmid DNA isolated as 
described in 2.2.8 and 2.2.9 respectively. Successful insertion of the coding sequence 
into the destination vector was determined by restriction digestion and subsequent 
analysis by agarose gel electrophoresis as described in 2.3.2 and 2.3.11 respectively. 
Successful constructs were independently sequenced (Eurofins) to verify the coding 
sequence was correct, in frame and free of errors. 
 
2.3.4 Ligation Reaction 
Approximately 100 ng of vector and a 1 to 9 fold molar excess of insert were mixed 
in a 1x ligation buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM Adenosine 5’-
triphosphate (ATP), 10 mM DTT, pH 7.5), to which 1 µL (400 U) T4 DNA Ligase 
(NEB) (in 10 mM Tris-HCl, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA, 50 % 
glycerol, pH 7.4 @ 25 °C) was added. Total reaction mix was incubated at 16 °C 
overnight and competent TOP10 cells subsequently transformed with ligation 
products as described in 2.3.5.  
 
2.3.5 Transformation of E.coli Cells  
E.coli cells [TOP10 or BL21(DES)] were thawed on ice and 50 µL transferred to a 
15 ml tube.  To this tube, 1 µL (10 ng) of ligation product was added, followed by 
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incubation on ice for 5 minutes.  Cells were then heat-shocked at 42 °C for 30 
seconds before being returned to ice for a further 2-3 minutes. 250 µL SOC medium 
was added prior to incubation at 37 °C with shaking (200-250 rpm) for one hour.   
Following this incubation period, approximately 200 µL of the transformation 
mixture was spread onto a LB agar plate containing the appropriate antibiotic for the 
selection of transformants, followed by incubation overnight at 37 °C. A number of 
resulting colonies were cultured and the plasmid DNA isolated as described in 2.3.8 
and 2.3.9 respectively. Successful insertion of the coding sequence into the 
destination vector was determined by restriction digestion and subsequent analysis 
by agarose gel electrophoresis as described in 2.3.2 and 2.3.11 respectively. 
Successful constructs were independently sequenced to verify the coding sequence 
was correct, in frame, and free of errors. 
 
2.3.6 Preparation of Seed Stocks 
50 l of TOP10 competent cells were streaked onto an super optimal broth (SOB) 
agar plate (20 g/L bacto tryptone, 5 g/L bacto yeast extract, 0.5 g/L sodium chloride, 
0.186 g/L potassium chloride, 0.932 g/L magnesium chloride, 3.603 g/L glucose, 10 
g/L agar, pH 7) and incubated overnight at room temperature (20-22 °C). A single 
colony was used to inoculate 2 ml of SOB medium (20 g/L bacto tryptone, 5 g/L 
bacto yeast extract, 0.5 g/L sodium chloride, 0.186 g/L potassium chloride, 0.932 
g/L magnesium chloride, 3.603 g/L glucose, pH 7) and incubated overnight at room 
temperature (20-22 °C) with shaking (220rpm). 15 % glycerol (0.44 g/2ml) was 
added to the culture, which was then aliquoted and placed in a dry ice/ethanol bath 
for 5 minutes before storage at -80 °C.  
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2.3.7 Preparation of Competent Cells 
250 ml of SOB medium was inoculated with 1 vial of the seed stocks, as described in 
2.3.6, and grown at 20 °C till the culture reached an OD600 of 0.3. The culture was 
then centrifuged (3000 g at 4 °C for 10 minutes) and the pellet resuspended in 80 ml 
of ice cold CCMB80 buffer (0.98 g/L potassium acetate, 8.88 g/L calcium chloride, 
4 g/l magnesium chloride, 10 % glycerol, pH 6.4). Following incubation on ice for 
20 minutes, centrifugation was repeated (3000 g at 4 °C for 10 minutes). The pellet 
was resuspended in 10 ml of ice cold CCMB80 buffer. Chilled CCMB80 was added 
to yield a final OD600 of 1.0 to 1.5. The culture was incubated for 20 minutes on ice 
and then aliqouted before being stored at -80 °C.  
 
2.3.8 Growth of Bacterial Cultures  
For plasmid DNA amplification, homemade TOP10 E. coli competent cells, as 
described in 2.2.6 and 2.2.7, were used throughout.  Colonies were selected on LB 
agar plates containing the appropriate antibiotic.   
All vectors used confer ampicillin or kanamycin resistance to E. coli transformants.  
Ampicillin was added to both liquid and solid media (final concentration 100 
µg/mL) for selection and maintenance. Kanamycin was added to both liquid and 
solid media (final concentration 50 µg/mL) for selection and maintenance. 
From LB agar plates, 3 mL starter cultures were inoculated with single colonies of 
transformed cells, as described in 2.3.5, and grown overnight at 37 °C with shaking 
(200-250 rpm). For large-scale purification, cultures were subsequently diluted 1:500 
in fresh medium and growth continued overnight prior to isolation of plasmid DNA. 
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2.3.9 Isolation of Plasmid DNA from E. Coli 
Large-scale (midi-prep) and mini-prep plasmid DNA preparations were carried out 
using the S.N.A.P. Midiprep (Invitrogen) and GeneJet Plasmid Miniprep 
(Fermentas) kits respectively. Both procedures are based on the alkaline lysis method 
but use a support column to purify isolated plasmid DNA. Lysis is obtained with a 1 
% sodium dodecyl sulfate (SDS), 0.2 M NaOH solution; the alkaline mixture 
ruptures the cells and the detergent breaks apart the lipid membranes and solubilises 
the cellular proteins. The NaOH also denatures the DNA, generating single strands. 
The lysate is supplemented with potassium acetate (3 M) which neutralises the pH, 
allowing the DNA strands to renature. The potassium acetate also precipitates the 
SDS, along with the cellular debris. The E. coli chromosomal DNA, a partially 
renatured tangle at this step, is also trapped in the precipitate. The plasmid DNA 
remains in solution. The centrifuged samples are then applied to a silica membrane 
in spin columns, the plasmid DNA binds to the silica matrix of the columns allowing 
repeated washes with an ethanol-based buffer. The purified DNA is then eluted from 
the silica resin with dH2O and verified by restriction digestion and subsequent 
analysis by agarose gel electrophoresis, as described in 2.3.2 and 2.3.11.  
 
2.3.10 Quantification of Plasmid DNA 
Concentration and purity of final DNA preparations were assessed by agarose gel 
electrophoresis, as described in 2.3.11, and verified by UV-Vis spectroscopy 
(NanoDrop™ 1000 Spectrophotometer, Thermo Scientific).  
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2.3.11 Agarose Gel Electrophoresis of DNA 
Agarose gel electrophoresis was used to determine the size of PCR products, 
estimate concentration of DNA, confirm restriction digestion and for verification of 
successful ligation of inserts into destination vectors. 
0.8 % agar was dissolved in 1x TAE by heating.  The solution was allowed to cool 
prior to the addition of SYBR Safe DNA stain (40 mM Tris-acetate, 1 mM EDTA, 
pH ~8.3, Invitrogen) to facilitate visualisation of DNA. Gels were subsequently 
poured, covered in aluminium foil and allowed to set at room temperature (20-22 °C) 
for one hour before use.  Samples were prepared in a 6x DNA loading buffer (10 
mM Tris-HCL pH 7.6, 0.03 % bromophenol blue, 0.03 % xylene cyanol FF, 60 % 
glycerol, 60 mM EDTA). Agarose gels were electrophoresed in 1x TAE buffer at 
100 volts and DNA visualised under UV light once sufficient migration and 
separation had occurred.  1 Kbp O’GeneRuler DNA ladder (10 mM Tris-HCL pH 
7.6, 10 mM EDTA, 0.005 % bromophenol blue, 0.005 % xylene cyanol FF, 10 % 
glycerol) was used for estimation of fragment length and DNA concentration. 
2.4 Protein Expression and Purification 
2.4.1 Protein Expression in E.coli  
Competent cells from the E. coli host strain BL21(DES) were used for protein 
expression.    
Starter cultures were inoculated with a single colony and incubated overnight, then 
diluted 1:100 with fresh medium and grown to an OD600 of 0.6-0.7.  Protein 
expression was induced by the addition of Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to a final a 0.1 mM, and growth continued for a further 4 hours, or till they 
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reached an OD600 of 2.8, prior to harvesting of cells by centrifugation (4000 g at 4 
°C for 10 minutes). 
The supernatants were discarded and the pellets resuspended in an appropriate 
volume of ice-cold wash buffer (300 mM Na2HPO4, 300 mM NaCl) (~ 5 mL per 
gram of culture) supplemented with protease inhibitors [1x EDTA-free protease 
inhibitor cocktail, 1 mM Tris (2-carboxyethyl) phosphine hydrochloride (TCEP), 1 
mM phenylmethylsulfonyl fluoride (PMSF), 10 mM β-mercaptoethanol]. 
Resuspended cells were centrifuged (4000 g at 4 °C for 10 minutes). The 
supernatants were aspirated to waste, the pellets were weighted and stored at -80 °C 
or proceeded to cell lysis.  
The cell pellets were resuspended in 3-5 ml of lysis buffer (300 mM Na2HPO4, 300 
mM NaCl, 1x EDTA-free protease inhibitor cocktail, 1 mM TCEP, 1 mM PMSF, 10 
mM β-mercaptoethanol, 1% Triton X-100, 1 mg/ml lysozyme) per gram of wet cell 
pellet. The sample was passed through a 18-gauge needle fitted to a 20ml syringe 
twice. The suspensions were incubated at 4 °C for 60 minutes under gentle agitation 
by rotation. Suspended cells were sonicated over ice in short bursts until the lysate 
cleared. The sample was passed through a 25-gauge needle fitted to a 20ml syringe 
until no longer viscous. The cell suspension was centrifuged (12,000 g at 4 °C for 20 
minutes). The volume of supernatant was noted, the protein purified and the pellet 
was discarded. Samples were taken at each step for subsequent analysis by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting.   
 
2.4.2 Protein Purification  
Since all proteins under investigation were expressed as 6xHis, StrepII 
or Glutathione-S-transferase (GST) fusions, purification was carried out using 
affinity chromatography.   
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Protein was purified by affinity chromatography using Ni-NTA agarose (Qiagen), 
Strep-tactin Superflow Plus (Qiagen) or Glutathione Sepharose™ 4 Fast Flow resin 
(GE Healthcare).  The soluble fraction from the bacterial lysate, containing the 
protein of interest, was incubated with the appropriate affinity resin overnight or for 
90 minutes at 4 °C.  Following incubation, resin was loaded onto a 5 mL disposable 
column and the flow-through containing unbound material collected and stored at 4 
°C for subsequent analysis by SDS-PAGE and Western blotting.   
Packed resin was then washed in 2 x 5 bed volumes of a suitable wash buffer, prior 
to elution of the protein.   
Purification methods will be discussed in more detail in relevant chapters.  
 
2.4.3 Transfection of HEK293T Cells using FuGENE® 6 
HEK293T cells were cultured at 37 °C in a humidified atmosphere (5 % CO2 / 95 % 
O2) in DMEM (supplemented with 10 % (v/v) heat-inactivated foetal calf serum 
(FCS), penicillin and streptomycin [1 % (v/v)] and 1 % glutamine).  Cells were 
grown as adherent monolayers to between 60-70 % confluence prior to transfection.  
HEK293T cells were transiently transfected using FuGENE® 6, according to the 
manufacturer’s instructions.   
Briefly, FuGENE® 6 was first diluted in serum-free medium, mixed to homogeneity 
by brief vortex mixing, and incubated at room temperature (20-22 °C) for 5 minutes.  
Plasmid DNA was then added and incubation continued for 20 minutes, to allow the 
formation of lipid: DNA complexes.  The transfection reagent: DNA complex was 
then added to cells drop-wise, prior to incubation at 37 °C (5 % CO2 / 95 % O2).  
At 48 hours post-transfection, growth medium was removed and cells washed in ice-
cold phosphate buffer saline (PBS) [10 mM NaH2PO4 (pH 7.4), 0.14 M NaCl, 3 mM 
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KCl]. Flasks were agitated until all cells were in suspension, at which time cells were 
harvested by centrifugation (700 g for 5 minutes).   
 
 
2.4.4 Transfection of HEK293T Cells using Lipofectamine™ 2000 
FuGENE® 6 was replaced with Lipofectamine™ 2000 as the transfection reagent of 
choice as FuGENE® 6 became unavailable commercially in Ireland. 
HEK293T cells were cultured at 37 °C in a humidified atmosphere (5 % CO2 / 95 % 
O2) in DMEM (supplemented with 10 % (v/v) heat-inactivated FCS, penicillin and 
streptomycin [1 % (v/v)] and 1 % glutamine).  Cells were grown as adherent 
monolayers to between 60-70 % confluence prior to transfection. HEK293T cells 
were transiently transfected using Lipofectamine™ 2000 Transfection Reagent 
according to the manufacturer’s instructions.   
Briefly, cells were seeded 24 hours pre-transfection so that they were approximately 
70 % confluent at time of transfection. Lipofectamine™ 2000 and the plasmid DNA 
were first diluted separately in serum-free medium, mixed to homogeneity by brief 
vortex mixing, and incubated at room temperature (20-22 °C) for 5 minutes.  
Plasmid DNA was then added to Lipofectamine™ 2000 and incubation continued 
for 20 minutes, to allow the formation of lipid: DNA complexes.  The transfection 
reagent: DNA complex was then added to cells drop-wise, prior to incubation at 37 
°C (5 % CO2 / 95 % O2).  
At 24 hours post-transfection, growth medium was removed and cells washed in ice-
cold PBS. Flasks were agitated until all cells were in suspension, at which time cells 
were harvested by centrifugation (700 g for 5 minutes).   
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2.5 Detection and Analysis of Proteins 
2.5.1 SDS-PAGE 
Separation of proteins according to molecular mass was achieved by SDS-PAGE to 
allow detection of expression and estimation of purity.   
Protein was electrophoresed in 8-12 % (w/v) acrylamide or 8-20 % gradient gels.  
Samples were prepared in 5x loading buffer [250 mM Tris-HCl, pH 6.8, 50 % (v/v) 
glycerol, 10 % (w/v) SDS, 500 mM β-mercaptoethanol, 0.5 % bromophenol blue].  
Electrophoresis was carried out in 1x Tris-Glycine SDS buffer (025 mM Tris, 250 
mM glycine pH 8.3, 0.1 % SDS) for 90 minutes at 100 volts. PageRuler Plus 
Prestained Protein Ladder (Thermo Scientific) [62.5 mM Tris-H3PO4 (pH 7.5 at 
25°C), 1 mM EDTA, 2 % SDS, 10 mM DTT, 1 mM NaN3, 33 % glycerol] was used 
for estimating the molecular mass of the protein. 
 
2.5.2 Coomassie Brilliant Blue and Silver Staining 
Proteins present at ≥ 0.1 µg or ≥ 1 ng were visualised by Coomassie Brilliant Blue or 
silver staining, respectively.  Staining in Coomassie Brilliant Blue [0.1 % (w/v) 
Coomassie Brilliant Blue, 40 % (v/v) methanol, 10 % (v/v) acetic acid] was carried 
out for a minimum of 2 hours, prior to destaining [40 % (v/v) methanol, 10 % (v/v) 
acetic acid] overnight.   
Silver staining was carried out using Pierce Silver Stain Kit according to the 
manufacturer’s instructions. Gels were first washed twice in ultrapure water, then 
fixed [30 % (v/v) ethanol, 10 % (v/v) acetic acid], rinsed [10 % (v/v) ethanol, 
followed by ddMilliQ water twice], sensitised (0.2 g/L Na2SO3), rinsed a second 
time (ddMilliQ water) and incubated with silver nitrate. Gels were then rinsed in 
ddMilliQ and developed to the desired intensity. Development was terminated with 5 
% acetic acid and gels stored in ddMilliQ. 
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2.5.3 Western Blotting 
The specific detection of proteins of interest was achieved by Western blotting, more 
specifically, semi-dry or wet electroblotting.    
 
2.5.3.1 Semi-Dry Western Blotting 
Gels were washed for 5 minutes in ultrapure water followed by 2 x 5 minute washes 
in transfer buffer [10 mM CAPS, pH 11, 10 % (v/v) methanol].  Proteins were 
transferred from SDS-PAGE gels onto a polyvinylidene fluoride (PVDF) membrane 
in this transfer buffer for one hour at constant amperage of 78 mA using a semi-dry 
transfer unit at room temperature (20-22 °C).  Membranes were then blocked in 10 
% (w/v) dried skimmed milk (Marvel) in PBS-t [10 mM NaH2PO4 (pH 7.4), 0.14 M 
NaCl, 3 mM KCl, 0.05 % (v/v) Tween-20] for one hour at room temperature (20-22 
°C) or overnight at 4 °C.  Membranes were subsequently washed in PBS-t (5 
minutes) and incubated with the appropriate antibody or antibodies for one hour at 
room temperature (20-22 °C) or overnight at 4 °C. After washing in PBS-t (3 x 5 
minutes), membranes were incubated with appropriate secondary antibody for one 
hour at room temperature (20-22 °C). After washing in PBS-t (5 x 5 minutes), 
membranes were developed by incubation for 90 seconds with chemiluminescent 
(ECL) Western blotting substrate, and signal detected by X-ray film exposure 
(Kodak) for variable periods of time. 
 
2.5.3.2 Wet Western Blotting 
Gels were washed for 5 minutes in ultrapure water followed by 2 x 5 minute washes 
in transfer buffer.  Proteins were transferred from SDS-PAGE gels onto a PVDF 
membrane in transfer buffer at constant amperage of 78 mA for two hours using a 
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wet transfer unit at 4 °C.  Membranes were then blocked in 10 % (w/v) dried 
skimmed milk in PBS-t for one hour at room temperature (20-22 °C) or overnight at 
4 °C.  Membranes were subsequently washed in PBS-t (5 minutes) and incubated 
with the appropriate antibody or antibodies, for one hour at room temperature (20-22 
°C) or overnight at 4 °C. After washing in PBS-t (3 x 5 minutes), membranes were 
incubated with appropriate secondary antibody for one hour at room temperature 
(20-22 °C). After washing in PBS-t (5 x 5 minutes), membranes were developed by 
incubation for 90 seconds with chemiluminescent (ECL) Western blotting substrate 
(Roche), and signal detected by X-ray film exposure (Kodak) for variable periods of 
time. 
 
2.5.4 Stripping and Reprobing PVDF Membranes  
In order to visualise two bands on the same membrane or, where an antibody failed 
to detect any protein and an alternative was available, PVDF membranes were 
stripped using Restore Western Blot Stripping Buffer (ThermoScientific) and 
reprobed. 
Membranes were washed in PBS-t to remove ECL, prior to incubation with Restore 
Western Blot Stripping Buffer for 15 minutes at room temperature (20-22 °C).   
Following incubation, membranes were washed in PBS-t and subsequently blocked 
[10 % dried skimmed milk] for one hour at room temperature (20-22 °C) or 
overnight at 4 °C. Stripped membranes were then probed with alternative antibodies. 
  
50 
 
  
  
Chapter 3 Membrane 
Yeast Two Hybrid 
 
51 
 
C h a p t e r  3 | M e m b r a n e  Y e a s t  T w o  H y b r i d  |  
  
 
  
3.1 Introduction 
Integral membrane proteins, such as STRA6, represent one of the most biologically 
important protein classes, having key roles in a diverse range of processes including 
cell signalling, recognition and adhesion, molecular transport, cellular metabolism 
and maintenance of cellular structure. Approximately one-third of the predicted 
proteins of an organism are believed to be anchored in the lipid bilayer, with many 
involved in functions linked to disease. This has made membrane proteins of 
considerable diagnostic and therapeutic importance, and indeed approximately 60 % 
of currently available therapeutics are directed towards membrane receptors and ion 
channels (Arinaminpathy et al., 2009, Terstappen and Reggiani, 2001). As such, 
obtaining a thorough understanding of the function and mechanism of action of 
membrane proteins is of crucial importance. The high-throughput identification of 
membrane protein ‘interactomes’, maps of the protein–protein interactions, are 
crucial for understanding the function of an uncharacterised protein, particularly 
when interacting proteins have known functions and deductions about the potential 
role of the uncharacterised protein can be made. However, the construction of these 
interactomes is particularly challenging, as the hydrophobic nature of many 
membrane-spanning proteins makes them difficult to analyse using conventional 
interaction assays, particularly those suitable for use in a high-throughput format.  
The yeast two hybrid (YTH), system is one of the most popular and powerful tools 
to study protein-protein interactions. Since its introduction fourteen years ago, it has 
developed from a simple assay for the analysis of interactions between known 
proteins, into a routine system for the high throughput identification of novel protein 
interactions using libraries. However the traditional YTH, the Gal4/LexA system, 
depends on the analysed proteins localizing to the yeast cell nucleus and is therefore 
not suitable for studying membrane proteins. To address this problem an alternative 
system has been developed, known as the membrane yeast two hybrid assay 
52 
 
C h a p t e r  3 | M e m b r a n e  Y e a s t  T w o  H y b r i d  |  
  
 
  
(MYTH), by Stagljar et al. (Stagljar et al., 1998). The MYTH was originally 
developed by Johnsson and Varshavsky but was intended for the detection of 
interactions between soluble proteins (Johnsson and Varshavsky, 1994). The MYTH 
represents a powerful tool to facilitate the characterisation of membrane protein 
interactions and takes advantage of the concept of ‘split ubiquitin’, the observation 
that ubiquitin, a conserved 76 amino-acid protein that serves as a tag for proteins 
targeted for degradation by the 26S proteasome, can be divided into two stable 
moieties, an N-terminal fragment called NubI and a C-terminal fragment called Cub, 
which are capable of spontaneous in vivo reassociation into a stable full-length quasi-
native ubiquitin, or “split ubiquitin”. A point mutation in the N-terminal domain of 
ubiquitin (NubG), isoleucine 13 to glycine, reduces the affinity of the two halves for 
each other, such that NubG and Cub fail to assemble into split ubiquitin when 
coexpressed in yeast. In the MYTH, this principle is adapted for use as a ‘sensor’ of 
protein-protein interactions (PPIs). A membrane protein of interest serves as the 
‘bait’ and is tagged at its N- or C- terminus with a moiety consisting of Cub linked to 
an artificial transcription factor, comprising the Escherichia coli DNA-binding 
domain LexA and the activation domain of VP16 from herpes simplex virus. Preys 
are tagged at either their N- or C- terminus with the NubG fragment.  For high-
throughput screening applications, entire prey libraries can be generated from 
sources such as genomic or cDNA. The bait and prey are then coexpressed in an S. 
cerevisiae host. An interaction between these proteins brings the Cub and NubG 
moieties into close contact, allowing for reconstitution of split ubiquitin. The 
reporter protein is released by ubiquitin binding proteases (UBPs) responsible for the 
deconjugation of ubiquitin from modified proteins through the hydrolysis of the 
amide bond formed between the protein and the C-terminal residue of ubiquitin. 
Once released, the reporter molecule enters the nucleus where it will activate 
expression of reporter genes (HIS3, ADE2 and lacZ) under the control of promoters 
containing LexA binding sites. HIS3 and ADE2 activation enables the yeast to grow 
on defined minimal media lacking histidine and adenine. LacZ, encoding the enzyme 
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β-galactosidase, activation results in a colour development in the β-galactosidase 
assay.  
In the absence of a protein-protein interaction, the ADE2 reporter gene is not 
transcribed and therefore, a red-coloured intermediate accumulates in the adenine 
metabolic pathway. Activation of the ADE2 gene by a protein-protein interaction 
leads to expression of the ADE2 gene product and unblocks the pathway. For this 
reason, NMY51 cells expressing an interacting protein pair will display a very faint 
pink to white colour, depending on the strength of the interaction. In the absence of a 
protein-protein interaction, the NMY51 cells display a pink colour, similar to strains 
carrying an ade2 mutation. Use of appropriate selective media thus allows for 
convenient and highly specific selection of cells containing interacting bait-prey 
pairs.  
The MYTH permits large-scale screening of interactions between full-length 
membrane proteins, membrane associated proteins and cytoplasmic proteins from a 
range of organisms; the only requirement being that these membrane proteins have 
their N- and/or C- terminus located in the cytosol (Snider et al., 2010b). This system 
maintains eukaryotic proteins in an environment close to their physiological norm 
and allows post-translational modifications to occur, permitting the expression of 
correctly folded proteins (Causier, 2004).  Reports of PPIs using this system are 
becoming commonplace in the literature (Hooker et al., 2007, Egaña et al., 2009, 
Felkl and Leube, 2008, Paumi et al., 2008). The MYTH has been successfully used 
to detect both transient and stable interactions of exogenously and endogenously 
expressed proteins from a variety of organisms (Stagljar and Fields, 2002, Snider et 
al., 2010b, Snider et al., 2010a).  
    
 
  
54 
 
C h a p t e r  3 | M e m b r a n e  Y e a s t  T w o  H y b r i d  |  
  
 
  
Aims and Objectives  
A cell surface receptor for RBP was first described in the 1970s and further 
characterised in the 1980s and 1990s by a number of groups (Chen and Heller, 1977, 
Heller, 1975, Sivaprasadarao and Findlay, 1988a, Sivaprasadarao and Findlay, 
1988b, Sivaprasadarao et al., 1994). The molecular identify of this receptor remained 
elusive until 2008, when STRA6 was identified, coding for the high affinity cell-
surface receptor for RBP (Kawaguchi et al., 2008a). STRA6 was originally identified 
as a retinoic acid-stimulated gene in cancer cell lines, leading to suggestions that it 
may potentially be important in cancer biology (Bouillet et al., 1997). Homozygous 
mutations in the human STRA6 gene have been shown to cause a pleitropic, 
multisystem malformation syndrome (Pasutto et al., 2007), thus highlighting the 
importance of this receptor. Furthermore, STRA6 has recently been linked to 
JAK2/STAT5 signalling and insulin resistance (Berry and Noy, 2012). Given that 
STRA6 is not homologous to any other protein in the human genome and many 
questions regarding the receptors function remain unanswered (Blaner, 2007) 
possible protein interactions for the receptor were explored.  
To detect proteins that interact with full-length STRA6, a human kidney and a 
human brain library were screened using the MYTH in yeast. The DNA encoding the 
full-length human STRA6 was cloned in-frame with the C-terminal half of ubiquitin 
and the LexA-VP16 transcription factor in the pBT3-Suc vector. This construct was 
then used to screen for possible interactors in an adult human brain library and 
human kidney library, fused to the mutated form of ubiquitin in the pPR3-N vector 
(Dualsystems Biotech AG). The human kidney screen was repeated in the presence 
of RBP-ROH to identify any protein interactions dependent on the presence of holo-
RBP.  
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3.2 Materials and Methods 
3.2.1 Preparation for Library Screen using STRA6 as Bait  
3.2.1.1 MYTH Constructs  
The coding sequence for full-length human STRA6 (UniProt entry Q9BX79) 
obtained in the expression vector pBT3-SUC (Dualsystems Biotech) was a kind gift 
from Dr. Monika Wysocka-Kapcinsk. The plasmid incorporates an N-terminal signal 
sequence derived from the Saccharomyces cerevisiae invertase (SUC2) gene, to 
allow expression and translocation of membrane proteins in yeast as well as a C-
terminal LexA DNA binding domain. The plasmid also incorporates a Herpes 
simplex VP16 transactivator domain in combination with the C-terminal (Cub), 
amino acids 34-76, of yeast ubiquitin and a CYC1 promoter to drive gene 
expression.  Additionally, the pBT3-SUC vector contains the auxotrophic growth 
marker LEU2 which allows yeast expressing pBT3-SUC to grow on minimal media 
lacking leucine, as well as the ampicillin resistance marker. 
Control vectors, pCCW-Alg5, pAL-Alg5 and pDL2-Alg5 were provided by 
DUALsystems Biotech. pCCW-Alg5 contains the auxotrophic growth marker LEU2 
which allows yeast expressing pCCW-Alg5 to grow on minimal media lacking 
leucine. pAL-Alg5 and pDL2-Alg5 contain the auxotrophic growth marker TRP1 
which allows yeast expressing pAL-Alg5 or pDL2-Alg5 to grow on minimal media 
lacking tryptophan. The three vectors also contain the kanamycin resistance marker. 
The pAI-Alg5 construct expresses a fusion of the yeast ER protein Alg5 and the wild 
type N-terminal (NubI), amino acids 1-38, of yeast ubiquitin. pDL2-Alg5 expresses a 
fusion of the same protein along with the mutated N-terminal (NubG), amino acids 
1-38, of yeast ubiquitin.  
pPR3-N, the library vector, was provided by DUALsystems Biotech and contains the 
auxotrophic growth marker TRP1 which allows yeast expressing pPR3-N to grow on 
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minimal media lacking tryptophan. The vector contains the kanamycin resistance 
marker, a CYC1 promoter to drive gene expression, as well as the mutated N-
terminal (NubG), amino acids 1-38, of yeast ubiquitin.  
 
3.2.1.2 Determination of the Optimum pH for NMY51 Growth  
NMY51 cells previously transfected with the bait construct were streaked onto an 
yeast extract, peptone, adenine sulphate, dextrose (YPAD) agar plate (10 g/L bacto 
yeast extract, 20 g/L bacto peptone, 20 g/L glucose monohydrate, 40 mg/L adenine 
sulphate, 20 g/L bacto agar, pH 6) and incubated for 3 days at 30 °C. Single colonies 
were used to inoculate 10 ml selective dropout (SD) medium (6.7 g/L yeast nitrogen 
base without amino acids, 0.6 g/L dropout mix, 20 g/L glucose monohydrate), 
supplemented with uracil (Ura, 0.02 g/L), adenine (Ade, 0.02 g/L), tryptophan (Trp, 
0.02 g/L), and histidine (His, 0.02 g/L) and lacking leucine (Leu, 0.02g /L), with pHs 
of 6, 6.5, 7, or 7.5. The cultures were grown for 8 hours at 30 °C with shaking (200-
250 rpm). The OD546 was taken for the 4 cultures and the optimum pH determined. 
 
 
3.2.1.3 Transformation of Yeast with the Bait Construct and Control 
Plasmids  
NMY51 cells were streaked onto a YPAD agar plate and incubated for 3 days at 30 
°C. A single colony was used to inoculate 50 ml of YPAD medium (10 g/L bacto 
yeast extract, 20 g/L bacto peptone, 20 g/L glucose monohydrate, 40 mg/L adenine 
sulphate, pH 6) and grown overnight at 30 °C with shaking (200-250 rpm). Once the 
culture reached an OD546 of 0.6-0.8, the culture was centrifuged (5 minutes at 2500 
g) and resuspended in 2.5 ml water. 1.5 μg of DNA (bait construct, pCCW-Alg5, 
pPR3-N, pAL-Alg5 or pDL2-Alg5) was added to a 1.5 ml tubes. 300 μl of the 
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polyethylene glycol (PEG)/ lithium acetate (LiOAc) master mix (240 μl 50 % PEG, 
36 μl 1M LiOAc, 30 μl single-stranded carrier DNA) was added to each tube and 
vortexed briefly. 100 μl of the resuspended yeast cells were added to each tube and 
vortexed to thoroughly mix all the components. The mix was incubated in a 42 °C 
water bath for 45 minutes. The reaction was centrifuged (5 minutes at 700 g), pellets 
resuspended in 100 μl 0.9 % NaCl and plated onto SD agar plates (6.7 g/L yeast 
nitrogen base without amino acids, 0.6 g/L dropout mix, 20 g/L glucose 
monohydrate, 20 g/L bacto agar), supplemented with Ade, Trp, His, and Ura and 
lacking Leu (bait construct and pCCW-Alg5) or SD agar plates supplemented with 
Ade, His, Leu and Ura and lacking Trp (pPR3-N, pAL-Alg5 and pDL2-Alg5). 
All agar plates were incubated for 3-4 days at 30 °C. 
 
3.2.1.4 Verifying Bait Expression and Functionality 
As in 3.2.1.3 with minor changes; DNA used was bait construct and pAI-Alg5 or 
bait construct and pDL2-Alg5. Pelleted reactions were resuspended in 100 μl 0.9 % 
NaCl and plated onto SD agar plates supplemented with Ade, His, and Ura and 
lacking Leu and Trp, SD agar plates supplemented with Ade and Ura and lacking 
Trp, Leu and His, as well as SD agar plates supplemented with Ura and lacking Ade, 
Trp, Leu and His. All agar plates were incubated for 3-4 days at 30°C. 
 
3.2.1.5 Optimizing the Screening Stringency using a Pilot Screen 
NMY51 cells previously transfected with the bait construct were streaked onto an 
YPAD agar plate and incubated for 3 days at 30 °C. A single colony was used to 
inoculate 10 ml SD medium supplemented with Ade, Trp, His, and Ura and lacking 
Leu. The culture was grown for 8 hours at 30 °C with shaking (200-250 rpm). The 
culture was used to inoculate 100 ml SD medium supplemented with Ade, Trp, His, 
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and Ura and lacking Leu. The culture was grown overnight at 30 °C with shaking 
(200-250 rpm). A 1 ml aliquot of the culture was centrifuged (2500 g for 5 minutes) 
and the pellet resuspended in 1 ml water. The OD546 was measured and the amount 
of culture needed for 22.5 OD units calculated. This volume was aliquoted and 
centrifuged (700 g for 5 minutes). The pellet was resuspended in 150 ml 2x YPAD 
(20 g/L bacto yeast extract, 40 g/L bacto peptone, 40 g/L glucose monohydrate, 40 
mg/L adenine sulphate, pH 6). The cells were grown at 30 °C with vigorous shaking 
(250 rpm) to an OD546 of 0.6-0.7.  
The 150 ml culture was split into three 50 ml tubes and centrifuged (700 g for 5 
minutes). The pellets were resuspended in 30 ml of sterile water by vortexing and 
centrifuged again (700 g for 5 minutes). The supernatants were removed and each 
pellet was resuspended in 1 ml LiOAc/ Tris EDTA (TE) master mix [110 μl 1M 
LiOAc, 110 μl 10x TE (100 ml/L 1 M Tris-Cl pH 7.5, 20 ml/L 0.5 M EDTA pH 8.0), 
0.78 ml water] and transferred to a 1.5 ml tube. The reactions were centrifuged (700 
g for 5 minutes), the supernatants removed and the pellets resuspended in 600 μl of 
LiOAc/TE master mix (66 μl 1 M LiOAc, 66 μl 10x TE pH 7.5, 468 μl water). To 
each 50 m tube; 7 μg of pPR3-N, 100 μl of single stranded carrier DNA, 600 μl of 
cells and 2.5 ml of PEG/LiOAc mix (0.25 μl 1M LiOAc, 0.25 μl 10x TE pH7.5, 2 ml 
50 % PEG) were added. 
The reactions were vortexed for 1 minute to thoroughly mix all components and 
incubated at 30 °C for 45 minutes (mixing briefly every 15 minutes). 160 μl DMSO 
was added to each tube and mixed immediately by shaking (200-250 rpm). The tubes 
were incubated at 42 °C for 20 minutes. The cells were centrifuged (700 g for 5 
minutes) and resuspended in 3 ml 2x YPAD and pooled. The cells were incubated at 
30 °C for 90 minutes with slow shaking (150 rpm) and centrifuged (700 g for 5 
minutes). The pellet was resuspended in 3.6 ml 0.9 % NaCl. 300 μl of cells were 
spread onto SD agar plates supplemented with Ade and Ura and lacking Leu, Trp 
and His with 0, 1, 2, 5, 7.5 and 10 mM 3-amino-1 2 3-triazole (3-AT) and SD agar 
plates supplemented with Ura and lacking Leu, Ade, Trp and His with 0, 1, 2, 5, 7.5 
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and 10 mM 3-AT. 3-AT is a competitive inhibitor of imidazole-glycerol-phosphate 
dehydratase, the HIS3 gene product (Lalonde et al., 2008). The remaining 
resuspended cells were used to prepare 1:100, 1:1000 and 1:10,000 dilutions in 0.9 
% NaCl and 100 μl of each dilution plated onto a 100 mm diameter SD agar plate 
supplemented with Ade, His, and Ura and lacking Leu and Trp (used later to 
calculate the transformation efficiency). All agar plates were incubated at 30 °C for 
3-4 days. 
 
3.2.1.6 RBP Expression and Purification   
Pichia pastoris KM71H cells previously transformed with RBP, in the expression 
vector pPICZ-αA with a HA and 6xHis tag, were a kind gift from Dr Campos-
Sandoval. A single colony was used to inoculate a 1 L culture of yeast extract 
peptone dextrose (YPG) (10 g/L yeast extract, 20 g/L peptone, 2 % dextrose). The 
culture was incubated overnight at 30 °C. Once the culture had reached an OD600 of 
6 the culture were centrifuged (10,900 g for 15 minutes at 4 °C). Each pellet (from 
250 ml of culture) was used to inoculate 1 L of yeast extract peptone methanol 
(YPM) (10 g/L yeast extract, 20 g/L peptone, 1 % methanol) and the cultures were 
incubated overnight at 30 °C. After 16 hours, methanol was added to a final 
concentration of 1 % and incubation continued overnight at 30 °C. The cultures were 
centrifuged and the supernatant filtered (0.65 µM filter), as the protein is secreted 
into the supernatant. After filtering, the culture was incubated with pre-equilibrated 
Ni-NTA agarose (1 ml/4 L culture) overnight at 4 °C with gentle agitation by 
rotation. The culture was feed into a 50 ml column. The flow-through was collected 
and the resin was washed with 20 ml PBS. Protein was eluted using 20 ml elution 
buffer (120 g/L NaH2PO4, 29 g/L NaCl, 34 g/L imidazole, pH 7.5). The protein was 
dialysed against 1x PBS.  
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3.2.1.7 Functional Characterisation of RBP 
The binding of retinol to RBP was monitored by fluorimetric titration in a Cary 
Eclipse fluorescence spectrophotometer (Varian). The purified recombinant protein 
was diluted to a concentration of 2 μM in PBS buffer and small increments of retinol 
were added. The two were mixed and allowed to incubate for 5 min before recording 
the fluorescence emission of the retinol–RBP complex. For titration of RBP with 
retinol, excitation wavelength was 335 nm and emission was recorded at 470 nm.  
 
3.2.2 Library Screen using STRA6 as Bait  
3.2.2.1 Library Transformation and Selection of Interactors 
NMY51 cells previously transfected with the bait construct were streaked onto an 
YPAD agar plate and incubated for 3 days at 30 °C. A single colony was used to 
inoculate 10 ml SD medium supplemented with Ade, Trp, His, and Ura and lacking 
Leu. The culture was grown for 8 hours at 30 °C with shaking (200-250 rpm). The 
culture was used to inoculate 100 ml SD medium supplemented with Ade, Trp, His, 
and Ura and lacking Leu. The culture was grown overnight at 30 °C with shaking 
(200-250 rpm), a 1 ml aliquot of the culture was centrifuged (2500 g for 5 minutes) 
and the pellet resuspended in 1 ml water. The OD546 was measured and the amount 
of culture needed for 22.5 OD units calculated. This volume was aliquoted and 
centrifuged (700 g for 5 minutes). The pellet was resuspended in 150 ml 2x YPAD. 
The cells were grown at 30 °C with vigorous shaking (250 rpm) to an OD546 of 0.6-
0.7. The culture was split between four 50 ml tubes and centrifuged (700 g for 5 
minutes). The pellets were resuspended in 30 ml of sterile water by vortexing and 
centrifuged again (700 g for 5 minutes). The supernatants were removed and each 
pellet was resuspended in 1 ml LiOAc/TE master mix and transferred to a 1.5 ml 
tube. The reactions were centrifuged (700 g for 5 minutes), the supernatants removed 
61 
 
C h a p t e r  3 | M e m b r a n e  Y e a s t  T w o  H y b r i d  |  
  
 
  
and the pellets resuspended in 600 μl of LiOAc/TE master mix. To each 50 ml tube; 
7 μg of library plasmid, 100 μl of single stranded carrier DNA, 600 μl of cells and 
2.5 ml of PEG/LiOAc mix was added. 
The reaction was vortexed for 1 minute to thoroughly mix all components and 
incubated at 30 °C for 45 minutes (mixing briefly every 15 minutes). 160 μl DMSO 
was added to each tube and mixed immediately by shaking (200-250 rpm). The tubes 
were incubated at 42 °C for 20 minutes. The cells were centrifuged (700 g for 5 
minutes) and resuspended in 3 ml 2x YPAD and pooled. The cells were incubated at 
30 °C for 90 minutes with slow shaking (150 rpm) and centrifuged (700 g for 5 
minutes). The pellet was resuspended in 4.8 ml 0.9 % NaCl. 300 μl of cells were 
spread onto SD agar plates supplemented with Ade and Ura and lacking Leu, Trp 
and His with 2 mM 3-AT and SD agar plates supplemented with Ura and lacking 
Leu, Ade, Trp and His with 2 mM 3-AT. The remaining resuspended cells were used 
to prepare 1:100, 1:1000 and 1:10,000 dilutions in 0.9 % NaCl and 100 μl of each 
dilution  plated onto a 100 mm diameter SD agar plate supplemented with Ade, His, 
and Ura and lacking Leu and Trp (used later to calculate the transformation 
efficiency). All agar plates were incubated at 30 °C for 3-4 days. All resulting 
colonies were restreaked onto SD agar plates supplemented with Ura and lacking 
Leu, Ade, Trp and His with 2 mM 3-AT and incubated at 30 °C for 3-4 days. 
 
3.2.2.2 Assay for the Detection of β-Galactosidase Activity 
One circular filter paper was fitted directly onto the agar plate containing the yeast 
colonies, from 3.2.2.1, and incubated for 10 minutes. Each filter, and the 
corresponding agar plate, was marked with a number so each filter could be matched 
with the corresponding agar plate. The orientation of the filter relative to the agar 
plate was also marked. The filters were placed in liquid nitrogen for 5 minutes. The 
filters were then put into the lid of a Petri dish, colony side up and let thaw for 5 
minutes. Each filter was covered with overlay mix [5 g/L agarose, 1 ml/L bromo-
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chloro-indolyl-galactopyranoside (X-gal) stock solution (0.1 g x-gal, 1 ml N,N-
dimethylformamide), 1x PBS pH 7.4] and incubated at room temperature (20-22 °C) 
overnight. 
 
3.2.2.3 Plasmid Recovery from Yeast and Retransformation in E. coli 
3 ml of SD medium supplemented with Ade, His and Ura and lacking Leu and Trp 
was inoculated with a positive clone and incubated overnight at 30 °C with shaking 
(200-250 rpm). 2 ml of the culture was transferred to a 2 ml tube. The culture was 
centrifuged (5 minutes at 4000 g) and 250 μl resuspension buffer (GeneJet Plasmid 
Miniprep kit) added to the cell pellet and resuspended by vortexing. 100 μg of acid-
washed glass beads were added to the tube and vortexed for 5 minutes. Mini-prep 
plasmid DNA preparations were carried out using the GeneJet Plasmid Miniprep kit. 
TOP10 cells were transformed with 10 ng of DNA, the entire mixture plated onto a 
LB agar plate supplemented with 100 μg/ml ampicillin and incubated at 37 °C 
overnight. Plasmid DNA from two independent colonies was prepared using the 
GeneJet Plasmid Miniprep kit. Minipreps were digested with sfi 1 to release the 
insert of each prey.  
 
3.2.2.4 Confirmation of Positive Interactors 
NMY51 cells previously transfected with the bait construct were streaked onto an 
YPAD agar plate and incubated for 3 days at 37 °C. A single colony was used to 
inoculate SD medium (2 ml per bait/prey pair to be assayed) supplemented with Ade, 
Trp, His, and Ura and lacking Leu. The cells were grown at 30 °C with vigorous 
shaking (220 rpm) to an OD546 of 0.6-0.7. The culture was centrifuged (700 g for 5 
minutes) and the pellet resuspended in 1/20 volume sterile water. For each prey to be 
assayed, 1.5 μg prey plasmid was added to a tube along with 300 μl of PEG/LiOAc 
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mix (240 μl 50 % PEG, 35 μl 1M LiOAc, 25 μl single stranded carrier DNA) and 
100 μl of cells.  
The reactions were vortexed for 1 minute to thoroughly mix all components and 
incubated at 30 °C for 45 minutes (mixing briefly every 15 minutes). The tubes were 
incubated at 42 °C for 45 minutes. The cells were centrifuged (700 g for 5 minutes) 
and each pellet resuspended in 200 μl 0.9 % NaCl. 100 μl of cells were spread onto a 
SD agar plate supplemented with Ade, His and Ura and lacking Leu and Trp with 2 
mM 3-AT and SD agar plates supplemented with Ura and lacking Leu, Ade, Trp and 
His with 2 mM 3-AT. All agar plates were incubated at 30 °C for 3-4 days. 
Subsequent analysis for the detection of β-Galactosidase activity was performed as 
3.2.2.2 
 
3.2.2.5 Library Transformation and Selection of Interactors in the 
Presence of Holo-RBP 
NMY51 cells previously transfected with the bait construct were transfected with a 
human kidney library both in the presence and absence of RBP-ROH, to identify 
proteins that interact with STRA6 in the presence and absence of RBP-ROH. Library 
transformation and confirmation of positive interactors, as described in 3.2.2.1 and 
3.2.2.4 respectively, were performed as before with the inclusion of RBP-ROH on all 
agar plates. The RBP-ROH complex, at a 1:1 molar ratio, was added at the 
concentration of 2.3 M (normal levels of RBP in human serum range approximately 
between 1.9 M and 2.9 M). 
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3.2.3  Detection of Protein Expression 
Protein expression was analysed by SDS-PAGE and Western blotting.  In the 
detection of RBP, α-His-HRP (Roche) was used.   
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3.3 Results and Discussion  
3.3.1 Preparation for Library Screen using STRA6 as Bait  
3.3.1.1 Determination of the Optimum pH for NMY51 Growth  
NMY51 cells, previously transformed with the bait construct, were cultured in SD 
medium with a pH of 6, 6.5, 7 or 7.5. The OD546 was measured for the 4 cultures and 
the optimum pH determined. The culture with a pH of 6 had an OD546 of 0.850. The 
yeast colonies were bright red, as expected. The culture with a pH of 6.5 had an 
OD546 of 0.845, again cells were bright red. The culture with a pH of 7.0 had an 
OD546 of 0.763. The yeast cells were pinkish, which is not expected as this should 
only occur if an interacting bait-prey pair is present. In the absence of a protein-
protein interaction, the ADE2 reporter gene is not transcribed and therefore, a red-
coloured intermediate accumulates in the adenine metabolic pathway. Activation of 
the ADE2 gene by a protein-protein interaction leads to expression of the ADE2 gene 
product and unblocks the pathway. For this reason, NMY51 cells expressing an 
interacting protein pair will display a very faint pink to white colour, depending on 
the strength of the interaction. In the absence of a protein-protein interaction, 
NMY51 displays a pink colour; similar to strains carrying an ade2 mutation. The 
culture with a pH of 7.5 had an OD546 of 0.641. The yeast cells were white in colour, 
which is not expected as this should only occur if a strongly interacting bait-prey pair 
is present. It was therefore concluded that the optimum pH was 6 and this was used 
for all subsequent assays. 
 
3.3.1.2 Transformation of Yeast with the Bait Construct and Control 
Plasmids  
NMY51 cells were transformed with the bait construct or control constructs; pCCW-
Alg5, pPR3-N, pAL-Alg5 or pDL2-Alg5, and streaked onto SD selective agar plates. 
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NMY51 cells successfully transformed with the bait construct or pCCW-Alg5 will 
grow on minimal media lacking Leu as these constructs contain the LEU2 
auxotrophic growth marker. Likewise, NMY51 cells successfully transformed with 
pPR3-N, pAL-Alg5 or pDL2-Alg5 will grow on minimal media lacking Trp as these 
constructs contain the TRP1 auxotrophic growth marker. After 3-4 days the selective 
agar plates (lacking Leu, Bait and pCCW-Alg5 or Trp, pPR3-N, pAL-Alg5 and 
pDL2-Alg5) had over one hundred colonies, indicating transformation was 
successful. The transformed yeast cells were also spread on SD selective agar plates 
lacking both Leu and Trp. As expected, there was no growth on these agar plates 
indicating that growth on selective agar plates lacking Leu or Trp were specific and 
not due to contaminants.   
 
3.3.1.3 Verifying Bait Expression and Functionality 
The pAI-Alg5 construct expresses a fusion of the yeast ER protein Alg5 and the wild 
type Nub portion of yeast ubiquitin, whereas pDL2-Alg5 expresses a fusion of the 
same protein to the Nub portion bearing the isoleucine to glycine mutation at 
position 13 (NubG). If the bait is properly inserted into the membrane of yeast and 
the Cub-LexA-VP16 moiety is located on the cytosolic side of the membrane, 
coexpression of the bait with pAI-Alg5 results in rapid formation of split ubiquitin 
due to the strong affinity of wild type Nub for Cub. Consequently, the reporter genes 
are activated by LexA-VP16 cleaved off the bait by the UBPs. Reporter gene 
activation is assayed by growing the yeast transformants on selective media. 
Coexpression of the bait with pDL2-Alg5 should not lead to split ubiquitin formation 
as NubG has low affinity for Cub and the bait is unlikely to interact with Alg5. 
Consequently, yeast coexpressing the bait and Alg5-NubG should not grow on 
selective media and should be negative in the β-galactosidase assay. The control 
assay determines whether the bait is functional in the assay and whether it displays 
any Nonspecific background. 
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As illustrated in Figure 3.1, coexpression of the bait together with Alg5-NubI 
resulted in over one hundred colonies being present after transformation, signifying 
that the bait is expressed in the MYTH. Coexpression of the bait together with 
pDL2-Alg5 resulted in no colonies on selective agar plates, signifying there is no 
nonspecific background.  
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Figure 3.1: Verification of Bait Expression and Functionality 
Bait and pAL-Alg5 coexpressed in yeast and streaked on selective agar 
plates lacking (A) Leu and Trp, (B) Leu, Trp and His, (C) Leu, Trp, His and 
Ade.                                   
Bait and pDL2-Alg5 coexpressed in yeast and streaked on selective agar 
plates lacking (D) Leu and Trp,  (E) Leu, Trp and His, (F) Leu, Trp, His and 
Ade.  
Only coexpression of STRA6 with pAL-Alg5 resulted in growth on 
selective agar plates lacking Leu, Trp, His and Ade, indicating STRA6 is 
expressed. 
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3.3.1.3 Optimizing the Screening Stringency using a Pilot Screen 
The pilot screen simulates the conditions of a library screen but instead of a cDNA 
library, the corresponding empty library vector is transformed into the bait-bearing 
strain. The transformation mixture is then plated onto selective agar plates of 
increasing stringency supplemented with different amounts of 3-AT. Only when the 
bait construct and library vector interact should there be growth on agar plates 
lacking Leu, Trp, Ade and His. This is due to the fact that the reporter genes used in 
the MYTH are two auxotrophic growth markers (HIS3 and ADE2), whose activation 
enables the yeast to grow on defined minimal media lacking His or Ade, this is in 
addition to the auxotrophic growth markers (LEU2 and TRP1) expressed when 
NMY51 is successfully transformed with the two constructs. Since the bait is 
coexpressed with unfused NubG (expressed in the empty library vector pPR3-N), 
any colonies that arise on the selective agar plates must be background. Any 
background is due to the slight leakiness of the HIS3 gene. The pilot screen aims to 
adjust the screening conditions such that, in the following library screen, the absolute 
minimum of false positives are possible. Slight background growth on the selection 
agar plates can be removed by the addition of 1-10 mM 3-AT to the selection 
medium. As a competitive inhibitor of the HIS3 gene product, increasing levels of 3-
AT increase the stringency of HIS3 selection.  
NMY51 cells were transformed with the bait construct and the empty library vector 
and streaked onto selective agar plates. To find the optimal 3-AT concentration, 
selection agar plates were supplemented with 0, 1, 2, 5, 7.5 and 10 mM 3-AT. 2mM 
3-AT was found to eradicate all background, illustrated in Figure 3.2, and was 
therefore used in all subsequent assays.  
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Figure 3.2: Use of 3-Aminotriazole to Increase the Stringency of HIS3 Selection 
3-AT was used to remove any background due to leakiness of the HIS3 
gene. The bait construct and the empty library vector were coexpressed in 
yeast and streaked on selective agar plates lacking Leu, Trp, His and Ade 
with increasing amounts of 3-AT, (A) O mM (B) 1 mM (C) 2 mM. 2 mM 3-
AT was found to eradicate all background colonies and was used for 
subsequent experiements.                       
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3.3.1.4 Expression of RBP  
A large amount of soluble and active recombinant human RBP was required for use 
in the MYTH. Human RBP has been purified from plasma or urine, or produced as a 
recombinant protein expressed as inclusion bodies in Escherichia coli. In the first 
case, its affinity for TTR makes it long-winded to purify from blood, involving first 
a partial purification of the RBP–TTR complex and then a separation of both 
proteins by various methods. In the second, the recombinant RBP is expressed as 
inclusion bodies so requires a denaturation and refolding process to be active. 
Fortuitously, RBP has recently been successfully expressed using the methylotrophic 
yeast P. Pastoris (Wysocka-Kapcinska et al., 2010) without the need for laborious 
separation or refolding techniques and this system was employed. The human 
recombinant RBP, with an N-terminal His-tag to aid efficient purification, was 
successfully expressed under the control of the alcohol oxidase (AOX1) methanol 
inducible promoter and was secreted into the medium through the cell wall by the S. 
cerevisiae α-factor signal sequence, using the pPICZ-αA expression vector.  Protein 
was purified using Ni-NTA agarose, as illustrated in Figure 3.3. Protein was in large 
enough quantities, ~ 15 mg/ 4 L culture, and sufficiently pure to proceed to the 
functional characterisation. 
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Figure 3.3: Purification of RBP 
Representative Western blot showing fractions from the purification of RBP, 
as detected by α-His-HRP antibodies. 5 µl loaded per well. RBP was 
expressed in P. Pastoris. The protein was secreted into the medium, filtered 
to remove contaminants and incubated with Ni-NTA agarose. The 
supernatant (FT) was collected and the resin washed once (W) prior to 
elution of any bound material (ELUT). RBP was found to be migrating at an 
expected ~ 21 kDa and was found to be predominantly in the eluate. 
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3.3.1.5 Functional Characterisation of RBP 
The functionality of recombinant RBP was evaluated by testing its capacity to bind 
increasing concentrations of retinol. Upon excitation at 280 nm, the protein exhibited 
the typical fluorescence of the holo form: one peak with a maximum at 335 nm 
caused by the protein itself, and a second with a maximum at 470 nm, due to retinol 
bound to the protein. Retinol quenches the intrinsic RBP tryptophan fluorescence 
due to energy transfer to the vitamin resulting in an emission fluorescence peak at 
470 nm. 
3.3.2 Library Screen using STRA6 as Bait  
3.3.2.1 Library Transformation and Selection of Interactors 
An oligo(dT)-primed, size-selected (0.4–5 kb; average insert size, 1.3 kb) human 
cDNA library (kidney or brain) with 3 × 106 independent clones was constructed in 
the prey vector, pPR3-N, by Dualsystems Biotech and inserted N-terminally (in the 
case of the kidney library) and C-terminally (in the case of the second kidney library 
and the brain library) to the NubG sequence, generating the library in X-NubG and 
NubG-X orientation respectively (where X is a genomic DNA).  The yeast reporter 
strain NMY51 expressing the C-terminal tagged STRA6 bait was transformed with 
the cDNA library, yielding transformation efficiencies in the range of 5 × 105 to 2 × 
106 clones/μg DNA. Transformed NYM51 cells were streaked on selective agar 
plates to select for colonies containing interacting bait-prey pairs.  Library plasmids 
were isolated from positive clones and further processed for β-Galactosidase activity. 
 
3.3.2.2 Assay for the Detection of β-Galactosidase Activity 
In addition to the growth reporters HIS3 and ADE, the MYTH has the colour reporter 
lacZ. The lacZ gene encodes the bacterial enzyme β-galactosidase, which converts 
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the substrate X-gal into a blue compound. Yeast cells expressing β-galactosidase 
therefore turn blue when incubated with X-gal.  
β-Galactosidase expression was monitored using a colony lift filter assay with X-gal. 
Colonies expressing interacting bait-prey pairs were picked and restreaked on 
selective agar plates for the β-galactosidase assay, as illustrated in Figure 3.4. All 
clones positive for β-galactosidase were isolated, amplified in Escherichia coli, and 
analysed by restriction analysis for insert sizes.  
75 
 
C h a p t e r  3 | M e m b r a n e  Y e a s t  T w o  H y b r i d  |  
  
 
  
 
Figure 3.4:  Assay for the Detection of β-Galactosidase Activity 
The bait construct and prey plasmids, (A) Stress Associated Endoplasmic 
Reticulum Protein 1 (SERP1) (B) CD63, (C) PDZK1-Interacting protein 
1(PDZK1-IP1), (D) Proteolipid Protein 2 (PLP2), (E) osteopontin, (F) 
Ovarian Cancer Immuno Reactive Antigen Domain Containing Protein 2 
(OCIAD2), were coexpressed in yeast and streaked on minimal medium 
lacking Leu, Trp, His and Ade. Colonies were isolated using filter paper and 
the assay for β-Galactosidase activity was performed.  (A) - (F) Interacting 
bait-prey pairs, all positive in the β-Galactosidase activity assay, indicating 
that a strong interacting occurs.  
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3.3.2.3 Plasmid Recovery from Yeast and Retransformation in E. coli 
After the identification of colonies containing interacting bait-prey pairs, the next 
step is to isolate the library plasmid encoding the putative interactor. Each interactor 
was cultured in liquid medium, the yeast lysed and the bait and library plasmids 
purified. E. coli was transformed with the plasmid mix and the library plasmid 
selectively propagated on LB agar plates containing the antibiotic kanamycin. Since 
the library plasmids carry a kanamycin marker, whereas the bait plasmid carries an 
ampicillin marker, only E. coli which have taken up a library plasmid are able to 
grow under selection. 
As yeast can take up several plasmids during the transformation procedure, two E. 
coli colonies were picked from each transformation. Plasmids were prepared and 
digested with the restriction enzyme Sfi I, releasing the cDNA insert. If only one 
library plasmid was originally introduced into yeast, both digests will show an insert 
of the same size, illustrated in Figure 3.5. If the two inserts differ in size, the original 
yeast clone contained more than one library plasmid and both plasmids are then used 
for the confirmation assay as described in 3.2.2.5.  
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Figure 3.5: Isolation of Prey Plasmids  
Transformed NYM51 cells were streaked on selective agar plates to select 
for colonies containing interacting bait-prey pairs.  Library plasmids were 
isolated from positive clones and digested with the restriction enzyme Sfi I, 
releasing the cDNA insert. If only one library plasmid was originally 
introduced into yeast, both digests will show an insert of the same size. If 
the two inserts differ in size, the original yeast clone contained more than 
one library plasmid and both plasmids are then analysed further. 1-7 (a and 
b) represent positive clones, with some having inserts of the same size (such 
as 4a and 4b) and others (such as 1a and 1b) have inserts of different sizes.  
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3.3.3 Confirmation of Positive Interactors  
3.3.3.1 Confirmation of Positive Interactors (Kidney Library) 
Like any genetic selection system, the MYTH will isolate a certain number of false 
positives. These clones will result in growth on selective agar plates independent of a 
true interaction between the bait and a prey. False positives are eliminated by 
retransforming the isolated prey plasmids with the original bait plasmid. Only preys 
that yield colonies on selective agar plates when coexpressed with the bait are 
considered as true positives, as illustrated in Figure 3.6, and analysed further.  
The kidney library (X-NubG and NubG-X) contained a total of 130 colonies which 
scored as positives for the activation of the HIS3/ADE2/lacZ reporter genes. 47 of 
these potential hits were found to be true positives following retransformation into 
yeast along with the bait construct and subsequent assay for the detection of β-
Galactosidase activity. The plasmids were sent for sequencing and the prey plasmid 
identified using basic local alignment search tool (BLAST). The plasmids encoded: 
SERP1 (isolated from four colonies), CD63 (isolated from two colonies) and 
PDZK1-IP1 (isolated from one colony).  
All other potential hits were either expected hits such as ubiquitin, common false 
positives such as 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, which appears 
in approximately 22 % of screens, or partial hits which are not considered to be true 
interactors. Partial hits contain only part of the open reading frame of a protein.   
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Figure 3.6:  Confirmation of Positive Interactors 
The bait construct and isolated prey plasmid coexpressed in yeast and plated 
on selective agar plates lacking (A) Leu and Trp, (B) Leu, Trp, His and Ade 
(with 2mM 3-AT). 
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3.3.3.2 Confirmation of Positive Interactors (Brain Library) 
The brain library (NubG-X) contained 104 colonies which scored as positives for the 
activation of the HIS3/ADE2/lacZ reporter genes. 40 of these potential hits were 
found to be true positives following retransformation into yeast along with the bait 
construct and subsequent assay for the detection of β-Galactosidase activity. The 
plasmids were sent for sequencing and the prey plasmids identified using BLAST. 
The plasmids encoded: CD63 (isolated from three colonies), SERP1 (isolated from 
fourteen colonies), PDZK1-IP1 (isolated from one colony) and PLP2 (isolated from 
one colony).  
All other potential hits were either expected such as ubiquitin, common false 
positives such as B-cell receptor-associated protein 31, which appears in 
approximately 25% of screens, or partial hits which are not considered to be true 
interactors.  
 
3.3.3.3 Confirmation of Positive Interactors (Kidney Library +/-RBP-
ROH) 
NMY51 cells were transformed with the bait construct and the human kidney library 
(X-NubG and NubG-X) and streaked on selective agar plates supplemented with 
holo-RBP. After isolation, resulting prey plasmids were reintroduced into yeast with 
the original bait plasmid and again the cells were streaked on selective agar plates 
supplemented with holo-RBP. Prey plasmids were also streaked on selective agar 
plates that were not supplemented with holo-RBP. All prey-bait pairs that had 
growth on selective agar plates supplemented with holo-RBP also grew on selective 
agar plates that did not contain holo-RBP. This implies that the interactions are not 
dependent on the presence of holo-RBP. 
The kidney library (X-NubG and NubG-X) contained a total of 144 colonies which 
scored as positives for the activation of the HIS3/ADE2/lacZ reporter genes. 30 of 
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these potential hits were found to be true interactors following reintroduction of prey 
plasmids and the bait construct in yeast and subsequent analysis for the detection of 
β-Galactosidase activity. The plasmids were sent for sequencing and the hits 
identified using BLAST. The plasmids encoded: SERP1 (isolated from four 
colonies), PDZK1-IP1 (isolated from two colonies), OCIAD2 (isolated from one 
colony), CD63 (isolated from two colonies), MIF (isolated from one colony), CCL2 
(isolated from one colony), osteopontin (isolated from one colony), IFITM1 (isolated 
from two colonies), IFITM3 (isolated from one colony) and CXCL14 (isolated from 
one colony). All other potential hits were either expected hits such as ubiquitin, 
common false positives or partial hits which are not believed to be true interactors.  
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3.4 Concluding Discussion  
To elucidate any other role STRA6 may play in the body, novel protein interactions 
for STRA6 were explored. Proteins of known function tend to cluster together, with 
63 % of interactions occurring between proteins with a common functional 
assignment. Possible functions can therefore be assigned to a protein based on the 
known functions of its interacting partners (Schwikowski et al., 2000).  
The MYTH was employed to identify novel protein interactions for STRA6. Three 
screens were performed using STRA6 as the bait; a human kidney library screen, a 
human brain library screen and a human kidney library screen in the presence of 
holo-RBP. These libraries were chosen as STRA6 is expressed in both the kidney 
and brain (Bouillet et al., 1997). The kidney library was also screened in the 
presence of holo-RBP, in order to detect any protein interactions dependent on the 
presence of holo-RBP. Interestingly, it was recently reported that STRA6 interacts 
with CRBP only in the presence of holo-RBP (Berry et al., 2012b). 
All three screens resulted in 117 clones that induced activation of reporter genes in 
the presence of the STRA6. Only clones encoding full-length sequences in-frame 
with the N-terminal half of ubiquitin in pPR3-N were considered to be potential true 
interactors. Common false positives were also eliminated using information provided 
by Dualsystems Biotech, resulting in 11 unique protein interactors for STRA6. The 
human kidney library identified CD63, PDZK1-IP1 and SERP1 as potential STRA6 
interactors. The human brain library identified CD63, PDZK1-IP1, SERP1 and PLP2 
as potential STRA6 interactors. The human kidney library, in the presence of RBP-
ROH, identified CD63, PDZK1-IP1 and SERP1 as potential STRA6 interactors as 
well as previously undetected proteins; MCP-1, CCL2, CXCL14, IFITM1, IFITM3, 
MIF, OCIAD2, and osteopontin. These 11 proteins, 3 of which appeared in all three 
screens, need now to be verified independently of the MYTH and their biological 
relevance explored, this will be discussed in the next chapter.  
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Chapter 4 Hit Verification 
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4.1 Introduction 
The MYTH was used to identify potential PPIs for STRA6, the RBP receptor. The  
gene coding for this receptor was identified in 2008 (Kawaguchi et al., 2007) and 
since then a large amount of work has been conducted, aimed at identifying any 
other function the receptor may have (Kawaguchi et al., 2012, Berry and Noy, 2012, 
White et al., 2008). However, many questions regarding STRA6 remain unanswered, 
such as, does STRA6 act to regulate insulin responsiveness (Berry and Noy, 2012) 
and if so, how does STRA6 play a role in mediating insulin resistance and T2D? 
Furthermore, what role does STRA6 play in cancer biology (Szeto et al., 2001) and 
are the devastating consequences of human mutations only related to the disruption 
of the potential supply of retinol to the developing tissues (Pasutto et al., 2007) or are 
they a consequence of the interruption of other functions STRA6 may have. What is 
more, due to its implication in these disease states, STRA6, or any protein(s) which 
regulates its function, may potentially be drug targets.  
Undoubtedly, the function of STRA6 and its implication in disease needs to be 
established. Exploring interactions for STRA6 may answer these questions. Since 
PPIs play a role in nearly all events that take place in a cell, clues to the function of 
an uncharacterised protein can be obtained by investigating its interaction with other 
proteins whose functions are already known, termed “guilt by association” 
(Auerbach et al., 2002). The MYTH was chosen owing to the success of the YTH in 
detecting PPIs: it has been estimated that more than 50 % of all interactions 
described in the literature have been detected by the YTH (Xenarios et al., 2001). 
Using the MYTH, 11 novel protein interactions for STRA6 were detected. 
Generally, proteins are more likely to be true interactors, and are therefore 
considered to be potentially biologically relevant, if they share common features 
including, colocalization, functional correlation and shared interaction partners. The 
MYTH only detects protein interactions with cytosolic or membrane proteins as both 
Cub and NubG need to be located in the cytosol for the activation of reporter genes. 
Secreted hits include CCL2, CXCL14, and MIF. CCL2 is one of the key chemokines 
that regulate migration and infiltration of macrophages and is induced in various 
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diseases (Deshmane et al., 2009). CXCL14 is a member of the CXC chemokine 
family with unknown function (Wente et al., 2008). MIF is released by immune cells 
and activates ERK1/ERK2 signalling, upregulates TLR4 expression, suppresses p53 
activity and inhibits JABY activity (Calandra and Roger, 2003). As secreted 
proteins, CCL2, CXCL14 and MIF are not located at the plasma membrane with 
STRA6. These proteins may interact with STRA6 in the ER and could have a 
regulatory role in the trafficking of STRA6.  
SERP1 was the only hit detected that is expressed solely in the ER. SERP1, also 
known as ribosome-associated membrane protein 4 (RAMP4), is a Sec61-associated 
polypeptide that is induced by ER stress. SERP1 controls the glycosylation of major 
histocompatbility complex class II–associated invariant chain and interacts directly 
with calnexin, a membrane protein and molecular chaperone in the ER (Yamaguchi 
et al., 1999). Again, as an ER protein, SERP1 is not located at the plasma membrane 
with STRA6. This protein may interact with STRA6 in the ER and could have a 
regulatory role in the trafficking of STRA6. 
MYTH hits which are classed as; integral membrane proteins, membrane-associated 
proteins or cytoplasmic proteins could possibly interact with STRA6 at the plasma 
membrane.  CD63 and PDZK1-IP1, both of which appeared in all 3 screens, as well 
as PLP2 are all integral membrane/membrane-associated proteins. CD63 is a 
ubiquitously expressed protein found in late endocytic organelles and on the plasma 
membrane (Latysheva et al., 2006) and is a member of the tetraspanins, a large 
family of four transmembrane domain proteins (Tugues et al., 2013). Tetraspanins 
are believed to control compartmentalization of associated receptors into specialized 
protein networks or microdomains (also called tetraspanin-enriched microdomains, 
or TERMs). TERMs have been shown to regulate cell motility, trigger homotypic 
cell aggregation, and participate in various types of cell fusion and signalling 
through their ability to act as “molecular facilitators”, grouping specific cell-surface 
proteins and thus increasing the formation and stability of functional signalling 
complexes (Hemler, 2001, Maecker et al., 1997).  CD63 may function as a specific 
anchor of proteins in TERMs (Latysheva et al., 2006). PDZK1-IP1 or MAP17 is a 17 
kDa membrane associated protein expressed on both the plasma membrane and 
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golgi. The protein was first identified as a PDZK1 interacting protein in a yeast two 
hybrid screen (Kocher et al., 1998) and may regulate PDZK1 turnover (Silver et al., 
2003). Considering the previously reported function of these proteins, CD63 and 
PDZK1-IP1 may act to regulate the activity of STRA6 or/and anchor the protein in 
TERMs. Proteolipid protein 2 (PLP2) or A4 associates with chemokine receptor 1 
(CCR1) on the plasma membrane and may be involved in chemotaxis mediated by 
CCR1 (Lee et al., 2004).  PLP2 has appeared before in numerous MYTH screens and 
may be a common false positive in the MYTH (Pope and Lee, 2005, Lee et al., 
2004).  
IFITM1 and IFITM3 are also cell membrane proteins (Tanaka et al., 2005) and are 
both members of the interferon-inducible transmembrane protein family 9 (Yount et 
al., 2012). IFITM1 and IFITM3 play a key role in the antiproliferative action of 
Interferon-  (IFN- ). Considering the previously reported function of these 
proteins, it is unclear why they would interact with STRA6 and to what end. 
Osteopontin (OPN) or secreted phosphoprotein 1 (SPP1) (Fernández et al., 2011) is 
an highly phosphorylated, glycosylated  protein, and cytokine, found in all body 
fluids and the extracellular matrix of mineralised tissues (Huang et al., 2004, 
Denhardt and Noda, 1998), but is now known to have an intracellular function. 
Intracellular OPN can contribute to the diverse biological activities of OPN 
involving developmental, regenerative processes, immune defence and tumour-cell 
survival and metastasis (Sodek et al., 2002). OPN is a negative regulator of 
osteogenesis by inhibiting both proliferation and differentiation of osteoblastic cells 
(Huang et al., 2004). Interestingly, OPN expression has been found to be induced by 
RA (Park et al., 1997, Sodek et al., 2002, Harada et al., 1995). This provides a 
potential link to STRA6, as STRA6 is also induced by RA (Bouillet et al., 1997). 
OCIAD2 is a member of the OCIAD domain family. OCIAD2 was originally 
identified by its sequential similarity with ovian carcinoma immunoreactive antigen 
1.  However, the biological function of OCIAD2 has not been elucidated (Ishiyama 
et al., 2007).  OCIAD2 was previously detected by a colleague, Dr. Conor Breen, in 
an assay to identify any protein(s) that copurify with STRA6. In this assay, STRA6 
was overexpressed in HEK293T cells and purified using a strep-tactin resin. Any 
proteins that copurified with STRA6 were identified using mass spectrometry 
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(unpublished data). OCIAD2 was the only protein detected in both assays and for 
this reason, OCIAD2 is of particular interest.   
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Aims and Objectives  
The MYTH enables the identification of proteins that interact with a plasma 
membrane protein of interest.  Using STRA6 as the bait, we have screened a human 
kidney library, both in the presence and absence of holo-RBP and a human brain 
library in the absence of holo-RBP, to identify 117 protein sequences, or hits, that 
interact with STRA6. After the elimination of partial sequences and common false 
positives, 11 proteins remained. In the MYTH, due to overexpression and the 
elimination of proteins residing in different cellular compartments, detection of 
interactions that do not occur in vivo can occur. Therefore all potential interactions 
need to be verified independently of the MYTH (Lalonde et al., 2008) 
A stable HEK293T cell line inducibly expressing STRA6, containing HA 
(YPYDVPDYA) and StrepII tags (WSHPQFEK) on either the N- or C-terminus, 
was generated.  The StrepII tag allows affinity purification of STRA6 on a Strep-
Tactin resin, an engineered form of Streptavidin. This cell line was used to verify 
STRA6’s interaction with the hits. HEK293T lysates overexpressing the hits, 
purchased from Origene, were incubated with STRA6 bound to the Strep-Tactin 
resin. Any nonspecifically bound proteins were removed by washing the resin or 
alternatively, the rapid centrifugation through oil. Proteins interacting with STRA6 
were eluted from the resin along with STRA6 by the addition of elution buffer 
containing imidazole or 2xSDS buffer. Samples were taken for subsequent analysis 
by SDS-PAGE and Western blotting.  In addition, CD63, PDZK1-IP1, OCIAD2 and 
osteopontin were obtained in mammalian expression vectors (pcDNA3.1; for CD63 
and PDZK1-IP1, along with a HA tag, or pCMV6-entry; for OCIAD2 and 
osteopontin, along with  Myc and DDK tags). The stable HEK293T cell line 
inducibly expressing STRA6 was transfected with vectors coding for CD63, 
PDZK1-IP1, OCIAD2 or osteopontin. STRA6 was purified using the Strep-Tactin 
resin. Any nonspecifically bound proteins were removed by washing the resin or 
alternatively, rapid centrifugation through oil. Proteins interacting with STRA6 were 
eluted from the resin along with STRA6 by the addition of elution buffer containing 
imidazole or 2xSDS buffer. Samples were taken for subsequent analysis by SDS-
PAGE and Western blotting. CD63 and PDZK1-IP1 were expressed along with 
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STRA6 as they were considered to be in all likelihood true interactors due to their 
location at the plasma membrane and the fact that they were detected in all three 
screens. OCIAD2 and osteopontin were expressed along with STRA6 as they were 
believed to be of particular interest as osteopontin is induced by RA and OCIAD2 
was previously detected by Dr. Conor Breen in a mass spectrometry screen to 
identify proteins that copurify with STRA6  (unpublished data). Expression of these 
hits along with STRA6 in mammalian cells, given that the interaction is first verified 
by pull-down assays, allows for subsequent characterisation of the interaction, such 
as co-localization and knock-out studies.  
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4.2 Materials and Methods 
4.2.1 Expression and Purification of STRA6 in Pichia pastoris 
4.2.1.1 Expression of STRA6  
The coding sequence for human STRA6 (UniProt entry Q9BX79), in the expression 
vector pPICZA, designed to incorporate the gene encoding a green fluorescent 
protein (GFP) from the jellyfish Aequorea victoria as a marker of gene expression 
and a 6xHis tag, was a kind gift from Dr. Conor Breen. P. pastoris cells previously 
transformed with the STRA6  construct were streaked on a YPDS agar plate (10 g/L 
yeast extract, 20 g/L peptone, 182.2 g/L sorbitol, 2 % dextrose, 20 g/L agar) 
supplemented with 2 mg/ml Zeocin  and incubated at 30 °C for 48 hours. One colony 
was used to inoculate 10 ml BMGY (10 g/L yeast extract, 20 g/L peptone, 100 ml/L 
1M potassium phosphate buffer, 6.9 g/L yeast nitrogen base with ammonium sulfate 
without amino acids (YNB), 0.04 mg/L biotin, 10 ml/L glucose, pH 6.0) and 
incubated for 48 hours at 30 °C with shaking (220 rpm). The 10 ml culture was 
transferred to 400 ml BMMY (10 g/L yeast extract, 20 g/L peptone, 182.2 g/L 
sorbitol, 10 ml/L methanol) and incubated for 4 hours at room temperature (20-22 
°C) with constant shaking (220 rpm). After 4 hours, 0.5 % methanol (2 ml) was 
added to the culture and incubation continued for 24 hours at room temperature (20-
22 °C) with shaking (220 rpm). After 24 hours, 1 % methanol (4 ml) was added to 
the culture and incubation continued for 48 hours at room temperature (20-22 °C) 
with constant shaking (220 rpm). After 48 hours, an additional 1 % methanol (4 ml) 
was added to the culture and incubation continued for 24 hours at room temperature 
(20-22 °C) with constant shaking (220 rpm). The culture was centrifuged (700 g for 
10 minutes at 4 °C) and the supernatant was aspirated to waste. The pellet was 
resuspended in 15 ml cold wash buffer (4.585 g/L TES, 7.948 g/L NaCl, 0.022 g/L 
KCL, 0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4, 2.92 g/L 1x EDTA, pH 8.0).  The 
cells were centrifuged (700 g for 10 minutes at 4 °C) and the supernatant aspirated to 
waste. The pellets were weighed and yeast spaghetti produced by pressing yeast 
through a 50 ml tube with small holes into a beaker filled with liquid nitrogen. The 
holes were punched into the bottom of a 50 ml tube containing 10-20 ml of pellet 
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yeast. Pressure was created by manually inserting a piston of a 60 ml disposable 
syringe into the tube. The yeast spaghetti was stored at -80 °C prior to lysis and 
purification.  
 
4.2.1.2 Lysis and Purification of STRA6  
A ball mill (Retsch MM301) was used for cryogenic disruption of yeast cells. The 
yeast spaghetti, in a 50 ml tube, was cooled in liquid nitrogen along with a stainless 
steel grinding jar and grinding ball. Once cooled, the grinding jars were removed 
from the bath and emptied. The yeast spaghetti and grinding ball was transferred into 
the grinding jar. The jar was closed and transferred back into the liquid nitrogen bath 
for five minutes before being installed on the ball mill. The jar clamps were 
tightened. Grinding was done in five cycles of 3 minutes at 30 hz. Between each 
grinding cycle, the jars were removed from the mill and submerged into the liquid 
nitrogen bath. Grinding was continued once the bath boiling had subsided. Ground 
yeast cells were transferred into a 50 ml tube and resuspended in 5 ml lysis buffer 
(4.585 g/L TES, 7.948 g/L NaCl, 0.022 g/L KCL, 0.575 g/L Na2HPO4, 0.131 g/L 
NaH2PO4, 10µM EDTA, 0.5 g/L TCEP, 0.78 g/L β-mercaptoethanol, 1x EDTA-free 
protease inhibitor cocktail, 0.174 g/L PMSF, pH 8.0). The mixture was incubated for 
60 minutes at 4 °C under gentle agitation by rolling. The mixture was centrifuged 
(10 minutes at 1,500 g at 4 °C). The supernatant was added to a 5 ml pollyallomer 
Optiseal tube (Beckman) and centrifuged (150,000 g for 90 minutes at 4 °C) to 
isolate the membranes. The supernatant was aspirated to waste and the pellet was 
stored at -80 °C or preceded to solubilisation and purification.  
300 l of membrane solubilisation buffer (4.585 g/L TES, 7.948 g/L NaCl, 0.022 g/L 
KCL, 0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4, 0.5 g/L TCEP, 0.78 g/L β-
mercaptoethanol, 1x EDTA-free protease inhibitor cocktail, 0.174 g/L PMSF, 10 % 
v/v glycerol, 3 % DDM, pH 8.0) was added to the pellet and the pellet resuspended 
with the aid of a paintbrush. The resuspended cells were transferred to a new tube. 
300 l of membrane solubilisation buffer was used twice more to rinse the original 
tube and all 900 µl pooled. The resuspended cell membranes were passed through a 
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25-gauge needle twice and added to 4.1 ml of membrane solubilisation buffer. The 
mixture was incubated for 3 hours at 4 °C. 1.5 ml Ni-NTA agarose was pre-
equilibrated in column binding buffer (4.585 g/L TES, 7.948 g/L NaCl, 0.022 g/L 
KCL, 0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4, 0.5 g/L TCEP, 0.78 g/L β-
mercaptoethanol, 1x EDTA-free protease inhibitor cocktail, 0.174 g/L PMSF, 2.72 
g/L imidazole, 0.1 % DDM, pH 8.0) before being added to the solubilised pellet and 
incubated for 90 minutes at 4 °C. The mixture was added to a 5 ml column at 4 °C. 
The resin was allowed to settle and the flow-through was collected. The column was 
washed with 5 ml wash buffer 1 (4.585 g/L TES, 66.39 g/L NaCl, 0.022 g/L KCL, 
0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4, 0.5 g/L TCEP, 0.78 g/L β-
mercaptoethanol, 1x EDTA-free protease inhibitor cocktail, 0.174 g/L PMSF, 10 % 
(v/v) glycerol, 2.72 g/L, 1 % DDM, pH 8.0) and 5 ml wash buffer 2 (4.585 g/L TES, 
7.948 g/L NaCl, 0.022 g/L KCL, 0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4, 0.5 g/L 
TCEP, 0.78 g/L β-mercaptoethanol, 1x EDTA-free protease inhibitor cocktail, 0.174 
g/L PMSF, 1 % DDM ,6.8 g/L imidazole, pH 8.0).  The protein was eluted by the 
addition of 5 ml elution buffer (4.585 g/L TES, 7.948 g/L NaCl, 0.022 g/L KCL, 
0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4, 0.5 g/L TCEP, 0.78 g/L β-
mercaptoethanol, 1x EDTA-free protease inhibitor cocktail, 0.174 g/L PMSF, 10.21 
g/L imidazole, 1 % DDM, pH 8.0) to the column. Protein was dialysed to remove 
imidazole. Protein was concentrated and resuspended in a buffer (4.585 g/L TES, 
7.948 g/L NaCl, 0.022 g/L KCL, 0.575 g/L Na2HPO4, 0.131 g/L NaH2PO4) 
supplemented with glycerol and DDM to give a final concentration of 10 % glycerol 
with 1 % DDM. Samples were taken for subsequent analysis by Coomassie Brilliant 
Blue staining of SDS-PAGE gels and Western blotting.  
 
93 
 
C h a p t e r  4 | H i t  V e r i f i c a t i o n  |  
   
4.2.2 Expression and Purification of 6xHis Tagged STRA6 in    
 Mammalian Cells 
4.2.2.1 Expression of STRA6 
STRA6 (UniProt Q9BX79) with a 6xHis tag in the mammalian expression vector 
pcDNA3.1 was a kind gift from Dr. Darren Martin 
HEK293T cells were cultured at 37 °C in a humidified atmosphere (5 % CO2 / 95 % 
O2) in DMEM (supplemented with 10 % (v/v) heat-inactivated foetal bovine serum 
(FBS), penicillin and streptomycin [1 % (v/v)] and 1 % glutamine).  Cells were 
grown as adherent monolayers to between 60-70 % confluence prior to transfection 
with empty vector or the STRA6 construct.  HEK293T cells were transiently 
transfected using FuGENE® 6, according to the manufacturer’s instructions.   
At 48 hours post-transfection, growth medium was removed and cells washed in ice-
cold PBS. Flasks were agitated until all cells were in suspension, at which time cells 
were harvested (700 g for 5 minutes).  The supernatant was removed and discarded. 
Cells were stored at -80 °C or used to determine protein expression; Pellets were 
resuspended in 2 ml PBS, 80 µL of which was added to 20 µL of 5x SDS buffer. 
Cells were sonicated for 10 seconds at 10 % power on ice and heated at 70 °C for 5 
minutes. Cells were centrifuged (17,000 g for 5 minutes) and the supernatants 
collected. Protein expression was determined by SDS-PAGE and Western blotting. 
 
4.2.2.2 Lysis and Purification of STRA6  
Cell pellets were resuspended in 2 ml hypotonic buffer (47.66 g/L HEPES, 2.86 g/L 
MgCl2, 14.92 g/L KCl, 1.54 g/L DTT, 0.5 g/L TCEP, 0.78 g/L β-mercaptoethanol, 
1x EDTA-free protease inhibitor cocktail, 0.174 g/L PMSF). The cells were ruptured 
by sonicating the sample for 1 minute at 20 % power on ice. The mixture was 
converted to a 5 ml pollyallomer optiseal tube and centrifuged (1 hour at 100,000 g 
at 4 °C). The supernatant was discarded and the pellet was resuspended in 250 µl 
lysis buffer (6.9 g/L NaH2PO4H2O, 17.54 g/L NaCl, 0.68 g/L imidazole, 3 % DDM, 
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1x EDTA-free protease inhibitor cocktail, pH 8.0). The resuspended pellet was 
passed through a 25-gauge needle using a 1 ml syringe. The mixture was incubated 
on ice for 30 minutes and agitated occasionally. The mixture was sonicated at 10 % 
power for 30 seconds on ice and centrifuged (5 minutes at 17,000 g) to remove the 
insoluble fraction. 500 µl of Ni-NTA agarose was re-equilibrated in wash buffer (6.9 
g/L NaH2PO4H2O, 17.54 g/L NaCl, 1.36 g/L imidazole, 0.5 % DDM, 1x EDTA-free 
protease inhibitor cocktail, pH 8.0). The resin was added to the solubilised pellet and 
incubated overnight or for 90 minutes at 4 °C. The resin was centrifuged (700 g for 5 
minutes) and the supernatant was collected. The resin was washed twice with 500 µl 
wash buffer, centrifuged (700 g for 5 minutes) and the washes collected. The protein 
was incubated with 300 µl elution buffer (6.9 g/L NaH2PO4H2O, 17.54 g/L NaCl, 
0.68 g/L imidazole, 0.5 % DDM, 1x EDTA-free protease inhibitor cocktail, pH 8.0) 
for 5 minutes, centrifuged (700 g for 5 minutes) and the eluate collected. Protein 
expression was determined by SDS-PAGE and Western blotting. Following 
purification, protein concentrations were determined using the BCA assay (Smith et 
al., 1985). 
4.2.3 Expression and Purification of Myc/6xHis Tagged STRA6 in   
Mammalian Cells 
4.2.3.1 STRA6 Construct Design 
The coding sequence for human STRA6 (UniProt entry Q9BX79), in the expression 
vector pPICZA, was previously used for STRA6 expression in Pichia pastoris.  The 
coding sequence was amplified by PCR using the primers: 
 5’-AGCTGGGAATTCGCCACCATGTCGTCC -3’ which incorporates an EcoRI 
restriction site (underlined), and 5’- CGGCTTCTAGAGGGCTGGGCACCATT -3’ 
which incorporates a Xba1 restriction site, (also underlined). 
Following purification from an agarose gel, the STRA6 insert and the Myc 
(EQKLISEEDL)/6xHis gene fusion expression vector, pcDNA4, were digested with 
the restriction endonucleases, EcoRI and Xba1, and further purified from agarose 
gels.  The digested insert was subsequently ligated into pcDNA4.   
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Successful subcloning was confirmed by digestion, and further verified by 
sequencing. 
 
4.2.3.2 Expression of STRA6 
HEK293T cells were cultured at 37 °C in a humidified atmosphere (5 % CO2 / 95 % 
O2) in DMEM (supplemented with 10 % (v/v) heat-inactivated FBS, penicillin and 
streptomycin [1 % (v/v)] and 1 % glutamine).  Cells were grown as adherent 
monolayers to between 60-70 % confluence prior to transfection with empty vector 
or the STRA6 construct.  HEK293T cells were transiently transfected using 
FuGENE® 6, according to the manufacturer’s instructions.   
At 48 hours post-transfection, growth medium was removed and cells washed in ice-
cold PBS. Flasks were agitated until all cells were in suspension, at which time cells 
were harvested (700 g for 5 minutes).  The supernatant was removed and discarded. 
Cells where stored at -80 °C or used to determine protein expression.  
Protein expression was determined by SDS-PAGE and Western blotting. 
 
4.2.3.3 Lysis and Purification of STRA6 
As given in 4.2.2.2 
4.2.4 STRA6 Stable Cell Line  
4.2.4.1 STRA6 Stable Cell Line Induction 
Stable HEK293T cells inducibly expressing STRA6, in expression vector pN-TGSH 
along with a HA and StrepII tag on either the N- or C-terminus, were cultured at 37 
°C in a humidified atmosphere (5 % CO2 / 95 % O2) in DMEM (supplemented with 
10 % (v/v) heat-inactivated FBS, penicillin and streptomycin [1 % (v/v)], 1 % 
glutamine, 100 g/ml hygromycin B and 15 g/ml blasticidin) Cells were grown as 
adherent monolayers to between 60-70 % confluence prior to induction in DMEM 
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(supplemented with 10 % (v/v) heat-inactivated FBS, penicillin and streptomycin [1 
% (v/v)], 1 % glutamine and 1 g/ml tetracycline).  
At 24 hours post-induction, growth medium was removed and cells washed in ice-
cold PBS. Flasks were agitated until all cells were in suspension, at which time cells 
were harvested (700 g for 5 minutes).  The supernatant was removed and discarded. 
Cells where stored at -80 °C or used to determine protein expression.  
Protein expression was determined by SDS-PAGE and Western blotting. 
 
4.2.4.2 Purification of STRA6 
Cell pellets were resuspended in 1 ml of NP buffer (6.90 g/L NaH2PO4H2O, 17.54 
g/L NaCl, 1.54 g/L DTT, 0.5 g/L TCEP, 0.78 g/L β-mercaptoethanol, 1x EDTA-free 
protease inhibitor cocktail, 0.174 g/L PMSF, pH 8) supplement with 1 % Trition-X-
100.  Once resuspended, the cells were incubated at 4 °C for 1 hour with constant 
agitation.  The sample was then centrifuged (12,000 g for 20 minutes at 4 °C).  
Following centrifugation, the supernatant was harvested and the pellet discarded. 
Avidin was added to the cleared lysate at 5 µg/ml. STRA6 was purified using Strep-
Tactin superflow plus. 200 µl of a 50 % slurry of Strep-Tactin superflow plus was 
re-equilibrated in NP buffer. The cleared lysate was incubated with the resin for 90 
minutes at 4 °C.  The resin was centrifuged (700 g for 3 minutes at 4 °C) and the 
supernatant collected. The resin was washed twice with 200 µl NP buffer supplement 
with 0.5 % Trition-X-100, the resin was centrifuged (700 g for 3 minutes at 4 °C) 
and the washes collected. The resin was incubated with 200 µl NPD buffer (6.90 g/L 
NaH2PO4H2O, 17.54 g/L NaCl, 0.54 g/L desthiobiotin, 0.5 % Trition-X-100, pH 8) 
for 5 minutes. The resin was centrifuged (700 g for 3 minutes at 4 °C) and the eluate 
collected. Each fraction was analysed by SDS-PAGE and Western blotting. 
Following purification, protein concentrations were determined using the BCA assay 
(Smith et al., 1985).  
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4.2.5 STRA6 Binding Capacity of MYTH Hits 
4.2.5.1 STRA6 Binding Capacity of MYTH Hits with Washing 
Stable HEK293T cells, inducibly expressing STRA6 (as well as un-induced cells as 
a control), were centrifuged and resuspended in 1 ml of NP buffer supplement with 1 
% Trition-X-100.  Once resuspended, the cells were incubated at 4 °C for 1 hour 
with constant agitation.  The two samples were then centrifuged (12,000 g for 20 
minutes at 4 °C).  Following centrifugation, the supernatants were harvested and the 
pellets discarded. 
Avidin was added to the cleared lysates at 5 µg/ml. 2 x 200 µl of a 50 % slurry of 
Strep-Tactin resin was re-equilibrated in NP buffer. The cleared lysates were 
incubated with the resins for 90 minutes at 4 °C.  The resins were centrifuged (700 g 
for 3 minutes at 4 °C) and the supernatants collected. The resins were washed once 
with 200 µl NP buffer supplement with 0.5 % Trition-X-100, the resins were 
centrifuged (700 g for 3 minutes at 4 °C) and the washes collected. A HEK293T 
lysate overexpressing one of the MYTH hits (CCL2, CXCL14, IFITM1, IFITM3, 
MIF, PLP2 or SERP1) was added and incubated with the resins for 45 minutes at 4 
°C. The resins were centrifuged (700 g for 3 minutes at 4 °C) and the supernatant 
collected. The resins were washed once with 200 µl NP buffer supplement with 0.5 
% Trition-X-100, the resins centrifuged (700 g for 3 minutes at 4 °C) and the washes 
collected. The resin was incubated with NPD buffer for 5 minutes, the resins 
centrifuged (700 g for 3 minutes at 4 °C) and the eluate collected. Each fraction was 
analysed by SDS-PAGE and Western blotting to determine if a specific interaction 
had occurred.  
 
4.2.5.2 STRA6 Binding Capacity of MYTH Hits without Washing 
As in 4.2.5.1, however following incubation, instead of a tradition wash step to 
remove nonspecifically bound material, reactions were carefully resuspended prior to 
rapid centrifugation (6,800 g for 5 minutes) through an oil layer. A 3:2 dibutyl 
phthalate: dinonyl phthalate preparation was used to separate the aqueous, oil and 
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agarose layers. The pellet was incubated with 2x SDS sample buffer for 5 minutes at 
70 °C, prior to analysis of the supernatant by SDS-PAGE and Western blotting. 
 
4.2.6 Construct Design of MYTH Hits for Coexpression in 
Mammalian Cells with STRA6 
4.2.6.1 Construct Design of CD63  
The coding sequence for human CD63 (UniProt entry P08962), in the expression 
vector pPR3-N, had been previously used for CD63 expression in the MYTH.  The 
coding sequence was amplified by PCR using the primers: 
 5’- AGCTGGAAGCTTGCCACCATGGCGGTGGAAGGAGG -3’ which 
incorporates an HindII restriction site (underlined), and 5’- 
CGGCTGGCGGCCGCTTAAGCGTAATCTGGAACATCGTATGGGTACATC
ACCTCGTAGCCACTTCTG -3’ which incorporates a Not1 restriction site (also 
underlined) and a HA tag (in bold). 
Following purification from an agarose gel, CD63 and the mammalian expression 
vector pcDNA3.1 were digested with the restriction endonucleases, HindII and Not1, 
and further purified from agarose gels.  The digested insert was subsequently ligated 
into pcDNA3.1.  Successful subcloning was confirmed by digestion, and further 
verified by sequencing. 
 
4.2.6.2 Construct Design of PDZK1-IP1 
The coding sequence for human PDZK1-IP1 (UniProt entry Q13113), in the 
expression vector pPR3-N, had been previously used for PDZK1-IP1 expression in 
the MYTH.  The coding sequence was amplified by PCR using the primers: 
 5’- AGCTGGAAGCTTGCCACCATGTCGGCCCTCAGC -3’ which incorporates a 
HindII restriction site (underlined), and 5’- 
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CGGCTGGCGGCCGCTTAAGCGTAATCTGGAACATCGTATGGGTACATC
GGGGTGCTGC -3’ which incorporates a Not1 restriction site (also underlined) and 
a HA tag (in bold). 
Following purification from an agarose gel, PDZK1-IP1 and the mammalian 
expression vector pcDNA3.1 were digested with the restriction endonucleases, 
HindII and Not1, and further purified from agarose gels.  The digested insert was 
subsequently ligated into pcDNA3.1.  Successful subcloning was confirmed by 
digestion, and further verified by sequencing. 
 
4.2.6.3 Construct Design of OCIAD2 and Osteopontin 
The coding sequence for OCIAD2 (UniProt Q56VL3) and osteopontin (UniProt 
P10451), in the mammalian expression vector pCMV6-Entry incorporating a c-
terminal Myc (EQKLISEEDL) and DDK (DYKDDDDK) tag, were purchased from 
Origene.  
 
4.2.7 STRA6 Binding Capacity of Coexpressed MYTH Hits 
4.2.7.1 STRA6 and MYTH Hits Expression 
Stable HEK293T cells inducibly expressing STRA6, in expression vector pN-TGSH 
along with a HA and StrepII tag on either the N- or C-terminus, were cultured at 37 
°C in a humidified atmosphere (5 % CO2 / 95 % O2) in DMEM (supplemented with 
10 % (v/v) heat-inactivated FBS, penicillin and streptomycin [1 % (v/v)], 1 % 
glutamine, 100 g/ml hygromycin B and 15 g/ml blasticidin).  Cells were grown as 
adherent monolayers to between 60-70 % confluence prior to transfection with 
CD63, PDZK1-IP1, OCIAD2 or osteopontin.  HEK293T cells were transiently 
transfected using Lipofectamine™ 2000 Transfection reagent according to the 
manufacturer’s instructions.   
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Four hours after transfection, medium was changed, to DMEM (supplemented with 
10 % (v/v) heat-inactivated FBS, penicillin and streptomycin [1 % (v/v)], 1 % 
glutamine and 1 µg/ml tetracycline) to induce STRA6 expression. At 24 hours post-
transfection, growth medium was removed and cells washed in ice-cold PBS. Flasks 
were agitated until all cells were in suspension, at which time cells were harvested 
(700 g for 5 minutes).  The supernatant was removed and discarded. Cells where 
stored at -80 °C or used to determine protein expression.  
Protein expression was determined by SDS-PAGE and Western blotting. 
 
4.2.7.2 STRA6 Binding Capacity of MYTH Hits with Washing 
Stable HEK293T cells, inducibly expressing STRA6 (as well as un-induced cells as 
a control) and transiently expressing PDZK1-IP1, CD63, OCIAD2 or osteopontin 
were centrifuged and resuspended in 1 ml of NP buffer supplement with 1 % Trition-
X-100. Once resuspended, the cells were incubated at 4 °C for 1 hour with constant 
agitation.  The two samples were then centrifuged (12,000 g for 20 minutes at 4 °C).  
Following centrifugation, the supernatants were harvested and the pellets discarded. 
Avidin was added to the cleared lysates at 5 µg/ml. 2 x 200 µl of a 50 % slurry of 
Strep-Tactin resin was re-equilibrated in NP buffer. The cleared lysates were 
incubated with the resins for 90 minutes at 4 °C.  The resins were centrifuged (700 g 
for 3 minutes at 4 °C) and the supernatants collected. The resins were washed once 
with 200 µl NP buffer supplement with 0.5 % Trition-X-100, the resins were 
centrifuged (700 g for 3 minutes at 4 °C) and the washes collected. The resin was 
incubated with NPD buffer for 5 minutes, the resins centrifuged (700 g for 3 minutes 
at 4 °C) and the eluate collected. Each fraction was analysed by SDS-PAGE and 
Western blotting to determine if a specific interaction had occurred.  
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4.2.7.3 STRA6 Binding Capacity of MYTH Hits without Washing 
As in 4.2.7.2, however following incubation, reactions were carefully resuspended 
prior to rapid centrifugation (6,800 g for 5 minutes) through an oil layer, a 3:2 
dibutyl phthalate: dinonyl phthalate preparation, to separate the aqueous, oil and 
agarose layers. The pellet was incubated with 2x SDS sample buffer for 5 minutes at 
70 °C, prior to analysis of the supernatant by SDS-PAGE and Western blotting. 
 
4.2.8 Detection of Protein Expression 
Protein expression was analysed by SDS-PAGE and Western blotting.  In the 
detection of STRA6, α-His-HRP (Roche), α-myc (Cell Signalling), α-HA (Covance), 
α-mouse-HRP (Promega), α-STRA6 (Abnova) and α-rabbit-HRP (GE Healthcare) 
antibodies were used where appropriate. Lysates overexpressing the hits, purchased 
from Origene, were detected using α-myc and α-mouse-HRP antibodies. CD63 and 
PDZK1-IP1 constructs were detected using α-HA and α-mouse-HRP antibodies. 
OCIAD2 and osteopontin were detected using α-myc and α-mouse-HRP antibodies. 
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4.3 Results 
4.3.1 Expression and Purification of STRA6 in Pichia pastoris 
4.3.1.1 Expression of STRA6  
Pichia pastoris is an industrial methylotrohic yeast initially chosen for production of 
single-cell protein because of its ability to grow to very high cell density in simple 
defined medium. The advantage of using P. pastoris, as opposed to other eukaryotic 
expression systems such as insect and mammalian cells, is the comparatively high 
yields obtained from the yeast system, which allows recombinant proteins to be 
expressed at relatively low cost, without the need of a complex growth medium or 
culture conditions. What’s more, as a eukaryotic organism, P. Pastoris is capable of 
producing soluble, correctly folded recombinant proteins that have undergone all the 
posttranslational modifications required for functionality.  With its proven ability to 
express more than 300 proteins, P. Pastoris has become a consistent choice for 
heterologous protein production and is now the most commonly used host for 
eukaryotic membrane proteins (Hedfalk, 2013, Goncalves et al., 2013).  
The coding sequence for human STRA6, in the expression vector pPICZA, was 
designed to incorporate the coding sequence for GFP as a marker of gene expression 
and a 6xHis tag. Protein expression was determined by SDS-PAGE and Western 
blotting. After expression, a large quantity of STRA6 was obtained, approximately 
25 g/L, and continued onto lysis and purification.   
 
4.3.1.2 Lysis and Purification of STRA6  
A ball mill (Retsch MM301) was used for cryogenic disruption of yeast cells. Since 
STRA6 was expressed as a 6xHis fusion protein, purification was carried out using 
affinity chromatography. Protein was purified by immobilised metal ion affinity 
chromatography (IMAC) using Ni-NTA agarose.  Eluted fractions contained a large 
quantity of protein, as illustrated in Figure 4.1. Protein was aliqouted before storage 
at -20 °C. However protein was not soluble after storage at -20 °C and could no 
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longer be detected after two days of storage, presumably due to degradation. After 
considerable attempts to prevent degradation the decision was made to express 
STRA6 in HEK293T cells for subsequent binding assays.   
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Figure 4.1 STRA6 Purification using Ni-NTA 
Silver stained (12%) SDS-PAGE gel showing the purification of STRA6. 5 
µl loaded per well. The soluble fraction after lysis was incubated with Ni-
NTA agarose and the flow-through (FT) collected. The resin was washed 
twice (W1 and W2) prior to elution (E1). The elution step was repeated 
(E2) and the eluates pooled and concentrated (EC). Molecular weight 
markers (M) revealed STRA6 migrating at an expected ~ 74 kDa in the 
flow-through, washes and in the eluted fraction with some contamination.  
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4.3.2 Expression and Purification of STRA6 in Mammalian Cells 
HEK293T cells express STRA6 in its native form and thus represent an ideal 
mammalian expression system for overexpression of the recombinant receptor.  In 
addition, HEK293T cells are easy to grow and tend to transfect readily.   
After transfecting HEK293T cells with the STRA6 construct, expression remained 
unsuccessful or at least, undetectable by Western blotting, using α-STRA6 
antibodies, despite different combinations of conditions including DNA 
concentration, transfection reagent and collection time. Membrane isolation and Ni-
NTA purification were performed to isolate and concentrate any recombinant 
STRA6 present in the cells. Attempts were further encumbered by the presence of a 
Nonspecific band, using the α-his-HRP antibody, at approximately 74 kDa, the 
expected molecular weight for STRA6, as illustrated in Figure 4.2. This Nonspecific 
band was present in both transfected and untransfected cells to the same degree. 
Transfection efficiency may have been low resulting in the untransfected cell 
population outgrowing the transfected, resulting in a low yield of the protein of 
interest. It was therefore decided to design a new STRA6 construct with both a 
6xHis tag for purification and a Myc tag for detection.  
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Figure 4.2:  STRA6 Expression in HEK293T Cells 
Representative Western blot showing fractions from the expression of 
STRA6 as detected by α-His-HRP antibodies. 5 µl loaded per well. 
HEK293T cells were transfected with the STRA6 construct (1). 
Untransfected cells (2) and cells transfected with the empty vector (3) were 
used as a control. Cells were harvested and the soluble fraction, after lysis, 
applied to the gel. Molecular weight markers (M) revealed a band at the 
expected molecular weight, ~ 74 kDa, of STRA6 in all three lanes. The 
presence of this band in untransfected cells and cells transfected with the 
empty vector indicates that this band does not represent STRA6. STRA6 
may not be expressed in transfected cells or is difficult to detect due to the 
presence of this nonspecific band. 
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4.3.3 Expression and Purification of Myc/ 6xHis Tagged STRA6 in 
Mammalian Cells 
4.3.3.1 STRA6 Construct Design 
Following PCR, a band at the expected size, approximately 2000 bp, was visualised 
on an agarose gel. The PCR band was extracted, purified and ligated into 
pcDNA4_myc/his. Successful subcloning was confirmed by digestion and further 
verified by sequencing. 
 
4.3.3.2 Expression and Purification of STRA6 
HEK293T cells were transfected with the STRA6 construct. The cells were lysed 
and STRA6 immobilised on Ni-NTA agarose. After incubation, the resin was 
washed twice and any bound protein eluted. As illustrated in Figure 4.3, STRA6 was 
detectable in transfected cells at the expected molecular weight of 74 kDa and in 
sufficient quantities for downstream experiments, ~ 100 μg/ T75 flask. However, it 
was later decided to use a HEK293T cell line inducibly expressing STRA6 which 
had unexpectedly become available. Inducible expression resulted in higher levels of 
STRA6 expression than that observed using transient expression.  
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Figure 4.3:  Expression of Myc-Tagged STRA6 
Representative Western blot showing fractions from the expression of 
STRA6 as detected by α-myc and α-mouse-HRP antibodies. 5 µl loaded per 
well. HEK293T cells were transfected with the STRA6 construct using a 
number of different DNA concentrations, 2 μg (1), 5 μg (2), 7 μg (3). 
Untransfected cells (4) were used as a control. Cells were harvested and the 
soluble fraction, after lysis, applied to the gel. Molecular weight markers 
(M) revealed a band at the expected molecular weight, ~ 74 kDa, of STRA6 
in lanes 1-3, with no band in lane 4, indicating transfection was a success.  
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4.3.4 STRA6 Stable Cell Line  
4.3.4.1 Stable Cell Line Induction and Purification 
The stable HEK293T cell line inducibly expressing STRA6 along with a HA and 
StrepII tag on either the N- or C-terminus, using expression vector pN-TGSH, was 
generated by Dr. Conor Breen. The StrepII tag allows affinity purification of STRA6 
on a Strep-Tactin resin. The epitope tags were placed either at the N- or C-terminus 
of STRA6 as these epitope tags may inhibit STRA6 binding with other proteins. 
Therefore both constructs were used in binding assays.   
Cells were cultured and expression induced at 60-70 % confluency. At 24 hours 
post-transfection, cells were harvested. Cells were stored at -80 °C or used to 
determine protein expression. Protein expression was determined by SDS-PAGE and 
Western blotting, using α-HA and α-mouse-HRP antibodies. Once expression of the 
construct had been verified, the protein was purified using a Strep-Tactin resin. A 
large quantity of STRA6 was present in the eluted fraction, ~ 150 μg/ T75 flask, with 
little lost in the washes, illustrated in figure 4.4.   
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Figure 4.4:  STRA6 Purification using Strep-Tactin Resin 
Representative Western blot showing fractions from the purification of 
STRA6 as detected by α-HA and α-mouse-HRP antibodies. 5 µl loaded per 
well. STRA6 contains either an N- (NT) or C- (CT) terminal HA/strepII 
epitope tag allowing for the purification of STRA6 using Strep-Tactin 
superflow plus agarose. Untransfected cells (Untraf) were used as a control. 
The soluble fractions of the cleared HEK293T lysates were incubated with 
the Strep-Tactin resin.  The supernatants (FT) were then collected and the 
resins washed (W) followed by elution of bound proteins from the resins 
(E). Molecular weight markers (M) revealed STRA6 migrating at an 
expected ~ 74 kDa in both elutions with no protein lost in the FT or W.  
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4.3.5 STRA6 Binding Capacity of Hits 
4.3.5.1 STRA6 Binding Capacity of MYTH Hits with Washing 
Stable HEK293T cells inducibly expressing STRA6 were cultured, (un-induced cells 
were used as a control), harvested, lysed and the cleared lysates bound to the Strep-
Tactin resin, ~ 5 µg of protein. Avidin was added to the cleared lysate to prevent 
biotin present in the lysate binding the resin. Any nonspecifically bound proteins were 
removed by washing the resins with NP buffer. A HEK293T lysate overexpressing 
one of the hits (CCL2, CXCL14, IFITM1, IFITM3, MIF, PLP2 or SERP1), ~ 5 µg of 
protein, was incubated with the resins. The resins were washed again to remove any 
nonspecifically bound proteins and the protein eluted from the resin. The binding assay 
was performed at 4 °C to prevent aggregation of proteins. Each fraction was 
analysed by SDS-PAGE and Western blotting to determine if a specific interaction 
occurred. STRA6 was eluted from the resin alone, all hits were present in the 
supernatant, indicating that an interaction did not occur or a weak interaction 
occurred which could not be captured in this assay. STRA6 and PLP2 binding assay 
is illustrated in Figure 4.5 as an example of the results obtained 
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Figure 4.5:  STRA6 and PLP2 Binding Assay  
Representative Western blot showing lack of STRA6 binding capacity for 
PLP2, as detected by α-Flag (A), α-HA (B) and α-mouse-HRP antibodies. 5 
µl loaded per well. STRA6 contains either an N- (NT) or C- (CT) terminal 
HA/StrepII epitope tag. Un-induced cells (Unindu) were used as a control. 
The soluble fraction of the cleared HEK293T lysates were incubated with a 
Strep-Tactin resin, before the addition of the overexpressed PLP2 cleared 
lysate  The supernatants (FT) were then collected and the resins washed 
(W) followed by elution of any bound proteins from the resins (E). 
Molecular weight markers (M) revealed PLP2 migrating at an expected ~ 17 
kDa and STRA6 migrating at an expected ~ 74 kDa as expected. STRA6 is 
present in the elution. PLP2 is present in the FT, indicating no interaction 
occurred.  
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4.3.5.2 STRA6 Binding Capacity of MYTH Hits without Washing 
Stable HEK293T cells inducibly expressing STRA6 were cultured, harvested, lysed 
and the cleared lysates immobilised on a Strep-Tactin resin, ~ 5 µg of protein. Any 
nonspecifically bound proteins were removed by washing the resin. HEK293T lysate 
overexpressing one of the hits (CCL2, CXCL14, IFITM1, IFITM3, MIF, PLP2 or 
SERP1), ~ 5µg of protein, was incubated with the resin. Nonspecifically bound 
proteins were removed by the rapid centrifugation through oil, a 3:2 dibutyl 
phthalate: dinonyl phthalate preparation. This circumvents the wash step of 
traditional pull-down protocols, allowing even low affinity interactions to be 
detected (Sivaprasadarao and Findlay, 1988b). A 3:2 dibutyl phthalate: dinonyl 
phthalate preparation has a combined density of ~ 1.09 g/mL, whereas Strep-Tactin 
Superflow Plus has a higher density and free hits are of lower density than the oil 
mix, resulting in separation of hits from hits bound to STRA6 immobilised on the 
Strep-Tactin resin. Previously, the binding assay was performed at 4 °C to prevent 
aggregation of proteins and using a wash step to remove nonspecifically bound 
proteins. However, this did not result in any detectable interactions. STRA6 and 
PLP2 binding assay is illustrated in Figure 4.6 as an example of the results obtained. 
Performing the binding assay at 4 °C may inhibit STRA6 binding, therefore, the 
second binding assay, eliminating the wash step, was performed at room 
temperature.  
Each fraction was analysed by SDS-PAGE and Western blotting to determine if a 
specific interaction occurred. STRA6 was eluted from the resin alone, all hits were 
present in the aqueous phase, indicating that an interaction did not occur. 
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Figure 4.6:  STRA6 and PLP2 Binding Assay without Washing 
Representative Western blot showing lack of STRA6 binding capacity for 
PLP2, as detected by α-Flag (A), α-Ha (B) and α-mouse-HRP antibodies. 5 
µl loaded per well. STRA6 contains either an N- (NT) or C- (CT) terminal 
HA/StrepII epitope tag. Un-induced cells (C) were used as a control. 
Positive control for PLP2 (Pos) was also loaded. The soluble fraction of the 
cleared HEK293T lysates were incubated with a Strep-Tactin resin, before 
the addition of the overexpressed PLP2 cleared lysates. The mixture was 
added to an oil preparation and spun to separate the aqueous (AQ) phase 
and the agarose (AG) phase, containing the bound protein. Molecular 
weight markers (M) revealed PLP2 migrating at an expected ~ 17 kDa and 
STRA6 migrating at an expected ~ 74 kDa as expected. STRA6 is present in 
the agarose phase. PLP2 is present in the aqueous phase, indicating no 
interaction occurred.  
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4.3.6 STRA6 Binding Capacity of Coexpressed MYTH Hits 
4.3.6.1 CD63 and PDZK1-IP1 Construct Design  
Following PCR, a band at the expected size, 700 bp for CD63 and 350 bp for 
PDZK1-IP1, was visualised on an agarose gel. PCR band was extracted, digested, 
purified and ligated into pcDNA3.1. Successful subcloning was confirmed by 
digestion, as illustrated in Figure 4.7, and further verified by sequencing. 
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Figure 4.7:  CD63 and PDZK1-IP1 Construct Design  
CD63 and PDZK1-IP1 were both ligated into pcDNA3.1. Following 
ligation, digestion was performed to ensure successful subcloning. 
Digestions were loaded onto a 0.8 % agarose gel. A band at the expected 
size, 700 bp, for CD63 (highlighted by red arrow) and 350 bp for PDZK1-
IP1 (highlighted by green area), were detected, as well as a band at the 
expected size, 5428 bp, for the empty vector, pcDNA3.1 (highlighted by 
blue arrow). 
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4.3.6.2 STRA6 and MYTH Hits Expression 
Stable HEK293T cells with inducible STRA6 were cultured, transfected with 
PDZK1-IP1, CD63, OCIAD2 or osteopontin and STRA6 expression was induced 
(un-induced cells were used as a control). Cells were harvested 24 hours later and 
lysed. Protein expression was determined by SDS-PAGE and Western blotting. 
Expression of STRA6 with PDZK1-IP1 is illustrated in Figure 4.8. The MYTH hits 
were expressed along with STRA6 to ensure that if any intermediate protein(s) or in 
vivo post-translational modification(s) (PTM) were involved, the interaction would 
be captured. 
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Figure 4.8:     Expression of PDZK1-IP1 and STRA6 
Representative Western blot showing STRA6 expression with PDZK1-IP1, 
as detected by α-HA and α-mouse-HRP antibodies. STRA6 contains either 
an N- (NT) or C- (CT) terminal HA/StrepII epitope tag.  (1-3) 2 µl, 4 µl and 
8 µl respectively of lysed cells loaded per well. Molecular weight markers 
(M) revealed PDZK1-IP1 and STRA6 migrating at ~ 17 kDa and ~ 74 kDa 
respectively, as expected. 
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4.3.6.3 STRA6 Binding Capacity of PDZK1-IP1 with Washing  
Once expression of PDZK1-IP1, both in the presence (induced cells) and absence of 
STRA6 (un-induced cells), was verified, the cleared lysates were incubated with a 
Strep-Tactin resin. Nonspecifically bound proteins were removed from the resin by 
washing and bound material eluted from the resin, ~ 10 µg of protein. The binding 
assay was performed at 4 °C to prevent aggregation of proteins. Each fraction was 
analysed by SDS-PAGE and Western blotting to determine if a specific interaction 
occurred. STRA6 was present in the eluted fraction for the induced sample and 
PDZK1-IP1 was present in the supernatant indicating that the two did not interact, 
illustrated in Figure 4.9. 
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Figure 4.9:  STRA6 and PDZK1-IP1 Binding Assay  
Representative Western blot showing lack of STRA6 binding capacity for 
PDZK1-IP1, as detected by α-HA and α-mouse-HRP antibodies. 5 µl loaded 
per well. STRA6 contains either an N- (NT) or C- (CT) terminal HA/StrepII 
epitope tag. Un-induced cells (Uninduced) were used as a control. The 
soluble fraction of the cleared HEK293T lysates expressing both STRA6 
and PDZK1-IP1 were incubated with a Strep-Tactin resin, as well as un-
induced cells expressing only PDZK1-IP1. The supernatants (FT) were then 
collected and the resins washed (W) followed by elution of any bound 
proteins from the resins (E). Any protein still bound to the resin (R) was 
also loaded onto the gel. Molecular weight markers (M) revealed PDZK1-
IP1 migrating at an expected ~ 17 kDa and STRA6 migrating at an expected 
~ 74 kDa as expected. STRA6 is present in the elution. PDZK1-IP1 is 
present in the FT and washes, indicating no interaction occurred. 5 µl of the 
HEK293T lysate expressing only PDZK1-IP1 was used as a positive control 
(pos control). 
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4.3.6.4 STRA6 Binding Capacity of CD63 with Washing 
As in 4.3.6.3, however PDZK1-IP1 was replaced with CD63. STRA6 was present in 
the eluted fraction for the induced sample and CD63 was present in the supernatant, 
indicating that the two do not interact, illustrated in Figure 4.10.  
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Figure 4.10:  STRA6 and CD63 Binding Assay  
Representative Western blot showing lack of STRA6 binding capacity for 
CD63, as detected by α-HA and α-mouse-HRP antibodies. 5 µl loaded per 
well.STRA6 contains either an N- (NT) or C- (CT) terminal HA/StrepII 
epitope tag. Un-induced cells (Unind) were used as a control. The soluble 
fraction of the cleared HEK293T lysates expressing both STRA6 and CD63 
were incubated with a Strep-Tactin resin, as well as un-induced cells 
expressing only CD63. The supernatants (FT) were then collected and the 
resins washed (W) followed by elution of any bound proteins from the 
resins (E). Molecular weight markers (M) revealed CD63 migrating at an 
expected ~ 25 kDa and STRA6 migrating at an expected ~ 74 kDa as 
expected. STRA6 is present in the elution. CD63 is present in the FT, 
indicating no interaction occurred. 5 µl of the HEK293T lysate expressing 
only CD63 was used as a positive control (pos control). 
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4.3.6.5 STRA6 Binding Capacity of OCIAD2 with Washing 
As in 4.3.6.3, however PDZK1-IP1 was replaced with OCIAD2. STRA6 was present 
in the eluted fraction for the induced sample and OCIAD2 was present in the 
supernatant indicating that the two did not interact, illustrated in Figure 4.11. 
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Figure 4.11:  STRA6 and OCIAD2 Binding Assay  
Representative Western blot showing lack of STRA6 binding capacity for 
OCIAD2, as detected by α-Myc (A), α-HA (B) and α-mouse-HRP 
antibodies. 5 µl loaded per well. STRA6 contains either an N- (NT) or C- 
(CT) terminal HA/StrepII epitope tag. Un-induced cells (C) were used as a 
control. The soluble fraction of the cleared HEK293T lysates expressing 
both STRA6 and OCIAD2 were incubated with a Strep-Tactin resin, as well 
as un-induced cells expressing only OCIAD2. The supernatants (FT) were 
then collected and the resins washed (Wash) followed by elution of any 
bound proteins from the resins (Elut). Molecular weight markers (M) 
revealed OCIAD2 migrating at an expected ~ 17 kDa and STRA6 migrating 
at an expected ~ 74 kDa as expected. STRA6 is present in the elution. 
OCIAD2 is present in the FT, indicating no interaction occurred. 5 µl of the 
HEK293T lysate expressing only OCIAD2 was used as a positive control 
(pos). 
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4.3.6.6 STRA6 Binding Capacity of Osteopontin with Washing 
As in 4.3.6.3, however PDZK1-IP1 was replaced with osteopontin, STRA6 was 
present in the eluted fraction for the induced sample and osteopontin was present in 
the supernatant indicating that the two did not interact, illustrated in Figure 4.12.  
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Figure 4.12:  STRA6 and Osteopontin Binding Assay  
Representative Western blot showing lack of STRA6 binding capacity for 
osteopontin, as detected by α-Myc (A), α-HA (B) and α-mouse-HRP 
antibodies. 5 µl loaded per well. STRA6 contains either an N- (NT) or C- 
(CT) terminal HA/StrepII epitope tag. Un-induced cells (C) were used as a 
control. The soluble fraction of the cleared HEK293T lysates expressing 
both STRA6 and osteopontin were incubated with a Strep-Tactin resin, as 
well as un-induced cells expressing only osteopontin. The supernatants (FT) 
were then collected and the resins washed (Wash) followed by elution of 
any bound proteins from the resins (Elut). Molecular weight markers (M) 
revealed osteopontin migrating at an expected ~ 32 kDa and STRA6 
migrating at an expected ~ 74 kDa as expected. STRA6 is present in the 
elution. Osteopontin is present in the FT, indicating no interaction occurred. 
5 µl of the HEK293T lysate expressing only osteopontin was used as a 
positive control (pos). 
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4.3.6.7 STRA6 Binding Capacity of Coexpressed MYTH Hits without                                
Washing 
Stable HEK293T cells with inducible STRA6 were transfected with PDZK1-IPI, 
CD63, OCIAD2 or osteopontin and STRA6 expression induced (un-induced cells 
were used as a control). Cells were harvested and lysed. The cleared lysates were 
incubated with a Strep-Tactin resin, ~ 10 µg of protein. Any nonspecifically bound 
proteins were removed by the rapid centrifugation through oil, a 3:2 dibutyl 
phthalate: dinonyl phthalate preparation. This circumvents the wash step of 
traditional pull-down protocols, allowing even low affinity interactions to be 
detected.  Each fraction was analysed by SDS-PAGE and Western blotting to 
determine if a specific interaction had occurred. Previously, the binding assay was 
performed at 4 °C to prevent aggregation of proteins and using a wash step to 
remove nonspecifically bound proteins. However, this did not result in any detectable 
interactions. Performing the binding assay at 4 °C may inhibit STRA6 binding. 
Therefore, the second binding assay, eliminating the wash step, was performed at 
room temperature. STRA6 was eluted from the resin alone, PDZK1-IPI, CD63, 
OCIAD2 and osteopontin were present in the aqueous phase indicating that an 
interaction did not occur.   
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4.4 Discussion  
Using the MYTH, 11 novel protein interactions for STRA6 were detected. These 
potential interactions need to be verified independently of the MYTH. The MYTH 
can give a number of false positives; hits which do not interact with the bait in vivo. 
The  estimated reliability of the high-throughput MYTH has been suggested to be 
approximately fifty percent (Sprinzak et al., 2003). There are a number of reasons for 
a high level of false positives; proteins that bind and activate the reporter gene 
directly, “sticky” or incorrectly folded proteins that nonspecifically bind many baits, 
plasmid rearrangements or copy number changes that generate auto activators or 
alternations at one of the reporter genes that results in constitutive expression. 
Therefore, validation of all interacting proteins is needed before the interaction can 
be deemed biologically relevant (Stynen et al., 2012).  
The 11 novel protein interactions for STRA6 were to be verified using in vitro pull-
down assays. Recombinant STRA6, with a strepII epitope tag, was immobilised on a 
strep-tactin resin and the MYTH hits added individually. Nonspecifically bound 
proteins were removed with either a wash or the rapid centrifugation through an oil 
preparation designed to maintain low affinity interactions (Sivaprasadarao and 
Findlay, 1988b).  The binding assays were performed at 4 °C and room temperature 
(20 -22 °C) to ensure all possible chances of capturing an interaction. The STRA6 
construct contained a HA and StrepII tag on either the N- or C-terminus of STRA6. 
These epitope tags are necessary for the purification and detection of STRA6. Both 
constructs were used for pull-down assays to reduce the risk of the epitope tags 
preventing STRA6 interacting with the MYTH hits.  
The MYTH hits, bar PLP2, were all detected in the kidney library screen. STRA6 is 
expressed in its native form in HEK293T cells and thus represents an ideal 
mammalian expression system for overexpression of the recombinant receptor and 
the MYTH hits. A number of MYTH hits (PDZK1-IP1, CD63, OCIAD2 and 
osteopontin) were prioritised due to their cellular location (Kocher et al., 1998), the 
fact osteopontin is induced by RA (Park et al., 1997, Sodek et al., 2002, Harada et 
al., 1995) and as OCIAD2 was previously detected in an assay to identify any 
protein(s) that copurify with STRA6 (unpublished data). These proteins were 
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expressed with STRA6 in HEK293T cells to ensure that if any intermediate protein 
or in vivo post-translational modification (PTM) was involved, the interaction would 
be captured.  
Despite considerable efforts, the hits obtained in all three screens could not be 
verified using pull-down experiments. These hits may be false positives or form 
transient interactions with STRA6, which cannot be captured using pull-down 
experiments. Interestingly, binding of RBP with its receptor also proved hard to 
isolate, despite the interaction between STRA6 and RBP being captured in the 1980s 
(Sivaprasadarao and Findlay, 1988a), it wasn’t until 2008 that STRA6 was isolated 
and identified as the RBP receptor (Kawaguchi et al., 2007). A more specialised 
approach may be necessary to detect protein interactions for STRA6, aimed at 
capturing weak or transient interactions.  STRA6 was subject to a second assay to 
identify potential interacting proteins whereby recombinant STRA6 was purified and 
any bound proteins were identified using mass spectrometer (unpublished data).  
OCIAD2 was the only MYTH hit detected using both assays. It is not clear why 
recombinant OCIAD2 did not pull-down with STRA6.  The OCIAD2 construct 
contains a HA epitope tag on its C-terminus but as a small epitope tag (9 amino 
acids), this is unlikely to prevent the protein interacting with STRA6. Data presented 
in this thesis would imply that OCIAD2 does not interact with STRA6 despite 
several attempts and a range of different conditions.  
The detection of interacting proteins may require the presence of STRA6 in complex 
with holo-RBP and CRBP (Berry et al., 2012b). CRBP was not detected in the 
MYTH, even in the presence of RBP-ROH. Expression of CRBP in HEK293T cells 
has not been detected previously but CRBP has been shown to be expressed in 
kidney cells (Kato et al., 1984). Up to 90 % of known interactions were previously 
shown not to be detected using the traditional yeast two hybrid assay (Causier, 
2004), this may explain why CRBP was not detected, or this interacting may be too 
weak to detect using the MYTH.   
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5.1 Introduction 
STRA6 binds extracellular holo-RBP, facilitates the dissociation of the protein-
ligand complex and transfers retinol from the RBP to CRBP. STRA6 thus possesses 
a transport mechanism that is distinct from that of other transporters of small lipids 
(Redondo et al., 2008). Furthermore, the function of the protein is more complex 
than simply delivering retinol to extrahepatic tissues; STRA6 has been implicated in 
regulating biological activities such as insulin signalling and lipid metabolism (Berry 
et al., 2012b). STRA6 catalyses not only retinol influx but also efflux and exchange 
dependent on the presence of RBP and CRBP (Sivaprasadarao and Findlay, 1988b), 
(Kawaguchi et al., 2012). These observations raise important questions relating to 
the structural bases that underlie STRA6’s functions. 
Resolution of the 3-dimensional structure of the receptor will help elucidate the 
conformational switches that accompany retinol exchange between RBP and CRBP 
and shed light on the mechanisms by which transfer of retinol through the transporter 
triggers STRA6 signalling but as yet, this has not been accomplished. 
Characterisation of membrane proteins is challenging due to the protein’s 
hydrophobic surfaces, flexibility and lack of stability, leading to challenges at all 
levels, including expression, solubilisation, purification, crystallisation, data 
collection and structure solution. Currently, there are over 50,000 entries in the PDB 
repository of protein structures, but less than 1 % of these entries represent 
membrane proteins (Carpenter et al., 2008). Alternative ways in which to gain 
structural, and thereby functional, insight are, therefore, often necessary. To date, 
only the transmembrane topology of STRA6 is known (illustrated in Figure 5.1). 
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Figure 5.1:  Transmembrane Topology Model of STRA6. Taken from (White et al., 
2008) 
STRA6’s transmembrane topology (Kawaguchi et al., 2008b) with naturally 
occurring STRA6 mutations highlighted. Underlined sequence variants were 
recently identified (White et al., 2008). The nonsense sequence variant at 
amino acid 592 causes a premature stop codon on the COOH-terminus end 
of the STRA6 protein. Previously discovered sequence variants marked with 
asterisks are involved in human disease (Pasutto et al., 2007). Other 
sequence variants are missense mutations annotated in the GenBank 
database, and are not currently known to be associated with human disease 
(White et al., 2008).  
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Although computer programs predict 11 transmembrane domains for STRA6, its 
topology has been studied experimentally to suggest 9 transmembrane segments. 
This was achieved by inserting an epitope tag into all potential extracellular and 
intracellular domains of STRA6. The accessibility of each tag on the surface of live 
cells, the accessibility of each tag in permeabilized cells, and the effect of each tag 
on RBP binding and STRA6-mediated retinol uptake from the retinol-RBP complex 
was assessed. In addition, a new lysine accessibility technique combining cell-
surface biotinylation and tandem-affinity purification to study a region of the protein 
not revealed by the epitope tagging method was used. These studies not only 
revealed STRA6's extracellular, transmembrane, and intracellular domains but also 
implicated extracellular regions of STRA6 in RBP binding (Kawaguchi et al., 
2008b). 
The identification of a putative RBP-binding domain in the third extracellular loop 
region of STRA6 (V319 through L362), by mutation of residues Y335, G339 and 
G341 (Kawaguchi et al., 2008a), was the first observation made regarding 
experimentally determined structure-function relationships of the RBP receptor. 
More recently, the predicted large third intracellular loop (ICL3) of STRA6 has been 
suggested to be involved in binding CRBP (Berry et al., 2012b) and due to its large 
size, is a potential candidate for interactions within the receptor itself as well as with 
other proteins. As illustrated in Figure 5.2, STRA6-ICL3 is highly conserved. The 
importance of STRA6-ICL3 has been further enhanced by the discovery of human 
polymorphism P293L, associated with severe multisystem birth defects (Pasutto et 
al., 2007). STRA6-ICL3 was extracted from the full length protein and characterised 
in the hope of gaining insights into STRA6’s architecture and function, with 
particular attention to the binding of CRBP and the C-terminus of STRA6.  
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Figure 5.2:  Conserved Sequence of STRA6-ICL3 
Multiple sequence alignment using CLUSTAL 2.1 (Goujon et al., 2010). 
STRA6-ICL3 (amino acids 224-298) sequence aligned for human, sumatran 
orangutang, cow, mouse and rat (Uniport Q9BX79, Q5R7B4, Q0V8E7, 
O70491, Q4QR83 respectively). As illustrated, STRA6-ICL3 is highly 
conserved.  
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Characterisation of STRA6-ICL3 was achieved using a number of techniques; size-
exclusion chromatography (SEC) and SDS-PAGE to determine oligomeric size and 
circular dichroism (CD) in combination with the secondary structure prediction 
server Jpred to elucidate secondary structure. Functionality was explored using pull-
down assays to determine if STRA6-ICL3 does in fact bind CRBP. The binding 
activity for the C-terminus of STRA6 (L535-P667) was also determined. Finally, 
crystallisation of STRA6-ICL3 was attempted.  
Proteins often self-associate to oligomers for specific purposes. For newly identified 
proteins, such as STRA6, it is often unknown whether the protein exists in solution 
as a monomer, dimer, or other oligomer. Therefore, determining the molecular 
weight of a protein is an important step in understanding how it functions. Empirical 
techniques such as SEC and SDS-PAGE have been employed for protein molecular 
weight determination. SEC is a simple, fast and robust method for estimating the 
molecular weight of a protein in its native form, based on its elution position, and for 
monitoring protein oligomerization (Hong et al., 2012). The elucidation of the 
oligomeric size of STRA6-ICL3 may shed light on the oligomeric status of the full-
length protein and on the location of any putative oligomerization site(s). 
The protein’s secondary structure was explored using CD and Jpred. CD is a 
convenient and widely used spectroscopic technique that can be used to determine 
the secondary structural content of proteins and can give an indication as to whether 
the protein is folded. This is because the electronic transitions of polypeptide 
backbone peptide bonds in different conformations produce differential absorption 
spectra for left- and right-handed circularly polarized light in the far UV and vacuum 
UV wavelength ranges, which are both distinct and linearly independent. The 
information contained in CD spectra can be treated as a sum of the characteristic 
individual spectra arising from each type of secondary structure present in a protein 
sample. Empirical analysis methods usually utilize a reference database comprised of 
spectra of proteins whose crystal structures (and therefore their secondary structures) 
are known. Using singular value deconvolutions, principal component analyses, 
variable selection procedures or neural networks,  the fraction that each component 
structure contributes to the net experimental spectrum can be determined (Whitmore 
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and Wallace, 2004).  Jpred, a secondary structure prediction server that is a well-
used and accurate source of predicted secondary structure was also used (Cole et al., 
2008). 
Proteins function through interactions with other proteins in a highly specific manner 
and therefore, knowledge of how they interact is fundamental for any understanding 
of their function. Owing to evidence thus far that STRA6 may in fact also be a 
receptor for the intracellular RBP homologue, CRBP (Redondo et al., 2008), it is 
reasonable to suppose that STRA6-ICL3 may exhibit some interaction with CRBP. 
This possible interaction was explored using pull-down assays. The intracellular 
cytoplasmic tail of STRA6 is unusually large; lending plausibility to interaction 
within the protein itself. For this reason, the C-terminus of STRA6 (STRA6-CT) was 
expressed and the STRA6-CT binding activity of STRA6-ICL3 explored. 
X-ray crystallography is the method of choice for determining high-resolution 
structures of proteins. Structures of membrane proteins determined using X-ray 
crystallography highlight all the atomic details of the protein and also show any 
bound water, lipid and detergent molecules. However, despite protein 
crystallography being a well-established method, solving the structures of membrane 
proteins remains very challenging. Crystallisation of water-soluble domains which 
may fold independently, such as STRA6-ICL3, therefore, represents a realistic 
approach to generating structural and functional insights into the full length protein 
(Lacapère et al., 2007). 
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Aims and Objectives  
The aim was to characterise STRA6-ICL3. This region was expressed, purified and 
characterised as a chimera with a stabilising protein, the E.coli colicin E7 immunity 
protein (Im7, also known as IMME7). Im7 is a 87-residue (Hosse et al., 2006), 
monomeric (Dennis et al., 1998), scaffold protein. The protein is composed of four 
anti-parallel α-helices wrapped around a central hydrophobic core, as illustrated in 
Figure 5.3, which stabilises folding of the soluble protein. There are exposed 
connecting loops which, from other studies, can be derivatised without affecting the 
overall fold.  Im7 is an ideal protein scaffold due to its small size, robust helical 
structure, tolerance to extensive loop substitutions and ease of expression, active and 
in large amount using E.coli systems.  
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Figure 5.3:  Structure of Im7. Taken from (Whittaker et al., 2007) 
Structure of Im7 (PDB code 1AYI). The coding sequence for STRA6-ICL3 
(P224 – L298) was grafted onto Im7 between helices I and II (Val27 through 
Asp32) (Whittaker et al., 2007).  
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It has been demonstrated that Im7 is tolerant to loop exchange between helices I and 
II (Val27 through Asp32) (Juraja et al., 2006). Therefore, the coding sequence for 
STRA6-ICL3 (P224 – L298) was grafted into Im7 between these two helices to aid 
folding, solubility and stability of the expressed protein and to anchor the domain as 
it might be in its native state.  Chimeric loop STRA6-ICL3, in the E. coli expression 
vector pETd9, was a kind gift from Dr. Conor Breen and was designed to incorporate 
an N-terminal 6xHis tag; purification of the domain was therefore reliant upon 
affinity chromatography using Ni-NTA agarose.   
This chapter describes the characterisation of STRA6-ICL3 using a number of 
techniques including, SEC and SDS-PAGE to determine oligomeric size, CD to 
elucidate secondary structure and pull-down assays to determine if STRA6-ICL3 
does in fact bind CRBP and/or STRA6-CT. Crystallisation of STRA6-ICL3 is also 
being attempted. 
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5.2 Materials and Methods 
5.2.1 Expression of STRA6-ICL3 
5.2.1.1 Construct Design 
The third intracellular loop of STRA6 (P224 – L298) was grafted onto Im7 between 
helices I and II (Val27 through Asp32) and inserted into E.coli expression vector 
pET9d. The construct was a kind gift from Dr. Conor Breen. Im7, in the E.coli 
expression vector pTRC99a with restriction sites but not STRA6-ICL3, was a kind 
gift from Dr. Werner Vos 
 
5.2.1.2 Selection of Growth Medium for STRA6-ICL3 Expression  
BL21(DES) cells previously transformed with the STRA6-ICL3 construct were 
streaked onto a LB agar plate containing 50 µg/mL kanamycin and incubated 
overnight at 37 °C. Single colonies were used to inoculate 10 mL terrific broth (TB) 
medium (12 g/L tryptone, 24 g/L yeast extract, 4 ml/L glycerol, 12.5 g/L potassium 
diphosphate, 2.3 g/L potassium phosphate, pH 7.0), 10 mL LB medium or 10 ml 
super LB broth (SB) medium (32 g/L peptone, 20 g/L yeast extract, 5 g/L NaCl, pH 
7.0) and incubated overnight at 37 °C, with shaking (225-250 rpm).   
Following overnight growth, each culture (LB, TB or SB) was split into two cultures 
(1:50 dilution in fresh medium) and grown overnight at room temperature (20-22 °C) 
and 37 °C, with shaking (225-250 rpm).   
The cultures were centrifuged (4,000 g for 15 minutes at 4 °C), the supernatants  
discarded and the pellets resuspended in cold wash buffer (300 mM Na2HPO4, 300 
mM NaCl). Centrifugation was repeated and again the supernatants discarded. Cell 
pellets weight was noted and used to assess the most favourable medium and 
temperature for the growth of STRA6-ICL3.   
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5.2.1.3 Un-induced and IPTG-Induced Expression of STRA6-ICL3 in            
E.coli     
BL21(DES) cells expressing STRA6-ICL3 were streaked on an LB agar plate 
containing 50 µg/mL kanamycin and a single colony used to inoculate 10 mL TB 
medium and incubated overnight at 37 °C with shaking (225-250 rpm).   
Following overnight growth, the culture was divided in two  (diluted 1:100 into fresh 
medium) and grown to an OD600 of 0.6 to 0.8 at room temperature (20-22 °C).  
Protein expression was subsequently induced by the addition of 0.1 mM IPTG in one 
culture and left un-induced in the second culture. Growth continued overnight at 
room temperature (20-22 °C), with shaking (225-250 rpm).   
The cultures were centrifuged (4,000 g for 15 minutes at 4 °C), the supernatants  
discarded and the pellets resuspended in cold wash buffer (300 mM Na2HPO4, 300 
mM NaCl). Centrifugation was repeated and again the supernatants discarded. Cell 
pellets were resuspended in 3-5 ml of lysis buffer (300mM Na2HPO4, 300 mM 
NaCl, 1x EDTA-free protease inhibitor cocktail, 1 mM TCEP, 1 mM PMSF, 10 mM 
β-mercaptoethanol 1 % Triton X-100, 1 mg/ml lysozyme) per gram of wet cell 
pellet.  Resuspension and lysis of the cells was facilitated by passing the resuspended 
pellet through an 18-gauge needle fitted to a 20 ml syringe. Once resuspended, the 
cells were incubated at 4 °C for 1 hour with constant agitation. The sample was then 
sonicated at 15 % power for 1 minute. The sonication was repeated three times with 
1 minute breaks.  Following sonication, the samples were passed through a 25-gauge 
needle fitted to a 20 ml syringe until no longer viscous.  The samples were then 
centrifuged (12,000 g for 20 minutes at 4 °C), the supernatants harvested, the volume 
of the supernatants noted and the pellets discarded. Protein expression for both the 
induced and un-induced culture was determined by SDS-PAGE and Western 
blotting. 
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5.2.1.4 Buffer Selection for the Lysis of STRA6-ICL3 Expressing Cells 
BL21(DES) cells expressing STRA6-ICL3 were streaked onto an LB agar plate 
containing 50 µg/mL kanamycin and a single colony used to inoculate 10 mL TB 
medium and incubated overnight at 37 °C with shaking (225-250 rpm).   
Following overnight growth, the culture was diluted (1:100) into fresh medium and 
grown at room temperature (20-22 °C) with shaking (225-250 rpm) overnight, to an 
OD600 of ~ 2.8. The culture was centrifuged (4,000 g for 15 minutes at 4 °C), the 
supernatant discarded and the pellet resuspended in cold wash buffer. Centrifugation 
was repeated and again the supernatant discarded. The cell pellet was divided and 
resuspended in a range of different lysis buffers (3 ml/ g pellet), with varying pH, 
detergent type, salt type and salt concentration. Resuspension and lysis of the cells 
was facilitated by passing the resuspended pellets through an 18-gauge needle fitted 
to a 20 ml syringe.  Once resuspended, the cells were incubated at 4 °C for 1 hour 
with constant agitation.  The samples were then sonicated at 15 % power for 1 
minute. The sonication was repeated three times with 1 minute breaks.  Following 
sonication, the samples were passed through a 25-gauge needle fitted to a 20 ml 
syringe until no longer viscous.  The samples were then centrifuged (12,000 g for 20 
minutes at 4 °C) and the soluble fractions isolated.  Protein solubility was 
determined by SDS-PAGE and Western blotting. 200 µl of the supernatants were 
also added to a 96 well plate and stored at room temperature for 5 days. The 96 well 
plate was incubated at 37 °C for a following 4 days. The OD600 was read at a number 
of time points and the lysis buffer with the least aggregation determined. 
 
5.2.1.5 Expression and Purification of STRA6-ICL3  
BL21(DES) cells expressing STRA6-ICL3 were streaked onto an LB agar plate 
containing 50 µg/mL kanamycin and a single colony used to inoculate 10 mL TB 
medium and incubated overnight at 37 °C, with shaking (225-250 rpm).   
Following overnight growth, the culture was diluted (1:100) into fresh medium and 
grown at room temperature (20-22 °C) with shaking (225-250 rpm) overnight, to an 
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OD600 of ~ 2.8. The culture was centrifuged (4,000 g for 15 minutes at 4 °C), the 
supernatant  discarded and the pellet resuspended in cold wash buffer. Centrifugation 
was repeated and again the supernatant discarded. The cell pellet was stored at -80 
°C or continued onto lysis and purification.  
The cell pellet was resuspended in 3-5 ml of lysis buffer A (100 mM Tris, 50 mM 
NaCl, pH 8.5, 1 % N,N-Dimethyldodecylamine N-oxide (LDAO), 20 % glycerol, 1x 
EDTA-free protease inhibitor cocktail, 1 mM TCEP, 1 mM PMSF, 10 mM β-
mercaptoethanol, 1 mg/ml lysozyme) per gram of wet cell pellet.  Resuspension and 
lysis of the cells was facilitated by passing the resuspended pellet through an 18-
gauge needle fitted to a 20 ml syringe.  Once resuspended, the cells were incubated 
at 4 °C for 1 hour with constant agitation.  The sample was then sonicated at 15 % 
power for 1 minute. The sonication was repeated three times with 1 minute breaks.  
Following sonication, the sample was passed through a 25-gauge needle fitted to a 
20 ml syringe until no longer viscous.  The sample was then centrifuged (12,000 g 
for 20 minutes at 4 °C).  Following centrifugation, the supernatant was harvested, the 
volume of the supernatant noted and the pellet discarded.  
1.0 ml Ni-NTA agarose was pre-equilibrated in column binding buffer (100 mM 
Tris, 50 mM NaCl, pH 8.5, 0.5 % LDAO, 2.7 g/L imidazole, 20 % glycerol) before 
being added to the solubilised pellet and incubated for 90 minutes at 4 °C under 
gentle agitation by rotation. The mixture was added to a 5 ml column at 4 °C. The 
resin was allowed to settle and the flow-through was collected. The column was 
washed by the addition of wash buffer 1 (100 mM Tris, 1 M NaCl, pH 8.5, 0.5 % 
LDAO, 2.7 g/L imidazole, 20 % glycerol)  and wash buffer 2 (100 mM Tris, 50 mM 
NaCl, pH 8.5, 0.5 % LDAO, 4 g/L imidazole, 20 % glycerol) (5 mL per 1 mL bed 
volume).  The protein was eluted from the resin by the addition of 5 ml of elution 
buffer (100 mM Tris, 50 mM NaCl, pH 8.5, 0.5 % LDAO, 17 g/L imidazole, 20 % 
glycerol) to the column. Protein was dialysed against dialysis buffer (100 mM Tris, 
50 mM NaCl, pH 8.5, 0.5 % LDAO, 20 % glycerol) overnight at 4 °C to remove 
imidazole and the protein concentrated. Protein expression, solubility and purity 
were analysed by Coomassie Brilliant Blue staining of SDS-PAGE gels and Western 
blotting. 
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5.2.2 Expression and Purification of Im7  
BL21(DES) cells expressing Im7 were streaked onto an LB agar plate containing 50 
µg/mL ampicillin and a single colony used to inoculate 10 mL TB medium and 
incubated overnight at 37 °C, with shaking (225-250 rpm).   
Following overnight growth, the culture was diluted 1:100 into fresh medium and 
grown to an OD600 of 0.6 to 0.8 at room temperature (20-22 °C) with shaking (225-
250 rpm). Expression was induced using 0.1 mM IPTG. Growth continued 
overnight, to an OD600 of ~ 2.8, at room temperature (20-22 °C), with shaking (225-
250 rpm). The culture was centrifuged (4,000 g for 15 minutes at 4 °C), the 
supernatant  discarded and the pellet resuspended in cold wash buffer. Centrifugation 
was repeated and again the supernatant discarded. The cell pellet was stored at -80 
°C or continued into lysis and purification.  
The cell pellet was resuspended in 3-5 ml of lysis buffer A per gram of wet cell 
pellet.  Resuspension and lysis of the cells was facilitated by passing the resuspended 
pellet through an 18-gauge needle fitted to a 20 ml syringe.  Once resuspended, the 
cells were incubated at 4 °C for 1 hour with constant agitation.  The sample was then 
sonicated at 15 % power for 1 minute. The sonication was repeated three times with 
1 minute breaks.  Following sonication, the sample was passed through a 25-gauge 
needle fitted to a 20 ml syringe until no longer viscous. The sample was then 
centrifuged (12,000 g for 20 minutes at 4 °C).  Following centrifugation, the 
supernatant was harvested, the volume of the supernatant noted and the pellet 
discarded.  
1.0 ml Ni-NTA agarose was pre-equilibrated in column binding buffer before being 
added to the solubilised pellet and incubated for 90 minutes at 4 °C under gentle 
agitation by rotation. The mixture was added to a 5 ml column at 4 °C. The resin was 
allowed to settle and the flow-through was collected. The column was washed by the 
addition of wash buffer 1 and wash buffer 2 (5 mL per 1 mL bed volume).  The 
protein was eluted from the resin by the addition of 5 ml of elution buffer to the 
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column. Protein was dialysed against dialysis buffer overnight at 4 °C to remove 
imidazole and the protein concentrated. Protein expression, solubility and purity 
were analysed by Coomassie Brilliant Blue staining of SDS-PAGE gels and Western 
blotting. 
 
5.2.3 Expression, Purification and Cleavage of CRBP 
5.2.3.1 Expression and Purification of CRBP 
CRBP (UniProt entry P09455) in the GST gene fusion expression vector, pGEX-4T-
3 was a kind gift from Dr. Lyndsey Brown 
BL21(DES) cells expressing CRBP were streaked onto an LB agar plate containing 
50 µg/mL kanamycin and incubated overnight at 37 °C. A single colony was used to 
inoculate 100 mL LB medium and incubated overnight at 37 °C, with shaking (225-
250 rpm).  Following overnight growth, the cultures was diluted (1:100) into fresh 
medium and grown to an OD600 of 0.6 to 0.8. Protein expression was subsequently 
induced by the addition of 0.1 mM IPTG and growth continued for 4 hours at room 
temperature (20-22 °C), with shaking (225-250 rpm). The culture was centrifuged 
(4,000 g for 15 minutes at 4 °C), the supernatant was discarded and the pellet 
resuspended in cold wash buffer. Centrifugation was repeated and again the 
supernatant discarded. The cell pellet was stored at -80 °C or continued into lysis and 
purification. 
The cell pellet was resuspended in 3-5 ml of lysis buffer I (1x PBS, 1 % Triton X-
100, 1x EDTA-free protease inhibitor cocktail, 1 mM TCEP, 1 mM PMSF, 10 mM 
β-mercaptoethanol, 1 mg/ml lysozyme) per gram of wet cell pellet.  Resuspension 
and lysis of the cells was facilitated by passing the resuspended pellet through an 18-
gauge needle fitted to a 20 ml syringe.  Once resuspended, the cells were incubated 
at 4 °C for 1 hour with constant agitation.  The sample was then sonicated at 15 % 
power for 1 minute. The sonication was repeated three times with 1 minute breaks.  
Following sonication, the sample was passed through a 25-gauge needle fitted to a 
20 ml syringe until no longer viscous.  The sample was then centrifuged (12,000 g 
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for 20 minutes at 4 °C).  Following centrifugation, the supernatant was harvested, the 
volume of the supernatant noted and the pellet discarded. The soluble fraction was 
incubated overnight at 4 °C with Glutathione Sepharose™ 4 Fast Flow under gentle 
agitation by rotation.  Following this incubation period, the cell lysate slurry mix was 
packed into a 5 mL disposable column and the flow-through collected.  The 
sedimented Sepharose was then washed by the addition of ice-cold PBS (5 mL per 1 
mL bed volume). Protein was either eluted from the resin using 5 ml elution buffer B 
(3 g/L glutathione, 6 g/L Tris-HCl, pH 8.0) or kept on the resin for cleavage. 
Samples were taken for subsequent analysis by Coomassie Brilliant Blue staining of 
SDS-PAGE gels and Western blotting. 
 
5.2.3.2 Cleavage of CRBP 
Following column packing as described previously, the Sepharose with bound fusion 
protein was washed in ten bed volumes of ice-cold PBS.  A thrombin mix (80 U/mL 
of starting bed volume in PBS) was then loaded directly onto the column, prior to 
incubation at room temperature (20-22 °C) overnight. The cleaved protein was 
subsequently eluted from the resin with three bed volumes of ice-cold PBS. The 
flow-through containing CRBP and thrombin was then applied to Benzamidine 
Sepharose™ 6B slurry, prepared according to the manufacturer’s instructions and 
incubated for a minimum of one hour at 4 °C, under gentle agitation by rotation, in 
order to remove the protease. The flow-through, containing the fusion protein only, 
was then reapplied to pre-washed 50 % slurry of Glutathione Sepharose™ 4 Fast 
Flow in order to remove any residual GST.   
5.2.4 Expression and Purification of STRA6-CT 
The coding sequence of the C-terminal region of STRA6 (L535-P667), in the GST 
gene fusion expression vector pGEX-4T-3 along with a C-terminus 6xHis epitope 
tag was a kind gift from Dr. Lyndsey Brown 
For expression and purification details refer to 5.2.3.1.  
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5.2.5 CRBP Binding Activity of STRA6-ICL3 
5.2.5.1 CRBP Binding Activity of STRA6-ICL3 with Washing 
STRA6-ICL3 was expressed in BL21(DES) cells as described in 5.2.1.5. The soluble 
bacterial lysate, ~ 5 µg of protein, was immobilised on a Ni-NTA agarose under 
gentle agitation by rotation, for 90 minutes at room temperature (20-22 °C). Ni-NTA 
agarose with no protein bound was used as a negative control. The resins were 
washed twice with 200µl wash buffer (100 mM Tris, 50 mM NaCl, 0.5 % LDAO, 20 
% glycerol, pH 8.5), centrifuged (700 g for 3 minutes) and the washes collected. 
Cleaved CRBP, ~ 5 µg of protein, +/- 0.5 µM retinol was incubated with the resins 
for 30 minutes at room temperature (20-22 °C). The resins were centrifuged (700 g 
for 5 minutes) and any nonspecifically bound proteins collected. The resins were 
incubated with elution buffer (100 mM Tris, 50 mM NaCl, 0.5 % LDAO, 17 g/L 
imidazole, 20 % glycerol, pH 8.5) for 5 minutes, the resins centrifuged (700 g for 3 
minutes) and the eluates collected. Samples were analysed by SDS-PAGE and 
Western blotting to ascertain the presence of any bound CRBP.  
 
5.2.5.2 CRBP Binding Activity of STRA6-ICL3 without Washing  
Protein: protein interactions were probed using a pull-down assay adapted to 
accommodate the low affinity binding of STRA6-ICL3 to CRBP. A 3:2 dibutyl 
phthalate: dinonyl phthalate preparation has a combined density of ~ 1.09 g/mL, 
whereas Ni-NTA agarose is of higher density and free CRBP of lower density than 
the oil mix, resulting in separation of CRBP in solution from CRBP bound to 
STRA6-ICL3 immobilised using Ni-NTA agarose.  
STRA6-ICL3 was expressed in BL21(DES) cells as described in 5.2.1.5. The soluble 
bacterial lysates, ~ 5 µg of protein, was immobilised on Ni-NTA agarose under 
gentle agitation by rotation, for 90 minutes at room temperature (20-22 °C). Ni-NTA 
agarose with no protein bound was used as a negative control. The resins were 
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washed twice with 200µl wash buffer. The resins were centrifuged (700 g for 3 
minutes) and the washes collected. Cleaved CRBP, ~ 5 µg of protein, +/- 0.5 µM 
retinol was incubated with the resins for 30 minutes at room temperature (20-22 °C). 
Following incubation, reactions were carefully resuspended prior to rapid 
centrifugation (6,800 g for 5 minutes) through an oil layer to separate the aqueous, 
oil and agarose layers. The pellets were incubated with 2x SDS sample buffer for 10 
minutes at 70 °C. Samples were analysed by SDS-PAGE and Western blotting to 
ascertain the presence of any bound CRBP. 
 
5.2.6 STRA6-CT Binding Activity of STRA6-ICL3 
5.2.6.1 STRA6-CT Binding Activity of STRA6-ICL3 with Washing 
STRA6-CT was expressed in BL21(DES) cells as described in 5.2.4. The soluble 
bacterial lysate, ~ 5 µg of protein, was immobilised on Glutathione Sepharose™ 4 
Fast Flow resin under gentle agitation by rotation, for 90 minutes at room 
temperature (20-22 °C). Glutathione Sepharose™ 4 Fast Flow resin with no protein 
bound was used as a negative control. The resins were washed twice with 200µl 
PBS, centrifuged (700 g for 3 minutes) and the washes collected. STRA6-ICL3, ~ 5 
µg of protein, was incubated with the resins for 30 minutes at room temperature (20-
22 °C). The resins were centrifuged (700 g for 5 minutes) and any nonspecifically 
bound proteins collected. The resins were incubated with elution buffer for 5 minutes, 
the resins centrifuged (700 g for 3 minutes) and the eluates collected. Samples were 
analysed by SDS-PAGE and Western blotting to ascertain the presence of any bound 
STRA6-ICL3. The binding assay was repeated in the presence of 0.5 µM retinol.  
 
5.2.6.2 STRA6-CT Binding Activity of STRA6-ICL3 without Washing 
Protein: protein interactions were probed using a pull-down assay adapted to 
accommodate the low affinity binding of STRA6-ICL3 to STRA6-CT. A 3:2 dibutyl 
149 
 
          C h a p t e r  5 | T h i r d  I n t r a c e l l u l a r  L o o p  o f  S T R A 6  | 
 
phthalate: dinonyl phthalate preparation has a combined density of ~ 1.09 g/mL, 
whereas Glutathione Sepharose™ 4 Fast Flow is of higher density and free STRA6-
ICL3 of lower density than the oil mix, resulting in separation of STRA6-ICL3 in 
solution from STRA6-ICL3 bound to STRA6-CT immobilised using Glutathione 
Sepharose™ 4 Fast Flow.  
STRA6-CT was expressed in BL21(DES) cells as described in 5.2.4. The soluble 
bacterial lysate, ~ 5 µg of protein, was immobilised on Glutathione Sepharose™ 4 
Fast Flow resin under gentle agitation by rotation, for 90 minutes at room 
temperature (20-22 °C). Glutathione Sepharose™ 4 Fast Flow resin with no protein 
bound was used as a negative control. The resins were washed twice with 200µl 
PBS, centrifuged (700 g for 3 minutes) and the washes collected. STRA6-ICL3, ~ 5 
µg of protein, was incubated with the resins for 30 minutes at room temperature (20-
22 °C). Following incubation, reactions were carefully resuspended prior to rapid 
centrifugation (6,800 g for 5 minutes) through an oil layer to separate the aqueous, 
oil and agarose layers. The pellets were incubated with 2x SDS sample buffer for 10 
minutes at 70 °C. Samples were analysed by SDS-PAGE and Western blotting to 
ascertain the presence of any bound STRA6-ICL3. The binding assay was repeated 
in the presence of 0.5 µM retinol. 
 
5.2.7 Size-Exclusion Chromatography 
5.2.7.1 STRA6-ICL3 Subjected to Size-Exclusion Chromatography  
STRA6-ICL3 was expressed and purified as in 5.2.1.5. Purified STRA6-ICL3 was 
concentrated (to approximately 10 mg/ml) and centrifuged to remove any 
precipitation (12,000 g for 20 minutes at 4 °C) and subsequently chromatographed 
on gel filtration medium Superdex 200 (GE healthcare). The column was first 
equilibrated with several column volumes of dialysis buffer before the addition of 
0.5 ml STRA6-ICL3. The flow rate of the column was 0.3 ml/min. Fractions (0.5 ml) 
were collected and analysed by SDS-PAGE and Western blotting. β-amylase, 
alcohol dehydrogenase, BSA and carbonic anhydrase were chromatographed on the 
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same column under identical conditions to serve as molecular weight markers. The 
UV absorbance was measured at 280, 254 and 215 nm.  
 
5.2.7.2 Im7 Subjected to Size-Exclusion Chromatography  
Im7 was expressed and purified as in 5.2.2. Purified Im7 was concentrated (to 
approximately 10 mg/ml), centrifuged to remove any precipitation (12,000 g for 20 
minutes at 4 °C) and subsequently chromatographed on gel filtration medium 
Superdex 200. The column was first equilibrated with several column volumes of 
dialysis buffer before the addition of 0.5 ml Im7. The flow rate of the column was 
0.3 ml/min. Fractions (0.5 ml) were collected and analysed by SDS-PAGE and 
Western blotting. The UV absorbance was measured at 280, 254 and 215 nm.  
 
5.2.8 Circular Dichroism  
5.2.8.1 Circular Dichroism Spectra of STRA6-ICL3 
STRA6-ICL3 was expressed, purified and subjected to size-exclusion 
chromatography previous to the recording of the CD spectra. The 14 ml fraction 
from size-exclusion chromatography was used; the concentration adjusted to 0.2 
mg/ml and centrifuged to remove any precipitation (12,000 g for 20 minutes at 
4 °C). The far-UV CD spectra were recorded at room temperature (20-22 °C) using a 
JASCO J715 spectrapolarimeter over the wavelength range 180–280 nm. Spectra 
were recorded in duplicate and averaged. The percentage of secondary structure was 
calculated by deconvoluting the CD spectra using the program K2d from the 
DichroWeb CD secondary structure server 
[http://dichroweb.cryst.bbk.ac.uk/html/home.shtml (Andrade et al., 1993) ]. 
Recording of the CD spectra was carried out in Leeds University with the help of G. 
Nasir Khan. 
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5.2.8.2 Circular Dichroism Spectra of Im7 
As in 5.2.8.1, using the 18 ml fraction from size-exclusion chromatography.  
5.2.9 Crosslinking of STRA6-ICL3 
STRA6-ICL3 was expressed and purified as described in 5.2.1.5. For crosslinking 
studies, STRA6-ICL3 was dialysed against PBS. STRA6-ICL3 was treated with 
dimethyl 3, 3′ -dithiobispropionimidate (DTBP). STRA6-ICL3, ~ 5 µg, was 
incubated with the cross-linking agent, at a 50-fold molar excess in PBS, at room 
temperature (20-22 °C) for 30 minutes. Reactions were stopped with the addition of 
50 mM Tris. The reaction mixture was resolved on an SDS–PAGE gel under 
reducing conditions using 5x loading buffer and non-reducing conditions, using 5x 
non-reducing loading buffer [250 mM Tris-HCl, pH 6.8, 50 % (v/v) glycerol, 10 % 
(w/v) SDS, 0.5 % bromophenol blue] and subsequent analysed by Western blotting.  
 
5.2.10 Crystallisation of STRA6-ICL3 
STRA6-ICL3 was expressed, purified and subjected to size-exclusion 
chromatography. The 14 ml fraction was subsequently used and the concentration 
adjusted to 10 mg/ml prior to crystallization trials. The sample was centrifuged 
(12,000 g for 20 min) to remove initial precipitate and was crystallized in a hanging-
drop vapour diffusion set-up in 96 well-agar plates. Crystallization was carried out in 
Leeds University, with the help of Dr. Chi Trinh. 
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5.2.11 Detection of Protein Expression 
In the detection of STRA6-ICL3, Im7 and STRA6-CT; α-His-HRP antibody was 
used. In the detection of CRBP; α–CRBP and α-mouse-HRP antibodies were used. 
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5.3 Results 
5.3.1 Expression of STRA6-ICL3 
5.3.1.1 Selection of Growth Medium for STRA6-ICL3 Expression in E. 
coli   
STRA6-ICL3 (P224 – L298) was grafted onto Im7 between helices I and II (Val27 
through Asp32) and inserted into E.coli expression vector pET9d. BL21(DES) cells, 
transformed with the construct, were used to inoculate TB medium, LB medium or 
SB medium and cultures grown at room temperature (20-22 °C) or 37 °C. The 
culture with the largest pellet weight was deemed the most favourable medium and 
temperature for growth of STRA6-ICL3, TB medium at room temperature (20-22 
°C), and was therefore used for future expression.  
 
5.3.1.2 Un-induced and IPTG-Induced Expression of STRA6-ICL3 in E. 
coli  
STRA6-ICL3 expression in the presence and absence of IPTG was examined. 
Appropriate media were inoculated with cells expressing STRA6-ICL3. At an OD600 
of 0.6 one culture was induced, the other was not. Growth of both cultures continued 
overnight. Samples of the soluble fractions were taken for subsequent analysis by 
SDS-PAGE and Western blotting.  
STRA6-ICL3 had leaky expression and was detected in the presence and absence of 
IPTG. However more soluble protein was produced in the absence of IPTG than with 
0.1 mM IPTG, as illustrated in Figure 5.4. This may be due to the fact that the 
induced culture grew slower; cells had an OD600 of 1.9 after overnight induction 
versus an OD600 of 2.8 with un-induced expression. After overnight incubation, 
IPTG-induced cells had a pellet weight of 1.72 g/400 ml versus 5.45 g/400 ml with 
un-induced expression. Further expression of STRA6-ICL3 was carried out without 
the use of IPTG.   
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Figure 5.4:  IPTG-Induced and Un-induced Expression of STRA6-ICL3 
Representative Western blot showing the soluble bacterial lysates (5 µl). 
STRA6-ICL3 was expressed both in the presence (Ind) and absence 
(Unind) of IPTG, cells were lysed and the soluble fractions isolated.  
Protein was quantified using BCA and 5 µg of protein loaded in each lane. 
STRA6-ICL3, ~ 19.5 kDa, as detected by α-his-HRP antibody, is present for 
both induced and un-induced fractions however the un-induced fraction has 
a higher yield of soluble protein.   
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5.3.1.3 Buffer Selection for the Lysis of STRA6-ICL3 Expressing Cells 
STRA6-ICL3 was expressed in BL21(DES) cells. Once the culture reached an OD600 
of 2.8, the cell pellet was harvested and resuspended in a range of different lysis 
buffers with varying pH, detergent type, salt type and salt concentrations. In all, 36 
buffers were screened. After lysis, the soluble fractions were isolated and analysed 
using SDS-PAGE and Western blotting.  
The soluble fractions were also added to a 96 well plate and stored at room 
temperature (20-22 °C) for 5 days and subsequently incubated at 37 °C for a 
following 4 days. The OD600 was read at a number of time points, illustrated in 
Figure 5.5. The STRA6-ICL3 bacterial lysate contained the least amount of 
aggregates using lysis buffer A and was therefore used for all further experiments.  
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Figure 5.5:  Lysis of STRA6-ICL3 and Detection of Aggregation 
STRA6-ICL3 expressing bacterial cells were lysed with 36 different buffers 
and the soluble fractions incubated in a 96 well plate for 5 days at room 
temperature, followed by 4 day at 37 °C. The OD600 was then read. 
Illustrated here are the OD600 readings for 8 different buffers (Lysis buffers 
A-H). Lysis buffer A (100 mM Tris, 50 mM NaCl, pH 8.5, 1 % LDAO, 20 
% glycerol, 1x EDTA-free protease inhibitor cocktail, 1 mM TCEP, 1 mM 
PMSF and 10 mM β-mercaptoethanol) was found to have the least 
aggregation. Lysis buffers B-E substituted the 100 mM Tris for 20 mM, 40 
mM, 60 mM and 80 mM Tris respectively. Lysis buffers F-H substituted 50 
mM NaCl for 75 mM, 100 mM and 125 mM NaCl respectively.  
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5.3.1.4 Purification of STRA6-ICL3  
The large, third intracellular loop of STRA6 was purified via its 6xHis tag using Ni-
NTA agarose.  Samples were taken for subsequent analysis by Coomassie Brilliant 
Blue staining of SDS-PAGE gels and Western blotting, illustrated in Figure 5.6. 
Although a significant amount of the protein of interest bound to the Ni-NTA 
agarose and was subsequently eluted from the resin in a 5 mL fraction, a small 
quantity was lost in the second wash. The protein preparation contained some 
contaminants but the protein of interest was of sufficient purity for downstream 
application. 
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Figure 5.6:  Purification of STRA6-ICL3 
(A) Coomassie Brilliant Blue stained (12%) SDS-PAGE gel showing the 
purification of STRA6-ICL3, ~ 19.5 kDa, using Ni-NTA agarose. 5 µl 
loaded for each fraction. Lysed cells (LYS), soluble fraction after 
centrifugation (SN) and insoluble fraction after centrifugation (PT) are 
shown. The soluble fraction of the cleared bacterial lysate was incubated 
with Ni-NTA to allow binding of the protein of interest.  The flow-through 
(FT) was then collected and the resin washed with wash buffer 1 and 2 
(W1, W2), prior to elution from the resin with 0.25 M imidazole (Elut). (B) 
Representative Western blot showing the purification of STRA6-ICL3 using 
Ni-NTA agarose, as detected by α-his-HRP antibody. STRA6-ICL3 is 
present in the lysed cells, soluble and insoluble fraction. After purification, 
STRA6-ICL3 is predominantly present in the eluate, with a small amount of 
STRA6-ICL3 present in the second wash.  
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5.3.2 Expression and Purification of Im7  
Im7 was expressed in E.coli, following induction with IPTG. Im7 was purified via 
its 6xHis tag by affinity chromatography, using Ni-NTA agarose, as illustrated in 
Figure 5.7.   
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Figure 5.7:  Purification of Im7 
Coomassie Brilliant Blue stained (12%) SDS-PAGE gel showing the 
purification of Im7, ~ 10 kDa, using Ni-NTA agarose. 5 µl loaded for each 
fraction. Lysed cells (LYS), soluble fraction after centrifugation (SN) and 
insoluble fraction after centrifugation (PT) are shown. The soluble fraction 
of the cleared bacterial lysate was incubated with Ni-NTA to allow binding 
of the protein of interest.  The flow-through (FT) was then collected and the 
resin washed with wash buffer 1 and 2 (W1, W2), prior to elution from the 
resin with 0.25 M imidazole (Elut). After purification, Im7 is predominantly 
present in the eluate, with little contaminants.  
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5.3.3 Expression, Purification and Cleavage of CRBP 
 5.3.3.1 Expression and Purification of CRBP 
CRBP was strongly expressed as a fusion protein in pGEX-4T-3, following 
induction with IPTG. CRBP was purified via its amino-terminal GST-tag using 
Glutathione Sepharose™ 4 Fast Flow.  
 
5.3.3.2 Cleavage of CRBP 
As CRBP was required in its native, untagged form in downstream functional assays, 
on-column enzymatic cleavage of the GST-tag was necessary.  The on-column 
method was chosen as it allows for removal of contaminants and ultimately, a higher 
purity end-product. 
On column thrombin cleavage of CRBP were analysed by Coomassie Brilliant Blue 
staining of SDS-PAGE gels and Western blotting. Majority of protein was found to 
be successfully cleaved.  
5.3.4 Expression and Purification of STRA6-CT 
STRA6-CT was strongly expressed as a fusion protein in pGEX-4T-3, following 
induction with IPTG. STRA6-CT was purified via its N-terminus GST epitope tag.  
5.3.5 CRBP Binding Activity of STRA6-ICL3 
The CRBP binding activity of STRA6-ICL3 was investigated using a traditional 
wash step or the rapid centrifugation through an oil preparation.  
STRA6-ICL3 was immobilised on Ni-NTA agarose and CRBP added in the presence 
and absence of retinol. After an appropriate incubation, any nonspecifically bound 
proteins were removed by washing the resin and any bound material eluted from the 
resin. Alternatively, nonspecifically bound proteins were removed by the rapid 
centrifugation through oil, a 3:2 dibutyl phthalate: dinonyl phthalate preparation. 
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This circumvents the wash step of traditional pull-down protocols, allowing even 
low affinity interactions to be detected.   
Each fraction was analysed by SDS-PAGE gels and Western blotting to determine if 
a specific interaction had occurred, illustrated in Figure 5.8. In both binding assays 
STRA6-ICL3 was eluted from the resin alone, CRBP was present in the supernatant, 
indicating that an interaction did not occur. The CRBP binding activity of STRA6-
ICL3 in the presence of retinol was also explored.  Again, in both binding assays 
STRA6-ICL3 was eluted from the resin alone, CRBP was present in the supernatant, 
indicating that an interaction did not occur.  
163 
 
          C h a p t e r  5 | T h i r d  I n t r a c e l l u l a r  L o o p  o f  S T R A 6  | 
 
Figure 5.8:  CRBP Binding Activity of STRA6-ICL3  
STRA6-ICL3, ~ 19.5 kDa, was expressed in E.coli and the soluble fraction 
of the cleared bacterial lysate was incubated with Ni-NTA agarose to allow 
binding of the protein of interest. CRBP, ~ 17 kDa, was then added to the 
resin and again incubated. The supernatants (FT) were then collected and 
the resins washed twice (W2), prior to elution (Elut). Empty resin was used 
as a control (con). Positive controls for both CRBP (CRBP pos) and 
STRA6-ICL3 (ICL3 pos) were also run on the gel. 5 µl loaded for each 
fraction. (A) Western blots as detected by α-CRBP and α-mouse-HRP 
antibodies. CRBP is present in the supernatants indicating an interaction 
does not occur (B) Western blots as detected by α-his-HRP antibody, 
STRA6-ICL3 is present in the elution. There is the presence of a second 
higher band, ~ 40 kDa, which may be the dimer form of STRA6-ICL3 
which was not fully reduced.  
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5.3.6 STRA6-CT Binding Activity of STRA6-ICL3 
The STRA6-CT binding activity of STRA6-ICL3 was investigated.  
STRA6-CT was immobilised on a Glutathione Sepharose™ 4 Fast Flow resin and 
STRA6-ICL3 added in the presence and absence of retinol. After an appropriate 
incubation, any nonspecifically bound proteins were removed by washing the resin and 
any bound material eluted from the resin. Alternatively, any nonspecifically bound 
proteins were removed by the rapid centrifugation through oil, a 3:2 dibutyl 
phthalate: dinonyl phthalate preparation. Each fraction was analysed by SDS-PAGE 
gels and Western blotting to determine if a specific interaction had occurred, 
illustrated in Figure 5.9. In both binding assays STRA6-CT was eluted from the resin 
alone, STRA6-ICL3 was present in the supernatant, indicating that an interaction did 
not occur. The STRA6-CT binding activity of STRA6-ICL3 in the presence of 
retinol was also explored.  Again, in both binding assays STRA6-ICL3 was present 
in the supernatant, indicating that an interaction did not occur. 
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Figure 5.9:  STRA6-CT Binding Activity of STRA6-ICL3 
STRA6-CT, ~ 42 kDa, was expressed in E.coli and immobilised using a 
Glutathione Sepharose™ 4 Fast Flow resin. Glutathione Sepharose™ 4 
Fast Flow resin with no protein bound was used as a negative control 
(con).  STRA6-ICL3 was incubated with the resins. The supernatants (FT) 
were then collected and the resins washed (W), prior to elution (ET). 
Positive controls for both STRA6-CT (pos C-T) and STRA6-ICL3 (pos 
ICL3) were also run on the gel. 5 µl loaded for each fraction. Western blots 
as detected by α-his-HRP antibody, STRA6-ICL3, ~ 19.5 kDa, is present in 
the FT whereas STRA6-CT is present in the ET, indicating an interaction 
does not occur.  
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5.3.7 Size-Exclusion Chromatography 
5.3.7.1 STRA6-ICL3 Subjected to Size-Exclusion Chromatography  
STRA6-ICL3 was subjected to size-exclusion chromatography on a Superdex 200 
10/300 GL resin, which separates globular proteins with MWs that range from 
approximately 10 to 600 kD, by fast protein liquid chromatography using an AKTA 
purifier (GE Healthcare). SEC was carried out at room temperature (20-22 °C) at a 
flow rate of 0.3 mL/min. The total column volume is approximately 24 mL. 
Results of size-exclusion chromatography are illustrated in Figure 5.11. The elution 
profile of BSA, β-amylase, alcohol dehydrogenase and carbonic anhydrase are 
illustrated in Figure 5.10. The protein elutes near BSA (molecular weight of 68,000). 
Analysis by SDS-PAGE and Western blotting of all the fractions resulted in a band 
for STRA6-ICL3 at 13 ml and 14 ml, indicating that the domain is running as a 
tetramer (~ 60 kDa). 
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Figure 5.10:  Size-Exclusion Chromatography Elution Profile of Calibrants 
Elution profile of calibrants. (A) Size-exclusion chromatography elution 
profile of β-amylase, alcohol dehydrogenase and carbonic anhydrase 
shows three major peaks at ~ 11 ml, ~ 12 ml and ~ 16 ml. These peaks are 
believed to be β-amylase (200 kDa), alcohol dehydrogenase (150 kDa), and 
carbonic anhydrase (29 kDa) respectively. (B) Size-exclusion 
chromatography of BSA shows a major peak at ~ 13 ml (68 kDa). 
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Figure 5.11:  Size-Exclusion Chromatography Elution Profile of STRA6-ICL3 
Size-exclusion chromatography elution profile of STRA6-ICL3. (A) 
Representative Western blot with eluted fractions (20 µl). Each fraction (0.5 
ml) was collected and fractions 10 ml to 17 ml (1-8) are shown here. 
STRA6-ICL3, ~ 19.5 kDa, as detected by α-his-HRP antibody, is present in 
the 13 ml and 14 ml fraction (B) Elution profile of STRA6-ICL3 shows one 
major peak at ~14 ml (MW of ~ 60 kDa). 
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5.3.7.2 Im7 Subjected to Size-Exclusion Chromatography  
Im7 itself was subjected to size-exclusion chromatography on a Superdex 200 
10/300 GL resin by fast protein liquid chromatography using an AKTA purifier.  
Results of size-exclusion chromatography of Im7 are given in Figure 5.12. The 
protein elutes near carbonic anhydrase (molecular weight of 29,000), ~ 16 ml. 
Analysis by SDS-PAGE and Western blotting of all the fractions resulted in a band 
for Im7 at 18 ml indicating that the protein is running as a monomer (~ 10 kDa).  
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Figure 5.12:  Size-Exclusion Chromatography Elution Profile of Im7 
Size-exclusion chromatography elution profile of Im7 shows one major 
peak at ~18ml (MW of ~ 10 kDa) 
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5.3.8 Circular Dichroism 
The structures of some thousands of proteins have been completely resolved by 
analysing the X-ray diffraction patterns of the crystallized molecule. However, 
crystallization of a protein is a difficult and not always feasible task. Therefore, 
techniques for prediction of secondary structure from more readily measurable 
protein characteristics have been developed. CD is a spectroscopic technique that can 
be used to determine the secondary structural content of proteins. CD is used also to 
confirm that expressed proteins are likely to be folded. 
The far-UV CD spectra of STRA6-ICL3 and Im7 are shown in Figure 5.12. The 
percentage of secondary structure was calculated by deconvoluting the CD spectra 
using the program K2d from the DichroWeb CD secondary structure server 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml (Andrade et al., 1993)). Im7 was 
found to be composed of 68 % α-helical, 4 % β-sheet and 28 % coil. STRA6-ICL3 
was found to be composed of 53 % α-helical, 9 % β-sheet and 38 % coil. STRA6-
IC3 decreased the α-helical content when inserted into Im7, thereby implying it is 
largely composed of β-sheet or random coil.  
Jpred (http://www.compbio.dundee.ac.uk/jpred) is a secondary structure prediction 
server powered by the Jnet algorithm. The recently updated Jnet algorithm provides 
a three-state (alpha-helix, beta-strand and coil) prediction of secondary structure at 
an accuracy of 81.5% (Cole et al., 2008). Interestingly, Jpred gave similar findings, 
with a 14.2 % reduction in the α-helical content when STRA6-ICL3 was inserted 
into Im7. 
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Figure 5.13:  CD spectra of Im7 and STRA6-ICL3 
The far-UV CD spectra of (A) Im7 and (B) STRA6-ICL3.  
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5.3.9 Crosslinking of STRA6-ICL3 
Chemical crosslinking is a technique involving the formation of covalent bonds 
between two proteins by using bifunctional reagents containing reactive end groups 
that react with functional groups-such as primary amines and sulfhydryls-of amino 
acid residues. If two proteins physically interact with each other, they can be 
covalently cross-linked. Crosslinking has been used for determination of the quaternary 
structure of homo-oligomeric proteins (Carpenter and Harrington, 1972).  
STRA6-ICL3 was treated with a cross-linking reagent DTBP. DTBP is a cleavable, 
amine to amine crosslinker. The reaction mixture was resolved on a SDS–PAGE gel 
under reducing and non-reducing conditions. STRA6-ICL3 ran as a monomer and 
dimer under reducing conditions but mostly as a dimer and tetramer under non-
reducing conditions, as illustrated in Figure 5.14. This experiment validates the 
information obtained using size-exclusion chromatography and ensures that the elution 
profile of STRA6-ICL3 is not due to the protein aggregating but rather STRA6-ICL3 
running as a tetramer.   
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Figure 5.14:  Crosslinking of STRA6-ICL3  
Western blot with the crosslinking of STRA6-ICL3 in the (A) absence and 
(B) presence of a reducing agent. 5 µl loaded per well. STRA6-ICL3 as 
detected by α-his-HRP antibody. Molecular weight markers (M) revealed 
STRA6-ICL3 migrating at an expected ~ 19.5 kDa in reducing conditions, 
as well as a ~ 35 kDa species, which was not fully reduced.  In the absence 
of a reducing agent, STRA6-ICL3 migrated at ~ 35 kDa and ~60 kDa. 
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5.3.10 Crystallisation of STRA6-ICL3 
For X-ray crystallization, STRA6-ICL3 was concentrated to 10 mg/ml. The sample 
was centrifuged (12,000 g for 20 min) to remove initial precipitate, and was 
crystallized in a hanging-drop vapour diffusion set-up in 96 well-agar plates. 
Crystallization trials were carried out in Leeds University, with the help of Dr. Chi 
Trinh. As yet, a STRA6-ICL3 crystal is eagerly awaited. Early indications show 
small thin needle shaped crystals (and several wells with salt crystals).  
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5.4 Discussion  
STRA6-ICL3 was expressed in E.coli as a chimera with the stabilising protein Im7 
and purified via its 6xHis tag by affinity chromatography using Ni-NTA agarose. 
Considerable effort was invested in identifying the optimum buffer for the lysis and 
storage of STRA6-ICL3 to ensure the protein did not aggregate at room temperature 
and could, therefore, be used for downstream experiments. Concentrated STRA6-
ICL3 was applied to a size-exclusion Superdex 200 resin. The elution profile of 
STRA6-ICL3 had one major peak for STRA6-ICL3 at ~ 14 ml, near BSA (molecular 
weight of 68,000 which elutes at ~ 13 ml), implying that STRA6-ICL3 runs as a 
tetramer. Cross-linking data also showed STRA6-ICL3 forms higher molecular 
weight species. A dimer and tetramer could be detected using the cross-linking 
reagent DTBP. These data suggest that native STRA6 is likely to occur as a tetramer 
and that at least some of the oligomerization sites are located on this large 
intracellular loop. This raises the possibility of a structural organisation not unlike 
the K+-channel (Miller, 2000), with the RBP molecule (one per tetramer) and 
potentially also CRBP sitting on top of a vestibule into the transport channel. 
Clearly, the stoichiometry of RBP binding with respect to the putative STRA6 
tetramer should be established. Future work includes finer refinement of the 
interaction site(s) by mutagenesis. 
The structure of STRA6-ICL3 was explored. CD spectroscopy and Jpred both 
showed that STRA6-ICL3 reduced the percentage of α-helix content of Im7 alone 
(by ~ 15 %), thereby suggesting STRA6-ICL3 is composed of β-sheet and random 
coil. Many proteins function as dimers or higher oligomers that are held together in 
part by the formation of a β-sheet. For example, a number of cytokines form β-sheet 
dimers or higher oligomers such as interleukin 8 (Il-8). β-sheet formation is critical 
in forming cell-cell junctions and clustering of ion channels and receptors. β-sheet 
formation between proteins constitutes an important form of molecular recognition 
between amide groups and represents one general mode of PPIs. For example, the X-
ray crystallographic structure of the complex between c-Raf1 and Ras-related protein 
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Rap-1A shows that the main-chains of the two proteins form an antiparallel β-sheet 
and their side-chains form a rich array of polar contacts (Maitra, 2000). 
Crystallization of STRA6-ICL3 was attempted by the hanging-drop, vapour-
diffusion method. Early indications show small thin needle shaped crystals (and 
several wells with salt crystals). The crystal structure of STRA6-ICL3 is eagerly 
awaited to further confirm the hypothesis proposed here.  
Due to its large size, the third intracellular loop of STRA6 is predicted to be of 
critical importance for binding within the receptor and other components. The 
binding capacity of STRA6-ICL3 for both STRA6-CT and CRBP was assessed. The 
protein was previously subjected to size-exclusion chromatography and cross-linking 
to ensure the protein had not aggregated and was shown to form a tetramer. STRA6-
ICL3 was pulled down using Ni-NTA agarose in the presence of both holo- and apo-
CRBP. CRBP was detected in the unbound fraction indicating that no interaction 
occurs. The binding of activity of STRA6-ICL3 for STRA6-CT was also explored. 
STRA6-ICL3 was found not to interact with STRA6-CT. The third intracellular loop 
of STRA6, expressed as a chimera with Im7, may not be sufficient to bind to CRBP 
as this interaction may require the full length protein. The presence of Im7 may also 
inhibit the interaction between STRA6-ICL3 and CRBP/STRA6-CT. 
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Membrane proteins are essential for many biological processes, particularly 
signalling and transport. A thorough understanding of protein-protein interactions is 
vital for understanding the role of the protein, furthermore, given that protein-protein 
interactions regulate nearly every living processes, it is also essential for the  
understanding of diseases and for drug discovery (Suter et al., 2008). The objective 
of the work undertaken in this thesis is aimed at a greater understanding of the RBP 
receptor, STRA6, with specific interest in the identification of interacting proteins. 
This approach utilises the MYTH, a type of yeast two hybrid which allows 
interactions between integral membrane proteins, membrane-associated proteins and 
cytoplasmic proteins to be detected (Snider et al., 2010a). This system maintains 
eukaryotic proteins in an environment close to their physiological norm and allows 
post-translational modifications to occur, allowing the expression of correctly folded 
and functional proteins (Causier, 2004).  
 
Three libraries were screened using STRA6 as the bait; a human kidney, and a 
human brain library and a human kidney library in the presence of holo-RBP. This 
resulted in 11 potential protein interactions for STRA6. From, the human kidney 
library CD63, PDZK1-IP1 and SERP1 were identified. The human brain library 
generated CD63, PDZK1-IP1, SERP1 and PLP2  and  the human kidney library, in 
the presence of RBP-ROH, generated CD63, PDZK1-IP1 and SERP1 as potential 
STRA6 interactors as well as previously undetected proteins; MCP-1, CCL2, 
CXCL14, IFITM1, IFITM3, MIF, OCIAD2, and osteopontin. Attempts were made 
to verify these MYTH hits independently of the MYTH. Despite considerable 
efforts, the hits obtained in all three screens could not be validated using pull-down 
experiments. This technology often results in a relatively large number of false-
positives for a number of reasons; the MYTH involves the overexpression of the 
protein of interest and prey, thus modifying the relative concentrations of potential 
interaction partners from the in vivo state. Furthermore, the use of heterologous 
systems can eliminate competing activities that exist in the native system and can 
also introduce novel competitors (Lalonde et al., 2008). The “hits” produced here 
appear not to interact with STRA6 and may simple be false positives. Alternatively, 
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these proteins may only form weak, transient interactions with STRA6 which are 
difficult to capture.  
 
Membrane proteins represent approximately one-third of the proteins encoded in the 
genome, yet fewer than 1% of them are of known structure. A deeper understanding 
of structure–function relationships of membrane proteins requires high-resolution 
structural information. A few decades ago, it was believed to be hardly possible to 
determine crystal structures for integral membrane proteins. However it is now 
known that determining 3-D structures for integral membrane proteins is possible 
though still very difficult. The majority of membrane proteins, with the exception of 
bacterial membrane proteins, are found naturally in very small quantities, and 
therefore not in sufficient quantities for crystallisation. Expression, particularly of 
eukaryotic membrane proteins using prokaryotic systems, is often problematic. Once 
synthesis of a membrane protein begins, the secretory machinery is engaged, and that 
protein must be targeted to and inserted into the membrane. For many cells, the bulk 
of the proteins synthesized are intracellular; such cells are not equipped to handle 
heavy traffic in newly synthesized membrane proteins. Hence, high-level expression 
of a membrane protein can saturate the secretory pathway, leading either to the 
build-up of toxic intermediates or to inclusion body formation. In addition, many 
membrane proteins are relatively unstable once solubilised in detergent. Therefore, 
purification procedures need to be fast and gentle to prevent significant deterioration 
of the protein during purification. (Loll, 2003).  
For these reasons, producing large quantities of soluble cytoplasmic fragments of 
membrane proteins in E. coli can be used in the quest for structural insights, for 
example, in the determination of the structures of the cytoplasmic N-terminal portion 
of transient receptor potential (TRP) channels (Moiseenkova-Bell and Wensel, 
2009).  
The predicted large third intracellular loop of STRA6 has been suggested to be 
involved in binding CRBP (Berry et al., 2012b) and due to its large size, is a 
potential candidate for interactions within the receptor itself as well as with other 
proteins. The importance of STRA6-ICL3 has been further enhanced by the 
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discovery of human polymorphism P293L, associated with severe multisystem birth 
defects (Pasutto et al., 2007). STRA6-ICL3 was extracted from the full length 
protein and characterised in the hope of gaining insights into STRA6’s architecture 
and function, with particular attention to the binding of CRBP and the C-terminus of 
STRA6. This region was expressed, purified and characterised as a chimera with a 
stabilising protein, Im7, to aid folding, solubility and stability of the expressed 
protein and to anchor the domain as it might be in its native state. Characterisation of 
STRA6-ICL3 was achieved using a number of techniques such as SEC and SDS-
PAGE to determine oligomeric size, CD to elucidate secondary structure (also to 
provide some evidence for it being folded) and pull-down assays to determine if 
STRA6-ICL3 does in fact bind CRBP and/or STRA6-CT. Crystallisation of STRA6-
ICL3 was also attempted.  
SEC and SDS-PAGE revealed that STRA6-ICL3 eluted at approximately 14 ml, 
(molecular weight of ~ 60,000) implying the protein migrates with a molecular mass 
which approximates that of a tetramer. Crosslinking was also used for determination of 
the oligomeric size. The crosslinking reagent DTBP, in combination with SDS-PAGE, 
revealed that STRA6-ICL3 runs as a dimer and tetramer under non-reducing conditions 
and as a monomer and dimer in the presence of a reducing agent. These data both imply 
that STRA6-ICL3 forms a tetramer and that the SEC data is not simply due to unfolded 
STRA6-ICL3 but rather reflects the functional form of the protein. The work presented 
here infers that native STRA6 is likely also to occur as a tetramer and that at least 
some of the oligomerization sites are located on this large intracellular loop.   
CD data revealed that incorporation of STRA6-ICL3 into Im7 reduced the 
percentage of α-helix in comparison to Im7 alone, implying that STRA6-ICL3 is 
mostly composed of β-sheet or random coil since the proportion of the latter forms 
increased significantly. Jpred, a secondary structure prediction server powered by the 
Jnet algorithm, gave similar results. Interestingly, many proteins function as dimers 
or higher oligomers held together in part by the formation of a β-sheet, such as Il-8 
(Maitra, 2000). 
Crystallization of STRA6-ICL3 was attempted by the hanging-drop, vapour-
diffusion method. Early indications show small thin needle shaped crystals (and 
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several wells with salt crystals). The crystal structure of STRA6-ICL3 is eagerly 
awaited. 
Due to its large size, the third intracellular loop of STRA6 is likely to be of critical 
importance for binding within the receptor and/or with other components. The 
binding capacity of STRA6-ICL3 for both STRA6-CT and CRBP was assessed. 
However neither interaction could be detected using pull-down assays despite 
several attempts in the presence and absence of retinol as well as using a traditional 
wash step and the rapid centrifugation through an oil preparation to remove unbound 
material. The third intracellular loop of STRA6, expressed as a chimera with Im7, 
may not be sufficient to bind to CRBP as this interaction may require the full length 
protein or post translational modification within the cell. The presence of Im7 may 
also inhibit the interaction between STRA6-ICL3 and CRBP/STRA6-CT.  
The work presented here provides compelling evidence that STRA6 functions as a 
tetramer. Further work is needed for finer refinement of the interaction site(s) by 
mutagenesis. However, it is clear that at least some of the oligomerization sites are 
located on the third intracellular loop of STRA6. Currently, there is no published 
data in relation to the secondary or tertiary structure of STRA6. The CD spectra of 
STRA6-ICL3, in comparison to the CD spectra for Im7 alone, implies the loop is 
composed of mainly β-sheet or random coil. STRA6-ICL3 did not interact with 
CRBP or STRA6-CT in pull-down experiments. This is unsurprising considering the 
full length protein did not identify CRBP as a potential interactor in the MYTH. 
Presumably these proteins form a weak or transient interaction which is difficult to 
capture and may require the presence of other proteins such as holo-RBP and 
functionally generated modifications.  
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